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ABSTRACT 
Neurological disorders include disorders such as migraine, tension-type headaches, 
Parkinson’s disease (PD), epilepsy, dementia, and Alzheimer’s disease (AD). Globally, PD is the 
second most common neurodegenerative disorder following AD. In developed countries, PD 
affects 1% of all population over 60 years of age. The prevalence of PD is increasing over the 
years and is expected to double by 2030. It is proposed that combination of dopaminergic drugs 
with monoamine oxidase B (MAO-B) inhibitors, anticholinergics, catechol-O-methyl transferase 
inhibitors, and other non-dopaminergic drugs can better alleviate levodopa-induced motor 
complications along with better control of motor symptoms. MAO-B inhibitors play a significant 
role in dopamine (DA) metabolism and can be used as monotherapy in the early stages of PD, or 
in combination with levodopa. Currently, there are only three MAO-B inhibitors that are 
approved by Food and Drug Administration (FDA): selegiline, rasagiline, and safinamide. 
Hence, there is the need to discover potent and selective MAO-B inhibitors for effective 
treatment of PD. 
About 60% of the marketed drugs today are either natural products or derivatives that are 
inspired from natural products. We studied plants with extensive traditional use in CNS-related 
disorders, in which the chloroform extract of C. urticifolia exhibited potent inhibition of MAO-A 
and -B. Calea urticifolia (Asteraceae) commonly known as “Juanislama” is native to the Central 
America. Bioassay-guided fractionation has been implemented for the isolation of the secondary 
metabolites from C. urticifolia. From the bioactive fraction, acacetin and a series of 
sesquiterpenes were isolated; acacetin was found to be the bioactive compound. A series of 
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acacetin analogs were designed with the aid of computational docking studies, to improve their 
selectivity towards MAO-B. The structures of the isolated compounds were determined on the 
basis of HR-MS and 1D- and 2D-NMR studies; configurations were partly established by ECD 
calculations. Monoamine oxidase assays were performed on the extracts, fractions, and purified 
compounds. Molecular modeling and molecular dynamic studies were used to predict the 
binding modes on the active sites of the MAO isoenzymes.   
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1.1. Natural Products in Drug Discovery 
Natural products are compounds that are derived from natural sources such as animals, 
microorganisms, or plants. The medicinal properties of natural products, particularly plants, have 
been known for more than 60,000 years, based on the evidence of the pollen deposits in one of 
the graves at a cave site of Shanidar, Iraq. The significance of natural products for health and 
medicine has been enormous throughout our evolution.
1
    
Natural sources play a significant role in healthcare, and their use has been extensively 
documented in various cultures. In 1985, it was estimated by the World Health Organization 
(WHO) that approximately 65% of the world’s population predominantly depended on plant-
derived traditional medicines for primary healthcare.
2
 Drugs of natural origin are classified as 
original natural products, semisynthetic products derived from natural products, or synthetic 
products based on natural-product cores.
3
 Natural products have always been a source for the 
treatment of injuries and diseases. After the advent of combinatorial chemistry and molecular 
biology during the earlier decades, natural products took a secondary role in drug discovery and 
development that made possible the rational design of chemical compounds, to interact with 
specific biological targets. A renewed interest in the use of natural products, more prominently 
their role as a basis for drug development, has been documented recently.
1
 
1.1.1. Evolution of Natural Products   
Natural products and their derivatives have always been a valuable source of therapeutic 
agents. Nonetheless, during the past decade, natural product research in pharmaceutical industry 
has greatly deteriorated, owing to the challenges such as lack of affinity of the traditional natural 
3 
 
product extract libraries with high throughput screening (HTS). Natural product structures were 
long recognized to have biochemical specificity, high chemical diversity, and additional 
molecular properties that would favor them as lead structures in drug discovery along with 
separating them from the libraries of synthetic and combinatorial compounds. Natural products 
differ from the combinatorial libraries and synthetic drugs in the number of solvated hydrogen 
bond acceptors and donors (higher in natural products), in the ratio of the total heavy atoms to 
the aromatic ring atoms (lower in natural products), and by larger molecular rigidity, along with 
better distribution of molecular properties.
4
  
The exploration of natural products as unique human therapeutics reached its highest in 
the pharmaceutical industry during 1970-1980. Among the 877 small-molecule new chemical 
entities (NCEs) that were introduced during 1981–2002, at least half [49%] were natural 
products, followed by semi-synthetic natural product analogs, or synthetic compounds based on 
natural product pharmacophores. The chart below shows the increased patent activity in the 
1980s, a flattened or slight drop between 1990 to 1999, and a further escalation between 2000 
and 2003.
4
 There were 13 natural product related drugs that were approved between 2005 and 
2007 (Figure 1.1).
5
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Figure 1.1. Worldwide pharmaceutical natural-product patents. Gold represents the total natural-
product patents, including small-molecule natural products as pharmaceuticals. Orange 
represents original natural product patents. Reprinted with permission from Macmillan 
Publishers Ltd: Koehn, F. E.; Carter, G. T. Nat. Rev. Drug Discovery. 2005, 4, 206-220, 
Copyright © 2005 Nature Publishing Group. [Permission# 4167820299191] 
There are various reasons for the decreased emphasis on natural product discovery in the 
pharmaceutical industries which include: 
1. The introduction of HTS against definite molecular targets prompting many companies to 
move to ‘screen friendly’ synthetic chemical libraries from natural products extract libraries 
2. Development of ‘combinatorial chemistry’ that led to the prospect of simple, drug-like 
screening libraries with wide chemical diversity 
3. Advances in genomics, cellular biology, and molecular biology led to an increase in the 
number of molecular targets and shortened the drug-discovery timelines 
4. A declined emphasis on infectious disease programs in pharmaceutical companies which is a 
traditional area of strength for natural products and 
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5. Possible uncertainities in the collection of biomaterials based on the 1991 Rio Convention on 
Biological Diversity. 
Due to the underlying challenges involved in natural product drug discovery for 
commercial scale production by pharmaceutical industries, there is the need for rapid screening, 
validated hit identification, and hit-to-lead development. Traditional resource intensive natural 
product programs which are based on the bioassay-guided isolation, structural elucidation, 
extract-library screening, and consequent production scale-up face competitive disadvantages 
when compared to methodologies utilizing well-defined synthetic chemical-libraries. However, 
the emerging trends combined with the current research and development (R&D) strategies have 
refocused attention towards natural products as a source of chemical diversity and lead 
generation.
4
 
1.1.2. Chemical Diversity of Natural Products 
Natural products, particularly plants, produce a diverse and vast variety of secondary 
metabolites, the majority of which are not directly involved in growth and development. These 
novel metabolites have been extensively investigated by organic chemists since the 1850s for 
various biological effects, thus prompting a reevaluation of the possible roles they play in plants, 
especially in relation to ecological interactions.
6
 Most of the small molecule natural products 
have chemical properties closely compliant with Lipinski’s Rule of Five for orally available 
compounds,
7
 while the remainder have higher molecular weights, and an increased number of 
stereogenic centers, and rotatable bonds, although with low log P values. This makes it evident 
that natural products are readily absorbed compared to synthetic drugs. Such properties along 
with the realization that their chemical diversity has been a better match to most of the successful 
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drugs compared to the diversity in synthetic compounds, enhanced interest in applying the 
natural chemical diversity to drug-discovery.
5
 
Secondary metabolites produced in plants primarily function in defense against pathogens 
and predators, along with a reproductive advantage as attractants of seed dispensers and 
pollinators. The study of the biochemistry of natural products involve many practical 
applications.
6
 Natural products have inspired advancements in organic chemistry, leading to 
developments in synthetic methodologies and to the prospect of making analogs of the original 
lead compounds with enhanced pharmaceutical or pharmacological properties. Natural product 
scaffolds have the advantage of being ‘privileged’ structures based on their ability to be 
successful drugs. These scaffolds are used as cores of compound libraries which are made by 
combinatorial techniques. Several such libraries are based on alkaloids, flavonoids, terpenoids, 
and polyketides. Currently, computational methods are used for the comparison of natural 
product likeness of the compound libraries, making it more successful for the design of natural 
product analogs and derivatives. These advancements and technologies could result in novel 
bioactive compounds that could be patented.
5
 
1.1.3. History of Natural Products in Drug Discovery   
The practice of medicine dates as far back as 2900 BC by the ancient Egyptians. The first 
known record of Egyptian pharmaceutical practice is “Ebers Papyrus”, that is dated to 1500 BC, 
with a description of over 700 drugs, of which mostly are from plant origin. The papyrus 
included details of different drug formulations including pills, ointments, infusions, poultices, 
snuffs, and gargles mixed with honey, milk, wine, and beer as vehicles. Dioscorides is the first 
documented source with the medicinal uses of natural substances, that dated back to 78 AD. 
There are thousands of medicinal plants that are relevant in modern medicine today, that were 
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described back then. Some hallmark examples of natural product derived drugs in modern 
pharmaceutical care include penicillin G, quinine, paclitaxel/taxol, vitamin A, digoxin, 
morphine, vincristine, theophylline, doxorubicin, artemisinin, camptothecin, and cyclosporine 
(Figure 1.2).
8
  
 
Figure 1.2. Chemical structures of some hallmarks of natural product derived drugs 
Natural products have always been the most prolific source of leads in drug development. 
There are many natural product based drugs approved by the Food and Drug Administration 
(FDA) which include huperzine, galantamine, and elliptinium from plants; ziconotide and 
exenatide from animals; daptomycin from microbes; natural product based synthetic or semi-
synthetic compounds such as caspofungin, micafungin, everolimus, tigecycline, and 
telithromycin. These compounds cover a series of therapeutic indications such as anti-diabetic, 
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anti-infective, and anti-cancer, among others, with a great diversity in their chemical structures 
(Figure 1.3).
5
   
 
Figure 1.3. Chemical structures of approved natural products and natural product based synthetic 
or semi-synthetic compounds 
Natural products play a significant role in the lead-discovery of drug development for the 
treatment of human diseases. Figure 1.4 demonstrates the number of new active substances 
(NASs) or NCEs approved over the years between 1981 to 2014. There are 175 molecules that 
were approved for the treatment of cancer between 1940s to 2014, of which 85 molecules were 
either from natural products or natural product derivatives. In 2014, 10 of the 44 approved small 
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molecule drugs were either unaltered natural products, botanical drugs, or natural product 
derivatives, accounting for 25% of the approved NCEs. The role of natural products in the drug 
discovery of small molecules was ~ 40% between 2000-2008, ~ 20% in 2009, 45% in 2010, and 
~ 13% in 2013. Natural products exhibit a continued and overwhelming contribution for the 
expansion of chemotherapeutic armamentarium.
9
 
 
Figure 1.4. New drugs approved by FDA. B: biological macromolecule; N: unaltered natural 
product; NB: botanical drug (mixture); ND: natural product derivative; S: synthetic drug; S*: 
synthetic drug with natural product (NP) pharmacophore; /NM: mimic of natural product; V: 
vaccine. Reprinted with permission from ACS Publications: Newman, D. J.; Cragg, G. M. J. Nat. 
Prod. 2016, 79, 629-661, Copyright © 2016 The American Chemical Society and American 
Society of Pharmacognosy. [Open access article] 
1.1.4. Role of Plants in Lead Discovery 
Plants played a significant role in the development of traditional medicine systems. WHO 
estimated that approximately 80% of the Asian and African population still depend on traditional 
medicine for primary healthcare.
10
 Plants play a crucial secondary role in the health-care sectors, 
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where 70-80% of people in developed countries use some form of complementary or alternative 
medicine such as acupuncture. Currently, herbal treatments gained popularity in traditional 
medicine and are highly lucrative in international marketplace. Plant products have an extensive 
history of use in the treatment of various diseases.
10
     
Plant-derived compounds may not directly serve as drugs, but provide leads for the 
development of potential analogs to treat various diseases. Plants helped researchers to better 
understand the disease, provided efficient and novel therapies possessing unique mechanisms of 
action, opened distinctive research avenues, and provided inspiration in the development of 
novel and future therapeutic agents. Plants represent a vast diversity on earth, but only a fraction 
of that has been explored. It is therefore expected that plants can deliver potential bioactive 
compounds and have the potential for development into selective therapeutic agents.
10
    
1.1.5. Challenges in Drug Discovery from Plants 
There are many challenges in natural-product based drug discovery, which include access 
and adequate supply, tediousness in working with natural products, and the complexities 
involved in natural product chemistry.
8
 Solubility is a common problem seen in the screening of 
extracts and the screening of extract libraries itself is problematic. Some of these issues could be 
alleviated using new techniques such as pre-fractionation of extracts. The isolation of active 
compounds could be facilitated using techniques like liquid chromatography-mass spectrometry 
(LC-MS) and liquid chromatography-nuclear magnetic resonance (LC-NMR), but the drug-
development from lead compounds isolated from plants have unique challenges. In general, 
natural products are isolated in small quantities which are insufficient for lead optimization, 
development, and clinical trials. Hence, collaborations with medicinal and synthetic chemists 
would help explore the possibilities of semi- or total-synthesis. Another way of improving the 
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development of natural product compounds is the creation of natural product libraries, which 
combine the natural product features with combinatorial chemistry.
11
 
A common and recurring concern with the isolation of compounds from plants, is their 
activity “hits” in multiple assays due to their interference with assay readout, rather than the 
specific target/compound interactions, termed as “pan-assay interference compounds” or 
PAINS.
12
 Some of the PAINS-type behaviors include redox reactivity, metal chelation, 
membrane disruption, aggregation, covalent protein labeling, structural decomposition, and 
fluorescence interference. There are several compound classes that fall under PAINS or potential 
PAINS. The other category include invalid metabolic panaceas (IMPS) that are located in the 
natural products, inside the center of the hyberbolic black hole (occurrence-bioactivity-effort 
space). IMPS are the prototypes of the improbable metabolic panaceas with feeble performance 
as drug leads. IMPS include other factors in addition to PAINS characteristics such as the 
presence of a reactive Michael acceptor, chemical aggregation, and fluorescence activity. The 
above mentioned factors are other challenges to be faced with isolation of compounds from 
plants.
12
    
1.2. Psychoactive Substances 
New psychoactive substances (NPS) refer to a wide range of compounds that elicit 
psychotomimetic effects. These include stimulants which are congeners of synthetic cathinones 
or amphetamine. They have street market names which include ‘plant food’, ‘designer drugs’, 
‘research chemicals’, or ‘bath salts’. However, NPS are not restricted to amphetamine like 
compounds, but also to cannabimimetics, hallucinogens, and sedative-hypnotics. NPS cannot be 
considered harmless as they not only exert psychostimulant effects, but can also cause lethal 
side-effects at higher doses.
13
 Based on their psychotropic effects, NPS can be classified into 
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various categories such as stimulants, entactogens/empathogens such as 3,4-
methylenedioxymethamphetamine (MDMA), hallucinogens, or as amphetamines, cathinones, 
phenethylamines, benzofurans, tryptamines, piperazines, piperidines/pipradols, and aminoindans, 
based on their chemical family. The synthetic cannabinoids include various chemically diverse 
substances that act on the CB1 receptor and are mostly hallucinogenic along with some stimulant 
properties.
14
  
1.2.1. Opioid Receptor Subtypes 
There are three types of opioid receptors that were initially identified: µ, δ, and κ in the 
mid-1970s. These opioid receptors were named after the drugs used in the study of these 
receptors: mu or µ coming from morphine which is known to induce miosis, hypothermia, 
bradycardia and analgesia, delta or δ from deferens induces analgesia as significant potentiators 
of mu-agonists, and kappa or κ known from ketocyclazocine inducing sedation, flexor-
depression, miosis effects.
15
 In 1996, an alternative terminology was proposed by the 
International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature 
and Drug Classification (NC-IUPHAR) which was rejected, and later a reconstituted Opioid 
Receptor Nomenclature Subcommittee (ORNS) proposed a reversal to the original nomenclature 
along with adding further commendations to the opioid receptor family and nociceptin/orphanin 
FQ (N/OFQ), a receptor which is selectively activated by an endogenous ligand.
16
 All the opioid 
receptors are members of one family of proteins and can be grouped as a single receptor family. 
The differences in these receptors arise from the gene duplication events during evolution.
16
 The 
opioid receptors are G-protein coupled receptors (GPCRs) that are significant for the regulation 
of nociception, awareness, and mood. These opioid GPCRs are activated by various endogenous 
peptides and a number of small-molecule agonists, from interactions with the orthosteric site that 
13 
 
is located in the extracellular portion of the seven transmembrane (7TM) bundle.
17
 The following 
table gives a summary of the opioid receptors and their endogenous ligands.  
Table 1.1. Opioid receptors and their endogenous ligands
16,18,19,20,21
 
Opioid 
Receptors 
Other 
Nomenclature 
Endogenous 
Ligand(s) 
Agonists Antagonists 
µ, mu, or 
MOP 
MOR, OP3 
β-endorphin, 
enkephalins, 
endomorphin-
1, 
endomorphin-2 
 
 
 
 
δ, delta, or 
DOP 
DOR, OP1 
Enkephalins, 
β-endorphin 
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κ, kappa, 
or KOP 
KOR, OP2 
Dynorphin A, 
dynorphin B, 
α-
neoendorphin 
 
 
 
NOP ORL1, OP4  N/OFQ 
  
Opioid receptors are extensively distributed in the human body and are significantly 
involved in various physiological processes, which include pain signaling in the peripheral and 
central nervous systems, respiration, reproduction, immunological response, growth, opioid 
induced constipation or abdominal pain, and opioid induced bowel dysfunction. The amino acid 
sequences in these opioid receptors are roughly 60% identical, indicating their common origin.
18
 
1.2.2. Cannabinoid Receptor Subtypes 
The endocannabinoid system include two cannabinoid receptors: CB1 and CB2. CB1 
receptors are located in high density in various areas of the brain and mediates the behavioral 
effects of the endocannabinoids. CB1 and CB2 receptors are also members of GPCRs with a 
protein structure characterized by 7TM and a C-terminal domain which associates with arrestins 
or G-proteins.
22
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Table 1.2. Cannabinoid receptors and their endogenous ligands
22,23
 
Cannabinoid 
Receptors 
Endogenous 
Ligands  
Agonists  Antagonists  
CB1 2-AG 
 
 
 
CB2 2-AG  
 
 
 
 Other endogenous cannabinoid receptor ligands that were isolated include N-
arachidonoylethanolamine [anandamide], noladin ether,
24
 virodhamine,
25
 N-
arachidonyldopamine, and docosatetraenylethanolamide.
26
 Activation of CB1 receptors result in 
antinociception, decrease in body temperature and spontaneous activity, memory-disruption, and 
16 
 
catalepsy.
22
 Activation of CB2 receptors result in immunomodulatory properties without any 
psychotropic effects.
27
 
 
Figure 1.5. Chemical structures of cannabinoid receptor endogenous ligands, agonists, and 
antagonists
28,29 
1.2.3. Therapeutic Potentials of Opioid and Cannabinoid Receptor Modulators 
Opioids are the most ancient and potent drugs that are used in the treatment of severe, 
acute pain including cancer pain. However, the continued use of opioids in chronic non-
malignant pain includes the risks of abuse, addiction, and overdosage along with adverse side-
effects such as respiratory depression, cognitive deficit, constipation, dizziness, nausea, 
endocrinopathy, sedation, and cardiac arrhythmia.
30
 
Simultaneous activation of one or more opioid receptor types, selective target of hetero-
oligomers, and opioid ligands which differentially activate discrete intracellular signalling 
cascades are few approaches to limit the tolerance of chronic opioid administration. The design 
of novel heteromer selective antibodies, agonists, or antagonists will help modulate the receptor 
complexes, and evaluate the analgesic potency. The identification of the signalling pathways 
responsible for the heterologous desensitization, and the cellular adaptations under chronic 
morphine exposure along with the development of the bivalent agonists, might help in the 
development of novel drugs for the prevention of acute or chronic tolerance or to extend the 
analgesic efficacy.
31
 Partial agonists occupy the major portion of receptors compared to full 
17 
 
agonists in order to produce a response of equivalent magnitude. Mixed agonists/antagonists acts 
as agonists at low concentrations and antagonists at high doses. Such compounds exhibit high 
analgesic effects, and may produce acute withdrawal syndrome when administered with a pure 
agonist. All three opioid receptors facilitate analgesia with different side effects due to variable 
regional expression, functional activity of receptors, and plasticity in various parts of peripheral 
and central organ systems.
30
 
The characterization of the CB receptor-independent and CB receptor-dependent 
mechanisms could be helpful in the development of multi-targeted polypharmacological 
compounds for diseases involving multiple mechanisms, especially the neurodegenerative and 
neuropsychiatric diseases, where the endocannabinoid system dysregulation plays a significant 
role.
32
  
My research is focused on the role of natural products in drug discovery. Part of my 
research involved the investigation of psychoactive medicinal plants that targeted opioid and 
cannabinoid receptors. Banisteriopsis caapi is one of the psychoactive medicinal plants that 
exhibited activity against opioid and cannabinoid receptors. The coming sections will discuss the 
neurological disorders associated with not only opioid and cannabinoid receptors, but also 
monoamine oxidase (MAO) isoenzymes along with their current therapies, highlighting the role 
of opioid and cannabinoid receptors and MAOs in the pathogenesis of these neurological 
disorders. 
1.3. Neurological Disorders 
According to the 2010 Global Burden of Disease-study (GBD), the burden of substance 
use disorders and neurological disorders were individally estimated. Neurological disorders 
include disorders such as Parkinson’s disease, epilepsy, and dementia. Neurological disorders 
18 
 
accounted for 28.6% of disability adjusted life years, while substance use disorders accounted for 
14.7% Between the years of 1990 and 2010, absolute daily-adjusted life years (DALYs) for 
neurological, substance use, and mental disorders increased from 182 million to 258 million 
DALYs, accounting for 41% raise (Figure 1.7).
33
   
 
Figure 1.6. DALY rates of neurological, substance use, and mental disorders by region. 
Reprinted with permission from Whiteford, H. A.; Ferrari, A. J.; Degenhardt, L.; Feigin, V.; Vos, 
T. PLOS One, 2010, 10, e0116820. Copyright © 2015 Whiteford et al. [Open access article]   
1.4. Parkinson’s Disease (PD) 
PD is the second most common neurodegenerative disorder following Alzheimer’s 
disease (AD). In industrialized areas, PD affects 1% of all population over 60 years of age. The 
prevalence of PD is increasing over the years and is expected to double by 2030.
34
 The incidence 
of PD seen in high income countries is 14 per 100,000 people in total population and 160 per 
100,000 in people aged 65 years or older. In United States, the disease frequency was estimated 
to be 1.3% in females and 2% in males in individuals aged 40 years. The prevalence of age-
related PD is lower in Africa than in the Americas and Europe, which reflects both mortality and 
19 
 
incidence, while the incidence in Asia is similar to that in the Americas and Europe. The 
incidence of PD is usually low in people below 50 years of age, and increases rapidly with age.
35
   
1.4.1. Pathogenesis 
PD is one of the common central nervous system (CNS) neurodegenerative disorders. 
The core pathology of PD includes the loss of dopaminergic nigral neurons and the formation of 
α-synuclein containing Lewy bodies.36 Genetic mutations and environmental toxins are 
considered to be some of the etiological triggers that are linked to PD, with an unknown pathway 
leading to cell-death. The most common pathway underlying in both the sporadic and genetic 
forms of the disorder, is the defective dopamine sequestration into the vesicles, resulting in the 
production of the reactive oxygen species in cytoplasm. This is the primary reason for the death 
of dopaminergic neurons in PD.
37
 
There are various pathogenic mechanisms resulting in the loss of dopaminergic neurons 
in PD. The first neurodegenerative change in PD is the loss of terminals in the striatum, followed 
by the accumulation of the aggregated proteins, Lewy neurites, in the nigral processes. The Lewy 
body like inclusions in the nigrostriatal terminals are accompanied by retrograde degeneration, 
and further accumulation of Lewy bodies, resulting in reactive gliosis and cell death. There are 
only three known mutant proteins resulting in PD among several monogenic familial forms: α-
synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1). The mutations in α-
synuclein results in the loss of normal function, and toxic effects of altered forms, thereby 
promoting dopamine accumulation in the cytoplasm. This would primarily lead to oxidative 
stress at nigrostriatal terminals where dopamine is synthesized and stored, triggering the above 
mentioned neurodegenerative changes. Mutations in parkin and UCHL1 promote buildup of 
dopamine in the cytoplasm by decreasing the clearance of α-synuclein toxic forms, which could 
20 
 
penetrate vesicles and result in the escape of small molecules like dopamine into the cytoplasm. 
Hence, the role of α-synuclein is evident in the recycling of synaptic vesicles, thereby resulting 
in the accumulation of the cytoplasmic dopamine, which is the final detrimental event causing 
the death of nigral dopaminergic neurons in PD.
37
 
 
Figure 1.7. A common pathway leading to nigral degeneration in PD. The terms highlighted in 
green and purple arrows represent the deleterious processes that lead to cell-death. The mutations 
in the genes for α-synuclein (PARK1), parkin (PARK2), and ubiquitin carboxy-terminal 
hydrolase L1 (PARK5) and defects in ubiquitin-proteasome pathway (UPP) result in dopamine 
accumulation in the cytoplasm. Reprinted with permission from Lotharius, J.; Brundin, P. Nat. 
Rev. Neurosci. 2002, 3, 932-942. Copyright © 2002 Nature Publishing Group. [Permission# 
4200060836415] 
Dopamine is synthesized in the cytoplasm and then sequestered to the monoaminergic 
vesicles. If unstored, dopamine will be auto-oxidized to superoxide radical [O2*
-
], hydrogen 
peroxide (H2O2), and dopamine-quinone which is a cytotoxic by-product of dopamine. 
Alternatively, it can be oxidized by MAO to H2O2 and 3,4-dihydroxyphenylacetic acid 
21 
 
(DOPAC), an inert metabolite. Presynaptic terminals are enriched with α-synuclein, where 50% 
is cytosolic and the other 50% is associated with the synaptic membranes. The secondary 
structure of α-synuclein is converted from predominant random coil to 83% α-helix when bound 
to phospholipid membranes. Mutation in Ala30Pro results in the impairment of the ability of the 
protein to bind to small phospholipid vesicles, while the mutation in Ala53Thr prevents its 
coalition with planar lipid membranes. α-synuclein has a significant neuronal function of 
regulating the synaptic vesicles formation through phospholipase D2 (PLD2) interactions from 
early endosomes. Mutations in α-synuclein could reduce the number of vesicles necessary for 
dopamine storage, resulting in dopamine accumulation in the cytoplasm, and thereby, increasing 
the oxidative stress levels.
37
 
    
 
 
 
 
 
 
 
 
 
Figure 1.8. α-synuclein and intracellular dopamine storage. Reprinted with permission from 
Lotharius, J.; Brundin, P. Nat. Rev. Neurosci. 2002, 3, 932-942. Copyright © 2002 Nature 
Publishing Group. [Permission# 4200060836415] 
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Dopamine metabolism can result in the formation of various cytotoxic molecules 
including hydroxyl radicals [OH*], superoxide anions [O
2
*
-
], and dopamine-quinone species 
[SQ*]. The breakdown of dopamine occurs spontaneously in the presence of iron, or is catalyzed 
by MAO in a reaction which generates H2O2. Though cells are not damaged by H2O2, the 
formation of hydroxyl radicals by Fenton reaction can result in cytotoxicity. In general, these 
cells use various antioxidant systems to scavenge these deleterious molecules. Glutathione 
(GSH) peroxidase uses reduced glutathione to detoxify the H2O2, while the oxidized glutathione 
(GSSG) is reduced by GSSG reductase and is reused. The electrophilic centers of several 
potentially toxic compounds are converted to thioether bonds by GSH-S-transferase. Superoxide 
is coverted to H2O2 by superoxide dismutase, while catalase converts H2O2 to molecular oxygen 
and water. The balance between the production and elimination due to an abnormal increase of 
reactive oxygen species is tilted in PD, resulting in an enhanced oxidative stress.
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Figure 1.9. a. Metabolism of dopamine in normal person. b. Pathogenesis in PD. Reprinted with 
permission from Lotharius, J.; Brundin, P. Nat. Rev. Neurosci. 2002, 3, 932-942. Copyright © 
2002 Nature Publishing Group. [Permission# 4200060836415] 
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1.4.2. Risk Factors 
There is an increased risk in developing parkinsonism or PD from contact with toxic 
environmental substances such as agricultural chemicals or drinking well-water, and specific 
living conditions such as farming and rural living. Environmental factors such as metals, 
herbicides, and pesticides result in increased levels of α-synuclein in the brain, thereby causing 
parkinsonian symptoms. Evidence showed the presence of an insecticide, dieldrin, which is a 
lipid-soluble, long lasting mitochondrial poison in patients with PD. Further evidence showed 
that PD is associated with the exposure to pesticides, resulting in the impairment of the 
mitochondrial function by inhibition of the mitochondrial complex I or by increase in oxidative 
stress.
38
   
1.4.3. Diagnosis 
Patients with PD experience both nonmotor and motor symptoms. The motor symptoms 
of PD include rigidity, tremor, bradykinesia, and postural instability, while the nonmotor 
symptoms include depression, autonomic dysfunction, sleep disorders, and olfactory 
disturbances.
38
 Parkinsonian disorders can be categorized into four different types: 
primary/idiopathic parkinsonism, secondary/acquired/symptomatic parkinsonism, 
heredodegenerative parkinsonism, and multiple system degeneration which includes 
parkinsonism along with its syndromes. Several features of PD such as tremor, postural 
instability, early gait abnormality such as freezing, response to levodopa, and pyramidal tract 
findings differentiate it from other parkinsonian disorders. There will be differences in the 
postsynaptic dopamine receptor density in patients with PD, which would result in poor response 
to levodopa therapy. Recent positron emission tomography (PET) imaging studies also showed 
relative preservation of dopamine receptors in progressive supranuclear palsy (PSP), proposing 
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downstream changes as probable mechanism for lack of response. Excellent initial responses are 
seen in patients with multiple systems atrophy (MSA), but they often develop levodopa related 
orofacial dyskinesias and the antiparkinsonian efficacy is lost. Although levodopa improvement 
differentiates PD, it does not distinguish PD with other parkinsonian disorders. Sub-cutaneous 
injection of apomorphine is used to distinguish PD from other parkinsonian disorders; 
nonetheless, this is not a superior test compared to levodopa therapy and contributes less to 
diagnostic evaluation.
39
 
Neuroimaging techniques are also useful to differentiate PD from other parkinsonian 
disorders. Prospective imaging studies include [
18
F]-fluorodopa PET, [
11
C]-raclopride imaging of 
D2 dopamine receptors, single photo emission tomography of the striatal dopamine reuptake 
sites, and high 1.5 T field strength heavily T2 weighted magnetic resonance imaging (MRI). One 
of the studies suggested that the brain parenchyma sonography could be highly specific for the 
differentiation of PD from atypical parkinsonism, but abnormal hyperechogenicity is also seen in 
both PD and essential tremor. Though these neuroimaging techniques are promising, there is the 
need for further improvement and resolution in sensitivity before their diagnostic potential is 
completely realized.
39
      
 
Figure 1.10. Chemical structures of levodopa, [
18
F]-fluorodopa, and [
11
C]-raclopride 
1.4.4. Current Therapies   
There is no cure for PD. Motor symptoms are clinically the major features of PD onset 
and progression. Since the 1960s, the treatment of PD has been focused on the supplement or  
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replacement of dopamine (DA). Currently, there are two major approaches in improving the 
dopaminergic activity in the brain: using exogenous agents to augment the secretion of dopamine 
and to target the related neurotransmission pathways.
40
 The most effective treatment to-date is 
levodopa that benefits almost all the PD patients; however, the long term use of levodopa could 
result in motor complications, such as levodopa-induced dyskinesia (LID), “on-off”, and 
“wearing-off” phenomena that can result in mild and non-disabling to incapacitating. Advanced 
stage PD patients have their motor complications emerged, and need a modified dosage, change 
in levodopa formulation, and combination with other drug treatments.
41
 These include MAO-B 
inhibitors (rasagiline, selegiline, and safinamide), catechol-O-methyltransferase (COMT) 
inhibitors (entacapone, tolcapone), DA receptor agonists (apomorphine), anticholinergics 
(orphenadrine, trihexyphenidyl, procyclidine), and  amantadine. Unfortunately, some of these 
drugs have some serious complications. Apomorphine shows the development of 
neuropsychiatric complications such as impulse control disorders, severe nausea, and vomiting. 
COMT inhibitors such as tolcapone exhibit life-threatening hepatotoxicity along with 
gastrointestinal symptoms. Amantadine could be used in early or late PD but its effects may 
wane with time, while the use of anticholinergics is limited due to their cognitive side effects.
40
 
Figure 1.11. Chemical structures of rasagiline, selegiline, safinamide, entacapone, tolcapone, 
apomorphine, orphenadrine, trihexyphenidyl, procyclidine, and amantadine. 
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1.4.5. Agents Under Investigation   
Since there is no cure for PD, the treatment for PD is aimed at treating the symptoms. 
Amino acid decarboxylase catalyzes L-Dopa to dopamine in the pre-synapse. DA is then released 
into the synaptic cleft, where it binds to D1-like [D1 and D5] and D2-like [D2, D3, and D4] 
receptors. In the glia cells, DA is metabolized to 3-methoxytyramine (3-MT) by COMT or to 
DOPAC by MAO-B isoenzyme. Dopamine transporters can also reuptake DA into the pre-
synapse. Hence, the treatment options include L-Dopa, D1-like and D2-like dopamine agonists, 
COMT-, and MAO-B inhibitors. Figure 1.13 shows the various stages at which the PD drugs are 
targeted.
42
  
 
Figure 1.12. Current and investigational agents for the treatment of PD. Reprinted with 
permission from Oertel, W.; Schulz, J. B. J. Neurochem. 2016, 139, 325-337. Copyright © 1999-
2017 John Wiley & Sons, Inc. [Permission# 4200061422503] 
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Table 1.3 shows the examples of drugs that are in various phases of clinical trials for PD. 
The drugs that are in the development for PD include adenosine 2a receptor (A2A) receptor 
antagonists, alpha-2 adrenergic receptor antagonists, glutamate receptor-5 antagonists, mixed 
action drugs, gene therapy, and neuroprotective targets. A2A receptor antagonists enhances the 
motor function by inhibiting the γ-amino butyric acid (GABA) release. Alpha-2 adrenergic 
receptor antagonists help in the management of dyskinesias, since the depletion of noradrenergic 
neurones is an additional component in the pathophysiology of PD. Overactivity of glutamate 
receptor-5 antagonists is linked with levodopa-induced dyskinesia and PD symptoms.
40, 43
     
Table 1.3. PD drugs under development in the pipeline. 
Structure/Name FDA Status Target 
 
Phase III 
A2A receptor 
antagonist 
 
Phase III 
A2A receptor 
antagonist 
 
Phase I 
A2A receptor 
antagonist 
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Unknown 
A2A receptor 
antagonist 
 
Phase II 
Alpha-2 
adrenergic 
receptor 
antagonist 
 
Phase II 
Glutamate 
receptor-5 
antagonist 
Table 1.4 represents the compounds that were discontinued from various phases of 
clinical trials for the treatment of PD. Preladenant is a non-xanthine A2A antagonist. Preladenant 
was orally active and exhibited good pharmacokinetic (PK) properties and excellent in vivo 
activity against parkinsonian symptoms. Preladenant was discontinued after phase III clinical 
trials due to the lack of evidence regarding its efficacy compared with placebo. Vipadenant is 
another non-xanthine compound that exhibited good oral bioavailability along with brain 
penetration and long plasma half-life. Despite promising phase II trials, vipadenant was 
discontinued in June 2010 by Vernalis and Biogen.
43
 Although pardoprunox was effective in 
early PD, it was discontinued due to tolerability issues.
40
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Table 1.4. Discontinued PD drugs.
43
   
Structure/Name FDA Status Target 
 
Discontinued 
after phase III 
A2A receptor 
antagonist 
 
Discontinued 
after Phase III 
A2A receptor 
antagonist 
 
Discontinued 
after phase III 
Partial 
dopamine [D2, 
D3] agonist and 
full serotonin 
receptor 
agonist 
[5HT1A] 
1.5. Monoamine Oxidases 
Over the past decade, the focus of MAOs has increased tremendously in the drug-
discovery and development efforts. The human MAO is tightly linked with the outer 
mitochondrial membrane encoded with distinct genes on the X-chromosome. Human MAO is 
characterized into two subtypes: MAO-A and MAO-B. MAOs are specialized flavin adenine 
dinucleotide [FAD] dependent enzymes, which catalyze the oxidative deamination reaction of 
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endogenous, dietary and xenobiotic amines. There are approximately 90 members in the human 
flavoproteome, of which MAO-A and –B are two of the six enzymes which are linked covalently 
through a flavin cofactor. Only MAO and L-pipecolate oxidase have FAD linked to the 8α-
methyl position of flavin through a cysteine-modified residue. MAO catalyzes the 
enantiospecific pro-R α-carbon oxidation of amine substrates to the imine products that usually 
undergo hydrolysis in order to produce an amine, aldehyde, and H2O2. H2O2 is a by-product of 
oxygen utilization through flavin regeneration.
44
 
There are 5 crystal structures for MAO-A and 38 crystal structures for MAO-B since 
2002 which help reveal the differences in the active site and substrate binding architectures in 
both MAOs. MAO-A and –B share about 70% sequence homology, with structural differences 
that would highly affect their functional specificity towards the inhibitor or substrate 
accomodation and catalysis. Human MAO-A crystallizes as a monomer, while human MAO-B 
crystallizes as a dimer. Human MAO-A has a monopartite cavity with a volume that extends to 
550 Å along with an extended entrance conformation [residues 108-118]. The critical residues 
for ligand selectivity in MAO-A are Phe208–Ile335 but Phe208 is not known to function as a 
gating residue. The surrounding protein region of the active site in both the MAOs are 
hydrophobic in nature.
44
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Figure 1.13. Crystal structure of human MAO-B. Reprinted with permission from Youdim, M. 
B. H.; Bakhle, Y. S. Br. J. Pharmacol. 2006, 147, S287-S296. Copyright © 2017 The British 
Pharmacological Society. [Permission# 4200070173884] 
MAO-B crystallizes as a dimer and includes a bipartite cavity with a distinct substrate 
and entrance cavities. The entrance cavity is hydrophobic in nature and is approximately 290 Å 
in volume and is covered by residues 99-112 as an entrance loop. The larger substrate cavity is 
approximately 420 Å in volume, and extends to the entrance cavity from the flavin cofactor. 
Ile199 and Tyr326 are the amino acids that function as gating residues between the substrate and 
entrance cavities and are significant for both inhibitor and substrate recognition. The aromatic 
cage region in MAO-A is formed by Tyr407/Tyr444, while Tyr398/Tyr435 residues form the 
cage in MAO-B. These residues are perpendicular to the isoalloxazine ring that is covalently 
linked, and forms a ‘bent’ conformation.   
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Figure 1.14. Differences in the human MAO-A and MAO-B architectures. Reprinted with 
permission from Chajkowski-Scarry, S.; Rimoldi, J. M. Future Med. Chem. 2014, 6, 697-717. 
Copyright © 2017 Future Science Group. [Permission# 4200681286869] 
1.6. Monoamine Oxidases as PD Targets 
MAOs are the key enzymes that are involved in the catalysis of the major inactivation 
pathway of catecholamine neurotransmitters such as dopamine, noradrenaline, and adrenaline 
along with 5-hydroxytryptamine as well. The initiation and progress of neurodegeneration 
depends on the augmented levels of oxidative-stress in the brain. Selective inhibition of MAOs 
in the brain contribute significantly in decreasing such stress. There are complex interactions 
undergoing between the MAOs and the free levels of iron in brain that may result in practical 
outcomes for depressive disorders. The concept of neuroprotection has been generated based on 
the clinical observations and consequent pharmacological analysis, reflecting the possibility of 
halting, slowing, maybe reversing of neurodegeneration in PD or AD. These aspects of MAOs 
and their inhibition indicates the importance of this pharmacological area and their 
therapeutics.
45
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1.6.1. MAO-B as a Target for PD 
Iproniazid was the original MAO inhibitor that was effectively used in the treatment of 
depression, until its clinical value was negotiated due to side-effects. Due to its hydrazine 
structure, iproniazid caused liver toxicity. This problem was overcomed by the development of 
other non-hydrazine MAO inhibitors like tranylcypromine, but these induced another significant 
side-effect called the ‘cheese reaction’.45  
 
Figure 1.15. Chemical structures of iproniazid and tranylcypromine 
Tyramine and other indirectly acting sympathomimetic amines present in certain foods 
such as cheeses and fermented drinks like wine and beer induce the cheese reaction. Dietary 
amines are metabolized in the liver and gut-wall by MAO under normal circumstances, and 
prevent them from entry into the systemic circulation. But in the presence of MAO inhibitors, 
this protective system is disturbed and so, tyramine and other monamines are not metabolized 
and hence enter the circulation; thereby releasing noradrenaline from peripheral adrenergic 
neurons, resulting in the release of severe hypertensive response, which could be fatal in certain 
cases. These serious side-effects discouraged the use of MAO inhibitors as antidepressants and 
paved way into looking into other areas.
45
  
34 
 
 
Figure 1.16. The ‘cheese reaction’. Reprinted with permission from Youdim, M. B. H.; Bakhle, 
Y. S. Br. J. Pharmacol. 2006, 147, S287-S296. Copyright © 2017 The British Pharmacological 
Society. [Permission# 4187860840706] 
The use of MAO inhibitors for the treatment of depressive disorders declined sharply 
after the realization of serious cardiovascular reactions due to ‘cheese effect’; the fact that 
selective MAO-B inhibition does not cause cheese effect has facilitated the development of 
selective MAO-B inhibitors for the symptomatic treatment of PD. Three selective MAO-B 
inhibitors namely selegiline, rasagiline, and safinamide are the currently approved FDA drugs 
that are used for the symptomatic treatment of PD. Hence MAO-B inhibitors have projected 
these drugs in the drug therapy of PD due to the potential of this group of drugs in the treatment 
of other neurodegenerative disorders.
46
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1.7. Summary 
Natural products are the most effective source of various drug leads. Artemisinin and 
taxol are examples of successful compounds which have been isolated from natural sources 
(plants). Natural products continue to provide wide structural diversity which is higher than any 
other source, and offer the opportunities of finding new lead compounds which are active against 
various biological targets. Less than 10% of the world’s diversity has been explored so far and 
so, there are more natural lead compounds that are awaiting discovery. Due to the continued 
need for novel drug-like leads against various challenging biological targets, the chemical 
diversity from natural products are relevant for the future of drug-discovery.    
The opium poppy is an ancient medicinal plant that is the major source for narcotic 
analgesics. The most common treatment for severe, chronic pain are opium alkaloids like 
morphine and similar drugs. But opioid drugs are known for their detrimental and unpleasant 
side effects. Hence, there is the need to develop novel agents for the management of neuropathic 
pain with fewer or no adverse-effects. We ultimately aim to identify new compounds with 
selective affinity for opioid and cannabinoid receptors. In Chapter 2, we describe the isolation 
and structural characterization of the secodary metabolites from Banisteriopsis caapi with 
radioligand displacement values to opioid and cannabinoid receptors. Radioligand displacement 
studies for opioid receptor subtypes and cannabinoid receptor subtypes were performed on the 
active fractions and purified bioactive compounds. 
There is the need to develop new MAO inhibitors that are selective to MAO-B along with 
potency and minimal side-effects. We ultimately aim to develop new PD drugs targeting MAO-B 
with no or minimal selectivity to MAO-A. MAO inhibition assays, enzyme kinetics and 
mechanism studies, time-dependent enzyme inhibition assay, and analysis of inhibitor binding 
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and reversibility with MAO-A and –B studies were performed on the purified bioactive 
compounds, following which molecular modeling studies were carried out to support our data. In 
Chapter 3, we describe the isolation and structural elucidation of secondary metabolites from 
Calea urticifolia with potent inhibition of MAOs. In Chapter 4, we present the molecular 
modeling studies on acacetin, a bioactive compound isolated from C. urticifolia, along with the 
design of selective MAO-B inhibitors. Finally, Chapter 5 demonstrates the syntheses and the 
biological results of the designed MAO-B inhibitors.   
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CHAPTER 2. ISOLATION AND STRUCTURAL ELUCIDATION OF BIOACTIVE 
SECONDARY METABOLITES FROM BANISTERIOPSIS CAAPI 
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2.1. Introduction 
Banisteriopsis caapi belongs to the family Malpighiaceae and is native to South America. 
B. caapi is known by the common names ayahuasca, yajé, natemä and caapi.
47
 The ayahuasca 
decoction which has B. caapi as the major constituent along with Psychotria viridis is a 
traditional drink used by the ethnic groups for medicinal, recreational, and ritual purposes.
48
 B. 
caapi is known to be a rich source of harmine and tetrahydroharmine, with harmaline to a lesser 
extent, which are indole alkaloids with a carboline moiety. In South America, this ceremonial 
beverage is known to be the spiritual core of various indigenous religions. The known medicinal 
properties include anthelmintic, vasorelaxant and antimicrobial properties along with 
ethnopsychiatric, rehabilitative, and sociopsychotherapeutic functions.
47
 The known properties 
along with our discovery of the affinity for opioid receptors by the crude extracts of B. caapi, led 
to the phytochemical study of this plant.  
There are several reports on the isolation and activity of various constituents of B. 
caapi
47, 49,50
 but none on its binding ability to the opioid receptors. Hence, we focused on the 
receptor binding ability of B. caapi to the opioid receptors: µ, κ, and δ. 
 
Figure 2.1. Chemical reduction of the major constituents during the decoction process 
2.1.1. Specific Aims of the Research 
Various efforts have been made to reduce addiction and increase the efficiency of 
morphine or codeine. Attempts are still being continued to reduce the abuse potential of these 
traditional agents. However, despite its disadvantages, the opioid receptors still play an important 
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role in health care and hence we focused on Banisteriopsis caapi, a plant native to the South 
America, which in our lab showed promising results in its binding ability to the opioid receptors. 
The plant was not screened previously for this ability and therefore we focused on identifying the 
compound(s) responsible for its opioid-receptor binding in order to determine the structure-
activity relationship (SAR) and synthesize new analogs of the bioactive secondary metabolites. 
In order to achieve the above goals, the following specific aims were considered: 
1. To fractionate the crude methanolic extract of B. caapi and separate various constituents by 
means of polarity or nature of the compounds using bioassay-guided fractionation 
2. To purify all the secondary metabolites present in the active fractions and the structural 
elucidation of the purified compounds  
3. To perform radioligand displacement binding affinity studies for opioid and cannabinoid 
receptors on the purified bioactive compounds   
2.2. Screening for Neurological Disorders 
The isolation of B. caapi was carried out in our lab along with other plants including 
Rhamnus purshiana, Arctostaphylos uva-ursi and Acacia xanthophloea, among others. The dried 
extracts of these plants were assayed for opioid/cannabinoid activity and MAO inhibition. The 
ethanolic (EtOH) extract of B. caapi showed promising activity against opioid receptors and the 
following results were obtained as shown in Table 2.1. This activity was compared to the 
available literature on the plant, B. caapi, and was observed that the opioid activity has not been 
previously reported. Hence, the current idea of taking this research further and determining the 
responsible compound(s) for the receptor-binding, isolating them, and improving their binding 
affinities through synthesis of analogs, and performing a SAR analysis, could lead to the 
discovery and development of potentially novel therapeutic agents.  
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Table 2.1. Radioligand displacement binding affinity of various plant extracts 
Sample Name 
Sample 
Type 
CB2  
%Inhibition  
Delta 
%Inhibition 
Kappa 
%Inhibition 
Mu 
%Inhibition 
Banisteriopsis 
caapi 
Leaves  28.8 79.1 64.9 73.0 
Rhamnus 
purshiana 
Bark - 30.0 - 20.9 
Arctostaphylos 
uva-ursi 
Leaves 8.0 0.5 - 23.9 
Acacia 
xanthophloea 
Root - 24.8 - 27.6 
Verbascum 
densiflorum 
Aerial 
part 
41.0 39.7 30.9 42.7 
Rubus idaeus Leaves 27.2 24.9 31.1 - 
Datura stramonium Seed 27.1 49.6 21.6 55.5 
Hyoscyamus niger Seed  24.8 27.1 - 9.5 
Nerium oleander 
Aerial 
part 
- 14.5 23.1 - 
Passiflora caerulea 
Aerial 
part 
- 58.9 25.3 48.6 
*Concentrated at 1mg/mL and dissolved in DMSO 
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2.3. Results and Discussion 
2.3.1. Bioassay Guided Fractionation of B. caapi 
The dried leaves of B. caapi are extracted with EtOH for at least 3 times and dried. The 
dried EtOH extract was divided into two equal portions and two different methods were 
employed to find better yield and activity. The first portion was subjected to organic treatment 
that includes successive extraction with hexane (Hex), dichloromethane (CH2Cl2), ethyl acetate 
(EtOAc), methanol (MeOH), and aqueous methanol. This extraction was done based on polarity 
and the dried portions were assayed for opioid-binding activity. The second portion of the dried 
EtOH extract was dissolved in MeOH: water (8:2), acidified with 1N HCl, and subjected to 
liquid-liquid partition with chloroform  (CHCl3) for 3 times, which yielded an organic and an 
aqueous portions. The aqueous layer was subjected to alkalinization using ammonium and was 
subjected to liquid-liquid extraction with CHCl3 for at least 3 times. The organic layer was dried 
with sodium sulfate and dried in a rotavapor at low pressure. The organic layer was known to 
contain the alkaloids while the rest (like tannins) were seen in the aqueous layer. The obtained 
extracts were then assayed for opioid receptor binding affinities. 
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Figure 2.2. Isolation procedure of various extracts of B. caapi 
The first portion of the dried EtOH extract was subjected to fractionation using silica gel 
column with 100% Hex increasing the polarity with EtOAc and MeOH and submitted for 
bioassay. The 50:50 Hex-EtOAc fraction showed the best radioligand displacement binding 
affinity [Table 2.2] for both cannabinoid and opioid receptors.  
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Table 2.2. Radioligand displacement binding affinity of B. caapi fractions 
Fraction 
CB1 
%Inhibition 
CB2 
%Inhibition 
Delta 
%Inhibition 
Kappa 
%Inhibition 
Mu 
%Inhibition 
100% Hex 22.6 26.8 - 6.9 1.5 
3:1 Hex-EtOAc 37.9 66.7 39.4 29.9 10.5 
1:1 Hex-EtOAc 86.0 86.9 79.3 55.8 62.9 
1:3 Hex-EtOAc 39.8 64.5 60.8 39.1 35.5 
 100% EtOAc 35.3 54.8 36.3 22.7 17.3 
9:1 EtOAc-
MeOH 
34.1 57.3 55.6 25.9 28.6 
3:1 EtOAc-
MeOH 
47.3 51.1 44.2 34.3 39.8 
 100% MeOH 64.4 43.8 30.3 15.6 19.5 
*Concentrated at 1mg/mL and dissolved in DMSO 
Based on the radioligand displacement values [Table 2.2], the 50:50 Hex-EtOAc fraction 
(2.6280g) was further subjected to bioassay-guided fractionation using CH2Cl2, Hex, EtOAc, and 
MeOH with increasing polarity and submitted for bioassay. The 9:1 CH2Cl2-EtOAc fraction 
showed the best radioligand displacement [Table 2.3] for both cannabinoid and opioid receptors. 
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Table 2.3. Radioligand displacement binding affinity of B. caapi fractions 
Sample Fraction 
CB1 
% 
Inhibition 
CB2 
% 
Inhibition 
Delta 
% 
Inhibition 
Kappa 
% 
Inhibition 
Mu 
% 
Inhibition 
A 1:1 CH2Cl2-Hex 13.8 27.2 - - 6.6 
B 4:1 CH2Cl2-Hex 22.0 33.9 - 1.8 2.8 
C 100% CH2Cl2 44.3 53.9 - 13.7 31.9 
D 19:1 CH2Cl2-EtOAc 66.7 56.6 44.8 24.9 37.7 
E 9:1 CH2Cl2-EtOAc 91.4 92.2 85.9 61.6 69.9 
F 4:1 CH2Cl2-EtOAc 30.3 72.5 86.4 46.9 63.1 
G 7:3 CH2Cl2-EtOAc 61.7 65.9 66.1 49.5 41.4 
H 3:2 CH2Cl2-EtOAc 52.1 59.6 36.5 19.9 42.9 
I 1:1 CH2Cl2-EtOAc - 52.7 56.8 19.1 26.8 
J 2:3 CH2Cl2-EtOAc 32.9 70.1 65.9 35.0 34.9 
K 100% EtOAc 48.0 71.1 72.8 45.2 41.4 
L 9:1 EtOAc-MeOH 66.0 55.9 85.5 45.6 56.9 
M 100% MeOH 15.3 17.1 38.8 8.7 10.4 
*Concentrated at 1mg/mL and dissolved in DMSO
Based on the radioligand displacement values [Table 2.3], the 9:1 CH2Cl2-EtOAc and 8:2 
CH2Cl2-EtOAc fractions (1.1960 g) were combined and subjected to bioassay-guided 
fractionation using CH2Cl2 and EtOAc that resulted in 12 sub-fractions that showed the 
following radioligand displacement values [Table 2.4] towards opioid and cannabinoid 
receptors. 
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Table 2.4. Radioligand displacement binding affinity of B. caapi sub-fractions 
Fraction # 
CB1 
%Inhibition 
CB2 
%Inhibition 
Delta 
%Inhibition 
Kappa 
%Inhibition 
Mu 
%Inhibition 
EF 1 BC 47.7 84.4 50.0 7.2 34.0 
EF 2 BC 16.5 65.6 - 3.2 2.6 
EF 3 BC 81.7 114.4 75.7 58.1 85.0 
EF 4 BC 69.8 64.8 58.9 30.8 76.6 
EF 5 BC 55.6 109.4 94.2 39.1 89.0 
EF 6 BC 48.0 108.5 72.4 59.5 53.6 
EF 7 BC - 61.5 30.3 0.7 33.4 
EF 8 BC 14.5 30.9 30.5 15.6 41.4 
EF 9 BC 28.2 10.9 89.7 14.3 46.9 
EF 10 BC 4.1 33.2 38.4 4.5 52.6 
EF 11 BC 20.5 14.8 26.6 38.3 76.5 
EF 12 BC 37.9 6.6 - - 16.2 
*Concentrated at 1mg/mL and dissolved in DMSO
The sub-fraction EF 3 BC (538 mg) showed interesting radioligand displacement values 
towards both opioid and cannabinoid receptors and hence was chosen for further fractionation. 
Sub-fraction 3 was subjected to gradient fractionation using Hex and EtOAc that yielded eight 
sub-fractions with the following radioligand displacement values towards opioid and 
cannabinoid receptors [Table 2.5]. 
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Table 2.5. Radioligand displacement binding affinity of B. caapi sub-fraction 3 
Fraction # 
CB1 
%Inhibition 
CB2 
%Inhibition 
Delta 
%Inhibition 
Kappa 
%Inhibition 
Mu 
%Inhibition 
EF 3.1 12.9 42.66 18.79 - 6.79 
EF 3.2 33.5 48.80 - - - 
EF 3.3 71.9 89.20 24.94 7.12 26.51 
EF 3.4 80.1 78.10 63.93 44.05 53.82 
EF 3.5 97.0 89.55 91.00 95.42 89.01 
EF 3.6 79.0 82.80 58.84 60.70 55.64 
EF 3.7 52.5 80.77 86.45 61.94 100.0 
EF 3.8 13.3 63.40 63.68 1.20 34.99 
*Concentrated at 1mg/mL and dissolved in DMSO
Fractions 3.3 and 3.4 were combined and subjected to fractionation. These fractions 
along with 3.5, 3.6, and 3.7 were also subjected to fractionation and were assayed for radioligand 
displacement values towards opioid and cannabinoid receptors. DE 1, DE 2, DE 3, DE 5, and DE 
4.1 showed the best radioligand displacement value towards CB2 cannabinoid receptor [Table 
2.6]. 
Table 2.6. Radioligand displacement binding affinity of B. caapi sub-fractions 
Fraction 
CB1 
%Inhibition 
CB2 
%Inhibition 
Delta 
%Inhibition 
Kappa 
%Inhibition 
Mu 
%Inhibition 
BC 3.6 AD 1 19.2 56.4 - - - 
BC 3.6 AD 2 11.5 15.0 10.8 - - 
BC 3.6 AD 4 - 4.4 13.6 - 13.8 
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BC 3.6 AD 5 - 3.4 - - - 
BC 3.6 AD 6 11.4 18.6 - 0.7 - 
BC 3.6 AD3 A1 2.0 1.9 10.9 - 2.8 
BC 3.6 AD3 A2 5.1 2.9 6.7 - 2.9 
BC 3.6 AD3 A3 9.6 2.5 4.5 2.5 3.4 
BC 3.6 AD3 B1 - - 7.4 - - 
BC 3.6 AD3 B2 - - 3.7 - 1.2 
BC 3.6 AD3 B3 - - 3.2 - 6.8 
BC 3.6 AD3 C1 6.3 1.0 - 1.2 11.5 
BC 3.6 AD3 C2 10.6 12.2 14.7 - - 
BC 3.6 AD3 C3 9.4 4.6 4.2 - - 
BC 3.6 AD3 D1 11.6 3.3 - - 0.4 
BC 3.6 AD3 D2 17.5 3.1 4.6 - 9.3 
BC 3.6 AD3 E 9.3 - - - - 
BC 3.6 I1 - - - - - 
BC 3.6 I2 - - - - - 
BC 3.6 I3 6.2 24.1 0.3 14.0 - 
DE 1 54.9 78.7 - 7.8 5.6 
DE 2 45.9 75.1 - - 16.9 
DE 3 38.2 77.8 - 7.2 5.2 
DE 5 30.2 72.2 24.1 - 32.2 
DE 4.1 44.6 79.5 - - 1.8 
DE 4.2 15.3 28.8 - - - 
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DE 4.3 - 9.7 - - 3.1 
DE 4.4 11.0 30.5 - - 6.7 
DE 4.5 74.6 75.4 78.5 62.2 75.4 
DE 4.6 - 7.4 - 2.5 - 
DE 4.7 - - - 12.0 - 
DE 4.8 2.8 11.6 15.5 - 21.3 
DE 4.9 34.4 71.5 73.9 51.8 70.9 
DE 4.10 30.9 44.9 59.1 25.7 56.4 
DE 4.11 10.5 14.7 32.9 26.0 36.2 
DE 4.12 - 8.7 9.5 11.0 12.1 
BC 4.4.1 10.7 34.4 - - - 
BC 4.4.2 67.8 68.1 90.4 63.8 87.4 
BC 4.4.3 11.0 17.3 9.0 10.2 42.9 
BC 4.4.5 13.2 33.6 44.9 15.6 39.3 
BC 4.4.6 9.6 24.4 27.4 - 14.0 
BC 4.4.8 - 1.9 - - 4.8 
BC 4.4.9 - - - - 19.7 
: False positives [chlorophyll] 
2.3.2. Molecular Structural Elucidation of Active Constituents 
The structural elucidation of the active constituents was carried out based on a 
combination of spectrometric and spectroscopic experiments that include High Resolution Mass 
Spectroscopy (HRMS) and multidimensional nuclear magnetic resonance (NMR) Spectroscopy. 
To elucidate the structure of unknown chemical compounds, NMR spectroscopy is considered to 
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be the most powerful tool.
51
 The planar structures of the new constituents are deduced from the
1
H-, 
13
C- and 2D-NMR spectroscopic analyses. 
1
H- 
1
H- Correlation Spectroscopy (COSY) is
used to determine the proton spin systems, while the Heteronuclear Multiple Quantum 
Correlation (HMQC) and Heteronuclear Multiple Bond Correlation (HMBC) 2D-NMR 
techniques are used to establish the single and multiple-bond connectivity. HMQC and HMBC 
are both proton-detected proton-carbon experiments but the former represents one bond 
correlations between carbons and protons while the later represents two and three bond 
correlations. HMBC experiments are considered powerful as the data is acquired with as little as 
1 mg of sample along with the assignment of quaternary carbons from nearby protons. 
Phytochemical investigation of the combined sub-fractions K-M from 50:50 Hex:EtOAc 
fraction when subjected to fractionation in a sephadex column using 1:1:1 Hex:CH2Cl2:MeOH, 
yielded the known triterpene, α-amyrin. The structure of the known compound was confirmed by 
comparison of its spectroscopic properties with published data.
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Figure 2.3. Chemical structure of α-amyrin 
2.3.2.1. Structural Elucidation of the Bioactive Fractions 
α-amyrin displayed the molecular formula C30H50O, assigned for its positive HRESIMS 
(m/z 426.3908 [M + H]
+
). 
1
H and 
13
C NMR spectroscopic data were compared with reported data
for α-amyrin and were found to be the same.53 The palmitate of α-amyrin was previously
reported from B. caapi.
54
 α-amyrin  has no known activity.
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2.4. Experimental Methods 
1
H and 
13
C NMR spectra were obtained on Bruker model AMX 500 and 400 NMR
spectrometers with standard pulse sequences, operating at 500 and 400 MHz in 
1
H and 125 and
100 MHz in 
13
C, respectively. The chemical shift values were reported in parts per million (ppm)
from trimethylsilane (TMS) using known solvent chemical shifts. Coupling constants were 
recorded in hertz (Hz). Standard pulse sequences were used for COSY, DEPT, HMBC, HSQC, 
TOCSY, and NOESY. Column chromatography was carried out on silica-gel [70-230 mesh, 
Merck] and Sephadex LH-20 [GE Healthcare, Uppsala, Sweden]. TLC [silica gel 60 F254] was 
used to monitor the fractions obtained from column chromatography. Silica gel 60 PF254+366 
plates (20 × 20 cm, 1 mm thick) were used to carry out the preparative TLC. 
2.4.1. Plant Material 
B. caapi was purchased from Bouncing Bear Botanicals Company, Lawrence, Kansas, 
United States, in May 2014. The leaves of B. caapi were investigated. 
2.4.2. Chemicals 
All the chemicals used were purchased from Sigma-Aldrich (Poole, Dorset, U.K.) with 
the following exceptions. [
3
H]CP 55,940 (174.8 Ci/mmol), [
3
H]DAMGO (53.4 Ci/mmol),
[
3
H]U-69,593 (42.7 Ci/mmol), and [
3
H]enkephalin (45 Ci/mmol) were obtained from
PerkinElmer Life Sciences Inc. (Boston, MA, USA) for the binding experiments. CP 55,940, 
DAMGO, DPDPE, and naloxone hydrochloride were all obtained from Tocris Bioscience 
(Ellisville, MO, USA). 
2.4.3. Cell Culture 
HEK293 cells (ATCC) were transfected stably with plasmids including cloned human 
cannabinoid receptor subtypes 1 and 2 obtained from Origene, Rockville, MD, USA. These cells 
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were preserved in a humidified incubator at 37 °C and 5% CO2 in a Dulbecco’s Modified Eagle’s 
medium (DMEM) nutrient mixture F-12 HAM supplemented with 2 mM L-glutamine, 10% fetal 
bovine serum, 1000 IU/mL penicillin, 1000 µg/mL of streptomycin, and 0.5 mg/mL G418 
antibiotic solution. HEK293 cells stably transfected with opioid receptor subtypes µ, δ, and κ, 
were used to perform the opioid receptor binding assays. These cells were maintained at 37 °C 
and 5% CO2 in a DMEM nutrient mixture supplemented with 2 mM L-glutamine, 10% fetal 
bovine serum, penicillin–streptomycin, and either 0.2 mg/mL (δ and µ) or 0.5 mg/mL (κ) G418 
or hygromycin B antibiotic solutions. 
2.4.4. Membrane Preparation 
Membranes for the radioligand binding assays were prepared by scraping the cells in cold 
Tris-HCl, pH 7.4, and centrifuged at 5200g at 4 °C for 10 min. The supernatant was then 
discarded, and the pellet resuspended in the same buffer, homogenized using a sonic 
dismembrator model 100 [Fisher Scientific, Pittsburgh, PA, USA] for 30 s, and centrifuged at 
1000g at 4 °C for 10 min. The supernatant was saved, and the pellet underwent the suspension 
and sonication process two additional times under the same conditions. The supernatants were 
then combined and centrifuged at 23300g at 4 °C for 40 min. The pellet was resuspended and 
aliquoted into 2 mL vials and was stored at ₋80 °C. The total protein concentration was 
determined using a Pierce Bicinchoninic Acid Assay (BCA) protein assay kit [Thermo Scientific, 
Rockford, IL, USA] according to the manufacturer’s instructions.55 The optimal membrane and
radioligand [KD] concentrations for each receptor batch were established through membrane-
evaluation and saturation binding experiments. 
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2.4.5. Radioligand Displacement for Cannabinoid Receptor Subtypes 
Saturation experiments determine the receptor number and radioligand affinity for the 
membrane. Cannabinoid samples were incubated for 90 minutes at 37 °C with gentle agitation in 
50 mM TrisHCl, 20 mM EDTA, 154 mM NaCl, 0.2% BSA, pH 7.4, and filtered through GF/C 
filterplates using a Perkin Elmer FilterMate Harvester. The assay plate was washed 10X with ice 
cold 50 mM TrisHCl, pH 7.4, 0.1% BSA. Radioactivity was quantified on a TopCount NXT 
Microplate Scintillation counter after the addition of MicroScint20 to the dried filterplate. 
Percent displacement was calculated to represent the ability of the samples to displace the 
radioligand binding for a given cannabinoid or opioid receptor subtype. 
% binding = 100 - (binding of compound - nonspecific binding)*100/specific binding. 
If a purified compound exhibited > ~50% displacement, then a competitive radioligand 
binding assay was performed with a serial dilution of independent triplicate dilutions between 
0.0017-300 µM for the test compound and between 0.017-3,000 nM for control compounds. The 
assays were tested with the same conditions stated above. The IC50 and Ki values were calculated 
by a non-linear curve fit model using GraphPad Prism 5.0 software (GraphPad Software, San 
Diego, California, USA). 
2.4.6. Radioligand Displacement for Opioid Receptor Subtypes 
Opioid binding assays were performed under the following conditions: 10 μM of each 
mixture was incubated with [
3
H]-DAMGO (µ), [
3
H]-U-69,593 (κ), or [3H]-DPDPE (δ) for 60
minutes in a 96-well plate. Percent binding was calculated as the average of the triplicates tested 
at 10μM. Each sample concentration point of the compounds tested in dose response was in 
triplicates, and each compound showing activity was tested at least three times. The reaction was 
terminated via rapid vacuum filtration through GF/B filters pre-soaked with 0.3% BSA using a 
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Perkin Elmer 96-well Unifilter followed by 10 washes with 50 mM Tris-HCl. Plates were read 
using a Perkin Elmer Topcount. Total binding was defined as binding in the presence of 1.0% 
DMSO. Nonspecific binding was the binding observed in the presence of 10 μM DAMGO (µ), 
U-69,593 (κ), or DPDPE (δ). Specific binding was defined as the difference between total and 
nonspecific binding. Percent binding was calculated using the following formula: 
% binding = 100 - (binding of compound - nonspecific binding)*100/specific binding. 
Ki and IC50 values were calculated using Graph-Pad Prism 5; each point on the graph is 
representative of n=3. The binding assays of the fatty acids were performed as two independent 
experiments, and the results were obtained. 
2.5. Summary 
Bioassay-guided fractionation of B. caapi resulted in the isolation of a known triterpene, 
α-amyrin. Follow-up studies showed that α-amyrin did not show any radioligand displacement 
values towards cannabinoid and/or opioid receptors. The chemical structure of the isolated 
triterpene (α-amyrin) was confirmed on the basis of 1D and 2D NMR spectroscopic studies, 
which were compared with published data.
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 This project was discontinued due to the limited
amounts of the bioactive fractions. 
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Part of this chapter has been published in the Journal of Natural Products, 2016, 79 (10), 2538-
2544 and has been formatted as per the University of Mississippi’s guidelines for thesis 
preparation. 
CHAPTER 3. ISOLATION AND STRUCTURAL ELUCIDATION OF BIOACTIVE 
SECONDARY METABOLITES FROM CALEA URTICIFOLIA 
Vedanjali Gogineni, Francisco León, Khaled M. Elokely, Manal A. Nael, Narayan D. 
Chaurasiya, Babu L. Tekwani, and Stephen J. Cutler 
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3.1. Introduction 
Asteraceae family includes over 1,600 genera and about 24,000 individual species, 
making it the largest family in the world with flowering plants. Most of the members from the 
Asteraceae family are known for their medicinal, economic and ornamental purposes.
56,57
 Calea
genus belongs to Heliantheae tribe and is known to include about 125 species inhabiting the 
subtropical and tropical regions of the world.
58
 Calea urticifolia, known by various vernacular
names including chilchaca, negrito, jaral de castilla, hierba del negro and juanislama,
59
 is found
to spread in Central America from Mexico to Panama, and the plant is used as folkloric medicine 
for the treatment of gastric ulcers and as a tropical bacteriocide.
59
 Previous phytochemical
studies on C. urticifolia revealed the presence of phenol derivatives,
60
 and sesquiterpenoids
including bisabolene
60
 and germacrane
61,62,63
 –types.
Sesquiterpene lactones are known for their extensive spectrum of biological activities 
including antitumor, antifungal, antibacterial, anti-inflammatory, phytotoxic, and cytotoxic 
properties,
64,65,66
 along with their use against malaria, ulcers, dysentery, and ringworm
infections.
67
 The inhibitory action of sesquiterpene lactones resulted from the presence of highly
electrophilic functional groups, by selectively alkylating through Michael-type addition to 
sulfhydryl proteins, in particular, to thiol groups, compared to other nucleophiles.
64,68
 Various
biological activities result from different skeletal types to understand the adaptive role of these 
constituents in plants, contributing to a complete understanding of these activities in 
pharmacological, botanical and medicinal disciplines.
69
We found that the CHCl3 extract of C. urticifolia displayed potent MAO enzymes’ 
inhibition. There are no reports on its binding ability to the MAO isoenzymes and hence, we 
focused on the binding ability of C. urticifolia to the MAO enzymes. 
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3.1.1. Specific Aims of the Research 
In order to achieve the above goals, the following specific aims were considered: 
1. To isolate and extract the crude fractions of C. urticifolia and separate various constituents
by means of polarity or nature of the compounds using bioassay-guided fractionation 
2. To purify all the secondary metabolites present in the active fractions and the structural
elucidation of the purified bioactive compounds 
3. To perform MAO inhibition, enzyme-kinetics and mechanistic studies, and binding affinity
studies on the purified bioactive compounds 
3.2. Screening for Neurological Disorders 
The isolation of C. urticifolia was carried out in our lab along with other plants including 
Hyoscyamus niger, Passiflora caerulae, Acacia xanthophloea, Perovskia atriplicifolia, and Salix 
laevigata. The dried extracts of these plants were assayed for opioid/cannabinoid activity and 
MAO inhibition. The CHCl3 extract of C. urticifolia showed promising inhibition of MAOs and 
the following results were obtained as shown in Table 3.1. This activity was compared to the 
available literature on the plant, C. urticifolia, and was observed that the MAO inhibiton has not 
been previously reported. Hence, the current idea of taking this research further and determining 
the responsible compound(s) for the MAO inhibition, isolating them, and synthesizing analogs 
with improved selectivity and potency could lead to the discovery and development of 
potentially novel PD agents. 
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Table 3.1. Monoamine oxidase inhibition results of various plant extracts 
Sample name Extract type MAO-A [IC50]
a
MAO-B [IC50]
a 
Hyoscyamus niger Seeds 57.072 ± 6.648
b 
13. 472 ± 0.892
b 
Passiflora caerulae Aerial part 53.796 ± 3.193
b 
9.157 ± 0.989
b 
Acacia xanthophloea Root 5.565 ± 0.071
b 
23.353 ± 3.324
b 
Calea urticifolia Leaves 2.491 ± 0.135
b 
1.857 ± 0.240
b 
Perovskia atriplicifolia Stems 36.546 ± 1.775
b 
10.959 ± 2.685
b 
Salix laevigata Leaves 17.449 ± 0.356
b 
32.817 ± 8.646
b 
Clorgyline 0.003 ± 0.00005
c
- 
Deprenyl - 0.088 ± 0.005
c
a
The IC50 values computed from the dose-response inhibition curves are mean ± SD of triplicate 
observations; 
b
µg/mL; 
c
µM  
3.3. Results and Discussion 
3.3.1. Bioassay Guided Fractionation of C. urticifolia 
Bioassay-guided fractionation has been implemented for the isolation of the secondary 
metabolites from C. urticifolia. Based on the preliminary results, The leaves of C. 
urticifolia were extracted with CHCl3 and concentrated under vacuum. The leaf extract was then 
fractionated in a silica gel column with 100% Hex increasing the polarity with EtOAc and 
MeOH, and the fractions were submitted for MAO inhibition assays. The 3:2 EtOAc-Hex 
fraction showed the best MAO inhibition [Table 3.2]. 
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Table 3.2. MAO inhibition results of C. urticifolia fractions 
Sample Code Fraction MAO-A [IC50]
a
MAO-B [IC50]
a 
Cu-1 100% Hex > 100
b 
> 100
b
 
Cu-2 1:4 EtOAc-Hex > 100
b
 59.85 ± 11.085
b
 
Cu-3 1:4 EtOAc-Hex (2) > 100
b
 11.61 ± 5.259
b
 
Cu-4 2:3 EtOAc-Hex 12.006 ± 0.421
b
 14.11 ± 1.398
b
 
Cu-5 3:2 EtOAc-Hex 3.911 ± 0.443
b
2.20 ± 0.007
b
Cu-6 4:1 EtOAc-Hex 8.757 ± 0.532
b
 8.13 ± 0.729
b
 
Cu-7 100% EtOAc 31.676 ± 2.556
b
 16.89 ± 1.898
b
 
Cu-8 1:9 MeOH-EtOAc 30.741 ± 1.795
b
 14.94 ± 1.475
b
 
Cu-9 1:3 MeOH-EtOAc 15.680 ± 0.427
b
 27.48 ± 0.042
b
 
Cu-10 1:1 MeOH-EtOAc 6.042 ± 0.351
b
 27.59 ± 3.954
b
 
Cu-11 100% MeOH 3.175 ± 0.252
b
 23.29 ± 0.703
b
 
Phenelzine 0.249 ± 0.002
c
 0.056 ± 0.009
c
 
a
The IC50 values computed from the dose-response inhibition curves are mean ± SD of triplicate 
observations; 
b
µg/mL; 
c
µM 
Based on the MAO inhibition, the 3:2 EtOAc-Hex fraction was subjected to further 
fractionation in a silica gel column using CH2Cl2 and EtOAc with increased polarities, and the 
sub-fractions were subjected for MAO inhibition assay. The sub-fractions Cu-5.5, Cu-5.6, Cu-
5.7, Cu-5.8, Cu-5.10, and Cu-5.12 showed the best MAO inhibition [Table 3.3]. 
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Table 3.3. MAO inhibition results of C. urticifolia sub-fractions 
Sample Code MAO-A [IC50]
a
MAO-B [IC50]
a 
Cu 5.1 29.790 ± 1.7770
b 
12.018 ± 0.674
b
 
Cu 5.2 > 100
b
 15.082 ± 0.009
b
 
Cu 5.3 > 100
b
 53.904 ± 8.321
b
 
Cu 5.4 78.691 ± 0.7879
b
 42.230 ± 0.038
b
 
Cu 5.5 1.009 ± 0.1070
b
0.958 ± 0.085
b
Cu 5.6 0.129 ± 0.0098
b
0.145 ± 0.0072
b
Cu 5.7 0.112 ± 0.0051
b
0.132 ± 0.0290
b
Cu 5.8 0.059 ± 0.0061
b
0.069 ± 0.0017
b
Cu 5.10 0.034 ± 0.0030
b
0.036 ± 0.0002
b
Cu 5.12 0.081 ± 0.0170
b
0.058 ± 0.0067
b
Cu 5.14 1.749 ± 0.2110
b
 1.715 ± 0.386
b
 
Clorgyline 0.0028 ± 0.0002
c
 - 
Deprenyl - 0.050 ± 0.0037
c
 
Phenelzine 0.227 ± 0.034
c
 0.065 ± 0.0070
c
 
a
The IC50 values computed from the dose-response inhibition curves are mean ± SD of triplicate 
observations; 
b
µg/mL; 
c
µM 
Figure 3.1 represents the isolation scheme of C. urticifolia. The isolation was performed 
in silica-gel columns. The active fractions and sub-fractions were purified to yield the bioactive 
compound/s along with other secondary metabolites. The purified fractions were submitted for 
MAO inhibition assay after each fractionation. 
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Figure 3.1. Isolation procedure of various extracts of C. urticifolia 
Table 3.4 shows the summary of the active fractions that have been purified based on the 
highest inhibition. Since, the subfraction Cu 5.10 was identified as the most potent fraction, it 
was rechromatographed by silica gel which yielded acacetin upon further purification. 
Silica gel column 
Cu 
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4
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Table 3.4. Inhibition of recombinant human monoamine oxidase–A and –B by CHCl3 extract, 
fractions, and acacetin isolated from Calea urticifolia  
Compound 
Monoamine oxidase-A 
IC50 value
a 
Monoamine oxidase-B 
IC50 value
a 
Calea urticifolia  
[CHCl3 extract] 
2.491 ± 0.135
b 
1.857 ± 0.240
b 
Fraction Cu-5 3.911 ± 0.443
b 
2.200 ± 0.007
b 
Subfraction Cu-5.10 0.034 ± 0.003
b 
0.036 ± 0.0002
b
 
Acacetin  0.121 ± 0.0014
c 
0.049 ± 0.0007
c
 
Phenelzine  0.238 ± 0.009
c 
0.143 ± 0.017
c 
a
The IC50 values computed from the dose-response inhibition curves are mean ± SD of triplicate 
observations; 
b
µg/mL; 
c
µM  
3.3.2. Molecular Structural Elucidation of the Active Constituents 
The molecular structural elucidation of active constituents was similar to those mentioned 
earlier. Refer to page 47. Phytochemical investigation of the fractions Cu-5.5 and Cu-5.10 
yielded acacetin, which was found to be the active constituent when MAO inhibition assay was 
performed. The phytochemical investigation of the fractions Cu-5.6, Cu-5.7, and Cu-5.8 yielded 
three novel bisabolenes: caleanolenes A-C, and three known germacranolides: 2,3-
epoxyjuanislamin, calealactone B, and calein C [Figure 3.2]. The structures of the known 
compounds were confirmed by comparison of their spectroscopic properties with published data. 
Structural characterization of the new isolated compounds was based on extensive spectroscopic 
analysis, and the configuration of caleanolenes A-C was established by DP4 probability analysis, 
and ECD calculations. 
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Figure 3.2. Chemical structures of the isolated secondary metabolites from C. urticifolia 
3.3.2.1. Structural Elucidation of Acacetin and Evaluation of its MAO Activity 
Acacetin displayed the molecular formula C16H12O5, assigned for its positive HRESIMS 
(m/z 285.0908 [M + H]
+
). 
1
H and 
13
C NMR spectroscopic data were compared with reported data 
for acacetin and were found to be the same.
70
 This is the first report on isolation of acacetin 
from C. urticifolia.  
Acacetin inhibited MAO-A and -B with IC50 values of 0.121 and 0.049 μM, respectively, 
which indicates a more preferential inhibition by acacetin of MAO-B over MAO-A [Figure 3.3]. 
Additionally, the potency of MAO inhibition by acacetin reported here is > 5-fold higher for 
MAO-A (0.121 μM vs 0.640 μM) and > 22-fold higher for MAO-B (0.049 μM vs 1.12 μM) 
compared to apigenin reported previously [Table 3.5].
71
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Figure 3.3. Concentration-response inhibition profile of recombinant human monoamine 
oxidase–A and –B by acacetin or phenelzine. Each point represents the mean value of at least 
three observations 
Table 3.5. Inhibition of recombinant human monoamine oxidase–A and –B by acacetin isolated 
from C. urticifolia and related flavonoids
71,72 
Compound 
Monoamine oxidase-A 
IC50 value
a 
Monoamine oxidase-B 
IC50 value
a 
Acacetin  0.121 ± 0.0014
b 
0.049 ± 0.0007
b 
Apigenin  0.640 ± 0.11
b 
1.12 ± 0.27
b 
Quercetin  2.44 ± 0.12
b 
38.66 ± 0.27
b 
Galangin  0.13 ± 0.01
b 
3.65 ± 0.150
b 
Naringenin  955 ± 129
b 
288 ± 18
b 
Phenelzine  0.238 ± 0.009
b 
0.143 ± 0.017
b 
a
The IC50 values computed from the dose-response inhibition curves are mean ± SD of triplicate 
observations; 
b
µM 
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The in vitro studies were reported to evaluate the mechanism and kinetics of the 
inhibition of human MAO-A and -B by acacetin. To understand the type of inhibition, we tested 
acacetin against both MAOs at different concentrations of a nonselective substrate (kynuramine). 
Two concentrations of acacetin were selected, one above and the other below its IC50 value. For 
every experiment, three sets of assays were performed at variable concentrations of the substrate: 
two concentrations of the inhibitor and one control without inhibitors. The data were analyzed by 
double-reciprocal Lineweaver–Burk plots to determine the Ki (i.e., inhibition/binding affinity) 
values. The results suggest that acacetin binds to human MAO-A at its active site and is therefore 
a competitive inhibitor [Figure 3.4B]. Similarly, MAO-B inhibition by acacetin was also 
competitive [Figure 3.4D].  
 
Figure 3.4. Kinetic characteristics of inhibition of recombinant human MAO-A analyzed with 
double-reciprocal Lineweaver-Burk plots. MAO-A and phenelzine (A) or acacetin (B), MAO-B 
with phenelzine (C) or acacetin (D). V = nmol/min/mg 
Ki values were computed from the double-reciprocal plots [Table 3.6]. The binding 
affinities of acacetin with both MAOs were compared with phenelzine, a standard MAO 
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inhibitor.
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 While acacetin had binding affinities for MAO-A (Ki: 0.0592 μM) similar to those for 
MAO-B (Ki: 0.049 μM), it was twice as potent an inhibitor of MAO-B (IC50: 0.049 μM) than 
MAO-A (IC50: 0.121 μM) [Table 3.6]. 
Table 3.6. Inhibition/binding affinity constant (Ki) values for inhibition of recombinant human 
MAO–A and –B by acacetin and phenelzinea 
Compound  
Monoamine oxidase-A Monoamine oxidase-B 
Ki (µM) Type of inhibition Ki (µM) Type of inhibition 
Acacetin  0.0592 ± 0.0029 
Competitive/ 
reversible 
0.049 ± 0.0036 
Competitive/ 
reversible 
Phenelzine 0.163 ± 0.014 Mixed/irreversible 0.124 ± 0.004 Mixed/irreversible 
a
Values are mean ± SD of triplicate experiments 
In order to analyze the time-dependent binding inhibition of MAO-A and -B, the 
enzymes were preincubated with each inhibitor for the indicated time (0–15 min) at 
concentrations that resulted in approximately 60–80% inhibition [Figure 3.5]. Simultaneously, 
controls without inhibitors were also evaluated. The activities of the enzymes were determined as 
mentioned in the experimental section, and the remaining enzyme activity percentage was 
plotted against the preincubation time to determine time-dependent inhibition. The results 
showed that inhibition of MAO-A and -B by acacetin was not time-dependent. 
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Figure 3.5. (A) Time-dependent inhibition of recombinant human MAO-A by phenelzine (0.600 
µM) and acacetin (0.500 µM). (B) Time-dependent inhibition of recombinant human MAO-B by 
phenelzine (0.200 µM) and acacetin (0.200 µM). The remaining activity was expressed as % of 
activity. Each point represents mean ± SD of triplicate values. 
The binding characteristics of acacetin were investigated by using dialysis to measure the 
dissociation of the enzyme–inhibitor complex. A high concentration of acacetin was incubated 
with the enzymes (MAO-A and -B) for 20 min. The enzyme–inhibitor complex mixtures were 
dialyzed overnight at 4 °C against buffer. The enzyme activies were analyzed before and after 
the dialysis [Figure  3.6]. During overnight dialysis, the recombinant human MAO-A lost about 
10–15% of activity. Incubation of MAO-A with 15.0 μM acacetin inhibited more than 95% of 
the enzyme activity [Figure 3.6A]. After the dialysis, more than 90% enzyme activity was 
recovered from enzyme–acacetin incubation mixtures [Figure 3.6A]. Similarly, MAO-B lost 
about 10–15% of the enzyme activity during overnight dialysis. Acacetin incubation (5.0 μM) 
with MAO-B resulted in 90% inhibition of the enzyme activity, which was later fully recovered 
after the dialysis [Figure 3.6B]. These observations suggest that MAO inhibition by acacetin is 
reversible due to the dissociable nature of their enzyme–inhibitor complexes. 
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Figure 3.6. (A) Analysis of nature of binding of acacetin with recombinant human MAO-A by 
recovery of catalytic activity of the enzyme after equilibrium dialysis dissociation. (B) Analysis 
of nature of binding of acacetin with recombinant human MAO-B by recovery of catalytic 
activity of the enzyme after equilibrium dialysis dissociation. Each bar shows mean ± SD of 
triplicate values. 
3.3.2.2.  Structural Elucidation of the Remaining Bioactive Fractions 
Caleanolene A was isolated as colorless oil. The molecular formula was determined as 
C19H30O4, on the basis of its positive HRESIMS data (m/z 345.2040 [M + Na]
+
). The IR 
spectrum showed absorption bands at 3353, 1736, 1013, 793 cm
-1
 indicating the presence of 
hydroxyl, ester, and olefinic functions. The 
1
H NMR spectrum [Table 3.7] showed resonances 
that attributed to three methyl groups: one tertiary methyl at δH 1.68 (3H, s) and two secondary 
methyl groups at δH 1.19 (6H, d, J = 6.9 Hz), that could be assigned to the methyl groups of an 
isopropyl group; two oxygenated methylene groups at δH 4.40 (1H, d, J = 12.18 Hz), 4.98 (1H, d, 
J = 12.18 Hz) and 4.0 (2H, s br); one oxygenated methine group at δH 4.26 (1H, s br); four 
signals of vinylic protons at δH 4.80 (1H, s), 4.83 (1H, s), 5.41 (1H, t, J = 6.7 Hz), and 5.85 (1H, 
s br) corresponding to one methylene group and two separated tri substituent double bonds, 
respectively. The 
13
C NMR [Table 3.7] and DEPT spectra disclosed 19 carbons which were 
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indicative of an isobutyryloxy group (δC 177.8; 34.1; 2C x 19.0). This data combined with the 
degrees of unsaturation suggested a ring system in the structure which is in agreement with a 
previous bisabolene skeleton reported from the Asteraceae family.
74,75
  
Table 3.7. NMR spectroscopic data of caleanolenes A-C in CDCl3 
a
Multiplicities were obtained from DEPT experiments; 
b
Based on COSY, HSQC, HMBC, and 
ROESY experiments; 
c
Spectra were recorded in CDCl3. 
The 
1
H1H COSY experiment [Figure 3.7] disclosed three partial structures, 
CHCH2CHCH2CH; CH2CH2CH, and CH(CH3)2, corresponding to the C-2, C-1, C-6, C-5, C-4; 
C-8, C-9, C-10, and C-2′, C-1′, C-3′. HMBC correlations [Figure 3.7] of the oxymethylene CH2-
 Caleanolene A Caleanolene B Caleanolene C
c
 
position     δC
b 
     δH mult. (J, Hz)
 δC
b 
     δH mult. (J, Hz)
a 
      δC
b δH mult. (J, Hz)
 
       
1 31.5 2.21, m 
2.00, m 
31.9 2.21, m 
1.99, m 
31.9 2.58, m 
2.30, m 
2 129.5 5.85, s br 129.4 5.87, s br 146.7 6.96, dd (2.6, 5.8) 
3 136.0  135.3  134.5  
4 67.5 4.26, m, m 67.4 4.27, s br 197.6  
5 37.1 2.17, m 
1.56, ddd (9.7, 9.8, 12.4 ) 
37.0 2.20, m 
1.53, m 
43.2 2.60, m 
2.41, m 
6 38.7 2.28, m 38.6 2.32, m 40.4 2.71, m 
7 152.1  150.9  148.7  
8 34.0 2.11, m 37.4 2.80, d (6.4) 37.2 2.79, d (6.9) 
9 26.1 2.19, m 
2.10, m 
127.9 5.77, ddd (6.7, 6.8, 15) 127.3 5.74, ddd (6.9,  
7.8, 15) 
10 125.5 5.41, t (6.7) 135.1 5.56, d (15) 135.6 5.56, d (15) 
11 135.1  72.0  72.1  
12 68.8 4.00, s 70.8 4.08, d (11.2) 
3.99, d (11.2) 
70.7 4.08, d (11.1) 
3.97, d (11.1) 
13 13.7 1.68, s 24.9 1.32, s 24.9 1.29, s 
14 108.5 4.83, s 
4.80, s 
109.8 4.87, s 
4.80, s 
111.2 4.87, s 
15 65.3 4.98, d (12.1) 65.3 5.01, d (12) 
4.40, d (12) 
60.9 4.75, s 
1′ 177.8  177.7  177.1  
2′ 34.1 2.59, quint (7) 34.1 2.61, , quint (7) 34.0 2.58, m 
3′ 19.0 1.19, m 19.0 1.20, m 19.0 1.16, m 
4′ 19.0 1.19, m 19.0 1.20, m 19.0 1.18, m 
1′′ ---- ---- 177.4  177.6  
2′′ ---- ---- 34.0 2.61, , quint (7) 34.0 2.58, m 
3′′ ---- ---- 19.0 1.20, m 19.0 1.16, m 
4′′ ---- ---- 19.0 1.20, m 19.0 1.18, m 
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15 to the signal at δC 177.8 C-1′ corresponding to the link between the isobutyryloxy group and 
the bisabolene skeleton, and the correlations of the protons CH2-12 to C-10, C-11 and C-13 
assisted in the linking of the second oxymethylene group. Additionally, the cross-peaks from 
CH2-15 to C-2, C-3, and C-4 helped to position the secondary hydroxyl and the double bond. 
The relative configuration of caleanolene A was deduced from the interpretation of the rotating 
frame overhauser effect (ROESY) spectra [Figure 3.7]. The ROESY correlation from CH2-12 
(δH 4.0) to H-10 (δH 5.41) led to the conclusion that the stereochemistry of the C-10, C-11 double 
bond is E. The correlation from H-6 (δH 2.28) to H-4 (δH 4.26) clearly showed that these protons 
are on the same face.  
 
Figure 3.7. Selected COSY, HMBC, and ROESY correlations for caleanolene A 
The absolute configuration of caleanolene A was established through experimental and 
theoretical electronic circular dichroism (ECD). The conformational space was searched using 
MacroModel (Schrödinger, LLC, New York) and the most abundant conformers according to 
Boltzmann distribution were optimized using the density functional theory (DFT) at m062x/6-
31+G(d,p) level
76
 [Figure 3.8].  
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Figure 3.8. Geometry optimized conformers of caleanolene A using DFT at the m062x/6-
31+G(d,p) level, and their contributions to the Boltzmann distribution 
The calculated ECD spectra obtained using time-dependent density functional theory 
(TDDFT) at B3LYP/6–31G** level in a PCM (polarizable continuum model) methanol solvent 
model of the (4S, 6S) and (4R, 6R) stereoisomers are shown in Figure 3.9. The calculated (4R, 
6R) stereoisomer showed excellent fit with the experimental data, with a negative Cotton effect 
at 210 nm [Figure 3.9]. Thus, the absolute configuration and the structure of the caleanolene A 
was established as (4R, 6R) 4,12-dihydroxy-15-isobutyryloxybisabola-2,7(14),10-triene.  
 
Figure 3.9. Experimental ECD spectrum of caleanolene A and calculated ECD spectra for the 
stereoisomers (4R, 6R) and (4S, 6S) 
Caleanolene B possessed a molecular formula of C23H36O6 as established by (+) 
HRESIMS data (m/z 431.2462 [M + Na]
+
). The analysis of its 
1
H, 
13
C [Table 3.7], and HSQC 
NMR data revealed the existence of one sp
2 methylene at δH 4.87 (1H, s) and 4.80 (1H, s), three 
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sp
2
 methines at δH 5.87 (1H, s br), 5.77 (1H, ddd, J = 6.7, 6.8, 15.0 Hz), and 5.56 (1H, d, J = 15.0 
Hz), implying the presence of one tri-substituted, and two di-substituted double bonds. 
Secondary and tertiary hydroxyl groups were present at δC 67.4 and 72.0, respectively. Two 
isobutyryloxy groups were confirmed with the signals at δH 2.61 (2H, m), and 1.21-1.18 (12H, 
m); the location of these groups at C-12 and C-15 was determined through its HMBC spectrum 
with the correlations observed between the protons at CH2 -12 at δH 3.99 (1H, d, J = 11.2 Hz) 
and 5.87 (1H, d, J = 11.2 Hz) and the signal at δC 177.4 C-1′ (detected by HMBC), and CH2-15 at 
δH 4.40 (1H, d, J = 12.0 Hz) and 5.01 (1H, d, J = 12.0 Hz) and the signal at δC 177.7 C-1′′ 
(detected by HMBC). The stereochemistry of the C-9 and C-10 double bond was determined to 
be E by considering the coupling constant (J9,10 = 15 Hz). The partial relative configuration of 
caleanolene B was deduced from a cross peak between H-4 and H-6 from the ROESY 
experiment, helping us to place these protons on the same face. However, the presence of the 
additional stereogenic center at C-11 enabled us to determine the absolute stereochemistry.  
The stereochemical properties were depicted using computational quantum mechanical 
calculations, through the comparison of experimental with calculated data. The geometry 
optimized conformers representing all four possible stereoisomers were analyzed by applying 
TDDFT ECD and NMR calculations. The experimental and calculated ECD spectra were 
compared for each stereoisomer. The isomer (4R, 6R, 11R) showed perfect match with the 
experimental data [Figure 3.10]. The ECD spectra displayed a prominent negative Cotton effect 
at ~210 nm. The NMR tensors were obtained by calculating the gauge-including atomic orbitals 
(GIAO) shielding constants of the conformers within 2 kcal/mol of the global minimum. 
Vibrational analysis was performed to confirmed minima. The DP4 calculations
77
 were executed 
at B3LYP/6-311+G(2d,p) level. The chemical shift (CS) values were calculated according to the 
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guide of the NMR CS assignment of small molecule structure.
78
 The DP4 probability analysis of 
the experimental and calculated CS values supported the ECD results that the (4R, 6R, 11R) was 
most probable by ~ 87.4 %. Thus, caleanolene B was determined as (4R, 6R, 11R) 4,11-
dihydroxy-12,15-diisobutyryloxybisabola-2,7(14),9-triene. 
 
Figure 3.10. Experimental ECD spectrum of caleanolene B and calculated ECD spectra for all 
the possible stereoisomers 
Caleanolene C, was purified as colorless oil and has the molecular formula of C23H34O6 that was 
established by (+) HRESIMS data (m/z 429.2305 [M + Na]
+
). The 
1
H NMR spectra was similar 
to that of caleanolene B, suggesting that the two compounds are closely related in structure. The 
major difference between the two compounds is the absence of the methine proton corresponding 
to the secondary hydroxyl as in caleanolene B. A detailed comparison of the 
1
H and 
13
C NMR 
signals of caleanolenes B and C [Table 3.7] revealed that the secondary hydroxyl in C-4 was 
oxidized as an α,β-unsaturated ketone in caleanolene C (δC 197.6). Additionally, the low shift of 
the proton signal of H-2 δH 6.96 (1H, dd, J =2.6, 5.8 Hz) confirmed the presence of an α,β-
unsaturated ketone. The structure was shown to be 4-oxo-11-hydroxy-12,15-
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diisobutyryloxybisabola-2,7(14),9-triene. The absolute stereochemistry was deduced to be (6R, 
11R) based on the matching of the calculated ECD spectrum with the experimental one [Figure 
3.11].  
 
Figure 3.11. Experimental ECD spectrum of caleanolene C and calculated ECD spectra for all 
the possible stereoisomers  
The isolated sesquiterpene lactones were assayed for their cytotoxic effects based on the 
previous reports that sesquiterpene lactones isolated from C. urticifolia have shown cytotoxic 
effects against U-937 lymphoma cell line,
62 
and induced apoptosis in human tumor cell line HL-
60.
79
 These sesquiterpene lactones also showed inhibitory effects on adipocyte differentiation,
80
 
and inhibitory effects on melanin biosynthesis through suppression of tyrosine expression.
81
  
Based on these preceding bioassays, the sesquiterpenes caleanolene A, 2,3-epoxyjuanislamin, 
calealactone B, and calein C were assayed for their cytotoxic activities against CA46 and Raji 
lymphoma, and the MCF7 breast cancer cell lines [Table 3.8]. 
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Table 3.8. Effects of caleanolene A, 2,3-epoxyjuanislamin, calealactone B, and calein C on the 
growth of the tumoral human cell lines. 
Compound 
IC50 (µM) 
CA46 RAJI MCF7 
Caleanolene A > 100  > 100 > 100 
2,3-Epoxyjuanislamin 2.9 ± 0.3 12.3 ± 0.2 10.6 ± 0.1 
Calealactone B 3.7 ± 0.6 17.5 ± 5.7 21.2 ± 4.8 
Calein C 5.6 ± 0.6 11.7 ± 0.09 9.8 ± 0.6 
Cells were cultured for 72h and the IC50 values were calculated as described in the experimental 
section. The data shown represent the means ± SE of 3-5 independent experiments with three 
determinations in each. 
3.4. Experimental Methods 
The general experimental methods were similar to those explained earlier. Refer to page 
48. 
3.4.1. Plant Material 
The plant Calea urticifolia was collected from the University of El Salvador Campus, 
San Salvador, El Salvador, in July 2014 and was identified by a botanist, Jenny Menjivar. A 
voucher specimen (3220) has been deposited in the herbarium of the Natural History Museum of 
El Salvador. 
3.4.2. Chemicals 
Human recombinant monoamine oxidase-A and monoamine oxidase-B enzymes were 
obtained from BD Biosciences (Bedford, MA, USA). Kynuramine, clorgyline, deprenyl, 
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phenelzine, and DMSO were purchased from Sigma Chemical (St. Louis, MO, USA). Acacetin 
has been confirmed by comparing its experimental data with those reported in the literature. 
3.4.3. Extraction and Isolation 
The dried leaves were ground to a powder, yielding 325 g, which was extracted with 
CHCl3 after maceration for 3 days. Removal of the solvent afforded a viscous residue (12.29 g). 
The extract showed good inhibition for MAO-A and -B with IC50 values of 2.49 and 1.85 μg/mL, 
respectively. The CHCl3 extract (12 g) was fractionated on a flash silica gel column using a 
polarity gradient that resulted in 10 fractions [F-1 (Hex); F-2 (4:1 Hex–EtOAc); F-3 (3:2 Hex–
EtOAc); F-4 (2:3 Hex–EtOAc); F-5 (1:4 Hex–EtOAc); F-6 (EtOAc); F-7 (9:1 EtOAc–MeOH); 
F-8 (75:25 EtOAc–MeOH); F-9 (1:1 EtOAc–MeOH); F-10 (MeOH)]. All fractions were tested 
for their biological activity. Fraction F-4 (2:3 Hex–EtOAc) showed IC50 values of 3.91 and 2.20 
μg/mL for MAO-A and -B, respectively, and hence F-4 was further fractionated using a silica 
column. Eleven subfractions were obtained in order of polarity with CH2Cl2 to MeOH [F-4A 
(CH2Cl2), F-4B (98:2 CH2Cl2–EtOAc), F-4C (95:5 CH2Cl2–EtOAc), F-4D (9:1 CH2Cl2–EtOAc), 
F-4E (4:1 CH2Cl2–EtOAc), F-4F (7:3 CH2Cl2–EtOAc), F-4G (3:2 CH2Cl2–EtOAc), F-4H (1:1 
CH2Cl2–EtOAc), F-4I (3:7 CH2Cl2–EtOAc), F-4J (EtOAc), F-4K (MeOH)], and these 
subfractions were subjected to bioassays. Subfraction F-4I showed a high percentage of 
inhibition for MAO-A and -B with IC50 values of 0.034 and 0.036 μg/mL, respectively. F-4I (3:7 
CH2Cl2–EtOAc) was subjected to a silica gel column eluted with CH2Cl2–acetone (9:1) to 
furnish acacetin (18 mg) (0.005% from dried plant material and 0.15% from CHCl3 extract). 
Fractions eluted with CH2Cl2-EtOAc (9:1 and 4:1) were combined, concentrated, and 
submitted to Sephadex LH-20 CC using CH2Cl2-MeOH (1:1) to give three subfractions. 
Subfraction 2 was rechromatographed by CC eluted with CH2Cl2-MeOH (30:1) to obtain 
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calealactone B (25 mg), and a mixture of compounds, that was further submitted to Sephadex 
LH-20 CC using CH2Cl2-MeOH (2:1) and by repeated preparative TLC using Hex-EtOAc as 
mobile phase (1:1) to yield 2,3-epoxyjuanislamin (15 mg) and calein C (5 mg). In subfraction 3 a 
solid was precipitated, and was separated by filtration and crystallized from Hex-EtOAc, to yield 
more acacetin (15 mg). Fractions eluted with CH2Cl2-EtOAc (7:3 and 3:2) were combined and 
subjected to flash silica CC using CH2Cl2 and acetone mixtures of increasing polarity to obtain 
five subfractions. Subfraction four was initially rechromatographed by SPE column with CH2Cl2, 
and stepwise elution to MeOH, yielding four subfractions (20 mL each) (CH2Cl2; 50:1 CH2Cl2-
MeOH; 20:1 CH2Cl2-MeOH; MeOH). Subfraction eluted with 50:1 CH2Cl2-MeOH was 
submitted to Sephadex LH-20 CC using CH2Cl2-MeOH (1:1), and by repeated preparative TLC 
using CH2Cl2-MeOH as mobile phase (50:1, 2 times) to yield compounds: caleanolene A (2.4 
mg), caleanolene B (1.1 mg), and caleanolene C (1.6 mg). 
Caleanolene A: colorless oil; [α]20D +22.8 (c 0.001, MeOH); IR (film, NaCl) max 3353, 
2921, 2852, 1736, 1642, 1453, 1378, 1258, 1013, 865, 793 cm
-1
; CD (MeOH, c 0.35 x 10
-3
 M) 
Δε (nm) -58.3 (210); 1H NMR and 13C NMR data, see Table 3.3; HRESIMS m/z [M +Na]+ 
345.2042 (calcd. for C19H30NaO4, 345.20418). 
Caleanolene B: colorless oil; [α]20D -11.4 (c 0.001, MeOH); IR (film, NaCl) max 3362, 
2920, 2851, 1738, 1558, 1462, 1260, 1084, 1020, 800 cm
-1
; CD (MeOH, c 0.35 x 10
-3
 M) Δε 
(nm) -27.4 (209); 
1
H NMR and 
13
C NMR data, see Table 3.3; HRESIMS m/z [M +Na]
+
 431.2456 
(calcd. for C23H36NaO6, 431.2410). 
Caleanolene C: colorless oil; [α]20D +14.3 (c 0.001, MeOH); IR (film, NaCl) max 3359, 
2958, 2922, 2852,1691, 1551, 1463, 1258, 1085, 1013, cm
-1
; CD (MeOH, c 0.35 x 10
-3
 M) Δε 
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(nm) -4.79 (228), +2.10 (248), -2.17 (267); 
1
H NMR and 
13
C NMR data, see Table 3.3; 
HRESIMS m/z [M +Na]
+
 429.2298 (calcd. for C23H34NaO6, 429.2253). 
3.4.4. MAO Inhibition Assay 
In order to investigate the effect of the isolated constituent acacetin from C. urticifolia on 
human recombinant MAO-A and MAO-B, the kynuramine deamination assay was performed in 
96-well plates as previously reported.
82
 A fixed concentration of substrate (kynuramine) and 
concentration response curve of inhibitor were used to determine the IC50 values. Kynuramine 
concentrations for MAO–A and –B were 80 and 50 μM, respectively. These concentrations were 
twice the apparent KM value for substrate binding.
83
 The concentrations run for 
fractions/constituents were from 0.001 to 100 μg/mL, acacetin from 0.001 to 100 μM for MAO-
A and 0.01 to 100 μM for MAO-B, and phenelzine from 0.001 to 100 μM for MAO-A and 
phenelzine from 0.01 to 100 μM for MAO-B. Reactions were performed in 200 μL of 0.1 M 
potassium phosphate buffer, pH 7.4. The inhibitors and compounds were dissolved in DMSO, 
diluted in the buffer solution, and preincubated at 37 °C for 10 min (1.0% of DMSO final). 
Reactions were initiated by the addition of 50 μL of MAO-A (to 5 μg/mL) and -B (to 10 μg/mL), 
incubated for 20 min at 37 °C, and terminated immediately by the addition of 75 μL of 2 N 
NaOH. The enzyme product formation (4-hydroxyquinoline) was recorded fluorometrically 
using a SpectraMax M5 fluorescence plate reader (Molecular Devices, Sunnyvale, CA, USA) 
with an excitation (320 nm) and emission (380 nm) wavelength, using the Soft Max Pro 
program. The assays were calculated as percent of product formation compared to the 
corresponding control (enzyme–substrate reaction) without inhibitors. Controls including 
samples where the enzyme or the substrate was added after stopping the reaction were checked 
simultaneously to determine the interference with the fluorescence measurements. The 
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determination of IC50 values for MAO–A and –B inhibition by the selected samples was 
performed using varying concentrations of the inhibitor and fixed concentration of the substrate. 
The IC50 values were calculated from the concentration-dependent inhibition curves using XLFit 
software. 
3.4.5. Enzyme Kinetics and Mechanism Studies 
Assays were performed at varying concentrations of kynuramine (1.90 to 500 μM) for the 
determination of the enzyme inhibition constants (Ki) for inhibition of MAO–A and –B with 
acacetin. In addition to controls without inhibitors, two concentrations (one below and one above 
the IC50 values) of the inhibitors [for MAO-A phenelzine (0.450 and 0.900 μM), acacetin (0.125 
and 0.250 μM), and for MAO-B phenelzine (0.050 and 0.100 μM), acacetin (0.045 and 0.090 
μM)] were used to determine the KM and Vmax values of the inhibitor. The results were expressed 
as double-reciprocal Lineweaver–Burk plots, and the kinetic data namely KM, Vmax, 
and Ki values, were calculated by SigmaPlot 12.3 with the Enzyme-Kinetics module using the 
Michaelis–Menten equation. The results were also analyzed for type of inhibition. 
3.4.6. Time-Dependent Enzyme Inhibition Assay 
In order to evaluate the inhibitors binding to both MAOs, each enzyme was preincubated 
for variable time periods (0–15 min) with the inhibitor at a concentration that results in 
approximately > 60% inhibition to verify whether the inhibition of the catalytic function was 
time-dependent. The concentrations of the inhibitor used to test the time-dependent inhibition 
with 20 μg/mL MAO-A were acacetin (0.500 μM) and phenelzine (0.600 μM) and with 50 
μg/mL MAO-B were acacetin (0.200 μM) and phenelzine (0.200 μM). Controls without 
inhibitors were also run. The enzyme activities were analyzed with the remaining enzyme 
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activity percentage plotted against the preincubation time to evaluate the time-dependent enzyme 
inhibition. 
3.4.7. Analysis of Inhibitor Binding and Reversibility with MAO–A and –B 
Many inhibitors result in the target enzyme inhibition by the formation of an enzyme–
inhibitor complex, which may be accelerated in the presence of high inhibitor concentration. The 
reversibility of acacetin binding to, and inhibition of MAO, was analyzed by incubating the 
enzyme with high inhibitor concentration followed by an extensive dialysis of the enzyme–
inhibitor complex and the recovery of enzyme catalytic activities. MAO-A (0.05 mg/mL protein) 
enzyme was incubated with acacetin (1.5 and 15.0 μM), and MAO-B (0.05 mg/mL protein) 
enzyme was incubated with acacetin (0.500 and 5.0 μM) in a total enzyme mixture of 1 mL 
volume including 100 mM potassium phosphate buffer (pH 7.4). After incubating for 20 min at 
37 °C, the reaction was stopped by cooling the reaction on ice. The samples were then dialyzed 
against potassium phosphate buffer for 14 h at 4 °C (three buffer changes). The same procedure 
was run using control enzyme (without inhibitor), and the enzyme activity was determined 
before and after dialysis. After extensive dialysis of the enzyme–inhibitor mixture, recovery of 
the enzyme catalytic activity provided the necessary information regarding the 
reversibility/irreversibility of the inhibitor binding with the enzyme. 
3.4.8. Molecular Modeling Calculations of Sesquiterpene Lactones 
Conformational search was carried out using MacroModel.
84
 We used mixed 
torsional/low-mode sampling method with intermediate torsion sampling. The energy window 
for saving conformers was defined as 5.02 kcal mol
−1
 to ensure thorough conformational search. 
The most abundant conformers according to Boltzmann distribution were subjected to DFT 
geometry optimization calculations protocol using Gaussian 09.  The M06-2X functional with 
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the 6-31+G(d,p) basis set was used for geometry optimization and  frequency  calculations.
76
 The 
NMR shielding tensors were calculated using the GIAO method of Gaussian 09 at B3LYP/ 6-
311+G(2d,p) functional level.
76
 To compute the ECD, we used TDDFT in Gaussian with B3LYP 
functional and 6-31G(d,p) basis set. PCM methanol solvent model was used. 
3.5. Summary 
Bioassay-guided fractionation of C. urticifolia resulted in the isolation of a flavonoid 
acacetin, as the most prominent MAO inhibitory constituent, with IC50 values of 121 and 49 nM 
for MAO-A and –B, respectively. Follow-up studies showed reversible binding of acacetin with 
human MAO-A and –B, resulting in competitive inhibition. Acacetin showed more preference 
towards MAO-B than to MAO-A, suggesting its potential for eliciting selective pharmacological 
effects that might be useful in the treatment of neurological and pyschiatric disorders. Further 
phytochemical investigation resulted in three novel bisabolenes: caleanolenes A-C, along with 
three known sesquiterpene lactones: 2,3-epoxyjuanislamin, calealactone B, and calein C. The 
chemical structures of the isolated compounds were determined on the basis of HRMS, IR, UV, 
and from 1D and 2D NMR spectroscopic studies. The configurations have been partly 
established using GIAO NMR and ECD calculations. The novel isolated compound: caleanolene 
A, and the known isolated compounds: 2,3-epoxyjuanislamin, calealactone B, and calein C were 
evaluated for cytotoxicity against the CA46 and Raji lymphoma, and the MCF7 breast cancer 
cell lines, with 2,3-epoxyjuanislamin showing the best activity in all cell lines (IC50 value range 
2.8 to 5.8 μM). In addition, the binding modes of acacetin at the enzymatic site of MAO-A and –
B were predicted through molecular modeling algorithms, illustrating the high improtance of 
ligand interaction with negative and positive free energy regions of the enzyme active site, 
described in the following chapter.  
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4.1. Introduction 
Molecular modeling studies will help identify the important interactions between the lead 
compounds and the residues on the active site. Ligand docking helps in understanding the 
surface complementarities of the receptor and the ligand, and the interactions between the ligand 
and receptor.
85,86
 
The modeling of MAO isoenzymes was done based on the available crystal structures 
downloaded from Research Collaboratory for Structural Bioinformatics (RCSB) protein data 
bank (PDB).
87
 We believe that the computational insights gained in this study would provide a 
platform to other medicinal chemists working in the area of MAO research, for the design and 
synthesis of novel MAO-B analogs. This could in turn result in the identification of new 
synthetic compounds with improved selectivity and potency for MAO-B. 
4.1.1. Specific Aims of the Research 
In order to achieve the above goals, the following specific aims were considered: 
1. To perform docking studies on acacetin to understand the binding modes of acacetin with 
the MAO active sites 
2. To establish the SAR of the virtual compounds obtained through docking studies which 
will help understand the major functional groups necessary to improve the selectivity and 
potency towards MAO-B 
3. To design selective MAO-B analogs which will be synthesized and biologically evaluated 
for MAO inhibition 
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4.2. Computational Methods 
4.2.1. Protein Preparation and Receptor Grid Generation 
The protein structural files of MAO-A (PDB ID: 2Z5Y)
88
 and MAO-B (PDB 
ID: 4A79)
89
 were downloaded from the protein databank repository.
87
 Protein structures were 
prepared by Protein Preparation Wizard (PrepWizard)
90,91
 of the Schrödinger suite to add 
missing hydrogen atoms, adjust bond orders, assign hydrogen bonds, and relax the protein–
ligand complex. The missing loops and amino acid side chains were filled using Prime.
92
 The 
center of the docking receptor grids was defined as the coordinate of cognate ligands. The 
potential of the nonpolar parts of the receptor was softened by scaling the van der Waals radius 
by a factor of 0.8 and partial charge cutoff of 0.25. The receptor thiol and hydroxyl groups were 
allowed to rotate for optimal hydrogen bond formation with predicted docked poses. Ligand 
sampling and preparation were performed using LigPrep
93
 of Schrödinger by using the 
OPLS2005 force field
94
 and charges. All possible ligand states at pH 7.4 were generated by 
Epik,
95
 and the known ligand stereogenic centers were retained during preparation.  
4.2.2. Docking and Scoring 
The compounds were then docked using Glide
96
 standard precision (SP) mode, and the 
top 5 poses were kept for analysis. The thermodynamic properties of the ligand binding pockets 
of MAO-A and MAO-B were then studied, in order to map the active site water molecules.
97
 The 
protein structures were prepared by PrepWizard.
88
 The partial charges of the amino acids were 
assigned by AmberFF94 charges, and the ligands with AM1BCC.
98,99
 The thermodynamic 
properties of the complex, apo, and ligand were calculated separately by using a probe of explicit 
water molecules. Then, the excess free energy water molecules that are supposed to be displaced 
by the ligand were determined. 
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4.3. Design of Selective MAO-B Inhibitors 
4.3.1. Observations of the Binding Modes of Acacetin 
Acacetin binds more favorably to MAO-B [Figure 4.1] with a better Glide docking score 
of −8.1 kcal/mol, emodel of −64 kcal/mol, and MMGBSA binding ΔG of −76 kcal/mol than with 
MAO-A [Figure 4.1] (Glide docking score = −6.2 kcal/mol, emodel = −30 kcal/mol, and ΔG = 
−54 kcal/mol). Acacetin tightly bound to MAO-B by forming a network of hydrogen bonds with 
the surrounding water molecules and amino acid residues. 
 
Figure 4.1. Binding modes of acacetin MAO-A (A) and with MAO-B (B) 
The enzyme kinetics and binding studies of acacetin mentioned in chapter 3 inspired us to 
use docking simulation to investigate the binding modes of acacetin in the structurally similar 
ligand binding pockets of MAO-A and MAO-B. The active site of MAO-A contains six water 
molecules [Figure 4.2] that form more than two hydrogen bonds with nonwaters. MAO-B 
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encloses 10 water molecules in the active site. Tyr 326 in MAO-B, which corresponds to Ile 335 
in MAO-A, plays an important role in imparting more polarity to the active site and attracting 
waters to the binding pocket [Figure 4.2]. Tyr 326 forms strong hydrogen bonds with two active 
site waters (W7b and W8b), while the Ile 335 of MAO-A is hydrophobic and only W6a is 
observed in close proximity to W7b. Five water molecules (W1–W5) have the same atomic 
coordinates in both enzymes, while one water (W6a) in MAO-A and five water molecules 
(W6b–W10b) in MAO-B are in different regions of the active site. 
 
Figure 4.2. Active site water molecules in MAO-A and MAO-B. MAO-A is displayed as pink 
and MAO-B as green cartoon. Water molecules of MAO-A are shown as red and those of MAO-
B as gray spheres. 
The thermodynamic properties of the active sites of MAO-A and -B crystal structures 
were inspected using SZMAP. The negative free energy regions of the ligand binding pocket of 
MAO-A and -B show a high tendency to hold water molecules and high affinity towards polar 
functional groups. The positive free energy regions prefer nonpolar molecular increments 
[Figure 4.3]. Water molecules in the crystal structures of MAO-A were carefully checked for 
their existence in favorable or unfavorable regions. W1, W4, W5, and W6a of MAO-A are 
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favorably located in thermodynamic stable positions, while W2 and W3 are in unfavorable 
regions. This means, by displacing W2 and/or W3 with hydrophobic groups, MAO-A activity of 
the ligands will increase. By improving the interaction with the four waters in the favorable 
positions or by displacing them with polar groups, acacetin can be further modified to be a more 
potent MAO-A modulator. The binding site of MAO-B contains W1, W3, W5, W6b, W7b, W8b, 
W9b, and W10b in thermodynamically favorable locations. W2 of MAO-B exists in an 
unfavorable region similar to that of MAO-A. The active site of MAO-B holds more negative 
free energy regions compared to MAO-A and, in particular, close to Phe 208 (MAO-A) and 
Ile199 (MAO-B). Enhancement of MAO-B inhibition can be achieved by considering 
appropriate functional groups that interact with the negative and positive free energy regions of 
the binding site. 
 
Figure 4.3. Thermodynamic properties of the ligand binding pockets of MAO-A and MAO-B. 
The regions that favor the presence of water molecules are shown as wheat-colored and those 
favoring nonpolar groups as pale cyan surfaces. The active sites of MAO-A and MAO-B are 
aligned A and B with the thermodynamic maps of MAO-A (A) and MAO-B (B), respectively. 
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Crystal structure water molecules that are in the wheat regions are supposed to be native ones, 
and those in the cyan areas are artificial because of crystallization. The thermodynamic map of 
MAO-A (C) shows less favorable regions for water and polar groups compared to that of MAO-
B (D). Two water molecules are found in close proximity to Tyr 326 of MAO-B (D). Water 
molecules are shown as red for MAO-A and gray spheres for MAO-B. 
Figure 4.4 represents the 2D interaction profiles of acacetin on MAO-A and MAO-B 
explaining the interactions between the ligand (acacetin) and the active sites. We observe a 
cationic-pi interaction between Arg51 of MAO-A and the aromatic ring of acacetin. Similarly, 
we observe a cationic-pi interaction between Tyr326 of MAO-B enzyme and the aromatic ring of 
acacetin. Water molecules in the active site interacted with the hydroxyl functional groups 
through hydrogen bonding in both the MAO isoenzymes.  
  
 
 
Figure 4.4. 2D interaction profiles of acacetin with MAO-A and MAO-B 
MAO-A MAO-B 
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The 2D interaction profile showed that there is opportunity for modifications at the R1 
and R2 positions. R2 has room for bulky groups such as nonpolar/lipophilic groups at R2 position 
which is the 4ʹ position of the flavone skeleton of acacetin to make the analogs MAO-B 
selective. The OH present at R1 position seems to show interaction with the MAO enzymes and 
there is room for small groups [Figure 4.5]. 
 
Figure 4.5. Crucial positions representing the modifications in acacetin 
4.3.2. Structure-Activity Relationship of Acacetin 
SAR is a correlation study between the drug-structure and its biological activity. SAR is 
essential for the design of compounds with high potency and less adverse effects. Developing 
SAR helps in determining the chemical groups at specified positions in the drug-structure, to 
improve the biological effects on the target. SAR is used by medicinal chemists to modify the 
drug-structures and test the modifications of the biological activities.   
The SAR of acacetin is explained in Figure 4.6. The selectivity of MAO inhibition 
(MAO-A vs MAO-B) depends on the substituents present on the B ring, and the presence of the 
double-bond present in position 2 and 3 of C ring. The presence of hydrophilic groups in the para 
position of B ring favors MAO-A inhibition, while the presence of lipophilic groups favors 
MAO-B inhibition. Shifting of B ring from postion-2 to position-3 decreases MAO-B inhibition. 
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Figure 4.6. Structure-activity relationship of acacetin 
4.4. Results and Discussion 
Based on the understanding of the binding modes of acacetin and the structure-activity 
relationship, sixteen analogs of acacetin were designed [Figure 4.7]. The sixteen analogs were 
drawn in ChemDraw and saved as individual .sdf files. The files were uploaded to the Maestro 
interface of the Schrӧdinger suite and were minimized to acquire their 3D conformations. The 
3D structures were then prepared using LigPrep, which prepares the ligands at certain pH ranges 
[pH 7.4 used]. The sixteen analogs were docked in the active sites of both MAO-A and –B using 
Glide docking to retrieve their docking scores and poses [Table 4.1]. 
 
Figure 4.7. Chemical structures of the 16 acacetin analogs  
90 
Table 4.1 shows the docking scores of acacetin and the sixteen acacetin analogs that 
were designed based on the SAR of acacetin. All the derivatives scored better than acacetin in 
MAO-B. All the sixteen compounds were synthesized and were assayed for their MAO-B 
inhibitory activity and potency. 
Table 4.1. Docking scores of acacetin analogs 
Compound 
MAO-A 
Docking score [kcal/mol] 
MAO-B 
Docking score [kcal/mol] 
1 - -15.243 
2 - -15.102 
3 - -15.663 
4 - -15.545 
5 - -16.172 
6 - -15.451 
7 - -14.912 
8 - -15.866 
9 - -16.084 
10 -2.240 -15.129 
11 - -14.667 
12 0.127 -14.989 
13 - -15.756 
14 - -14.807 
15 - -14.936 
16 - -15.452 
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Acacetin -6.2 -8.1 
4.5. Summary 
We designed sixteen acacetin analogs to study the effect of non-polar substituents. The 
analogs were designed based on the binding modes and the SAR of acacetin. Liphophilic groups 
were introduced on the R2 position to improve the MAO-B selectivity of these analogs. Two 
different series (flavonoid and pyridine) were designed to understand their selectivity towards 
MAO-B. Similarly oxygen and nitrogen substituents were used on the B ring with both flavonoid 
and pyridine series, to study the difference in their affinity for MAO-B. Furthermore, these 
analogs also showed excellent docking scores for MAO-B supporting our design. 
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CHAPTER 5. SYNTHESIS OF DESIGNED SELECTIVE MAO-B INHIBITORS 
Vedanjali Gogineni, Francisco León, Manal A. Nael, Narayan D. Chaurasiya, Babu L. Tekwani, 
Stephen J. Cutler, Christopher R. McCurdy, and John M. Rimoldi 
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5.1. Specific Aims of the Research 
The following specific aims were outlined: 
1. To synthesize analogs that were designed based on the docking studies of acacetin (See
Chapter 4) 
2. To purify the synthesized analogs and perform mass and HPLC purity analysis on the
purified compounds 
3. To perform MAO inhibition, enzyme-kinetics and mechanistic studies, and binding
affinity studies on the synthesized analogs 
5.2. Chemistry 
The synthesis of the flavonoid series was achieved through the methods illustrated in 
Scheme 1. 
Scheme 5.1. Synthesis of (oxygenated) flavonoid series [1-4] 
Reagents and conditions: (a) NaOH 50%, EtOH, rt, 16-20 h (b) I2, DMSO, 140 °C, 4-6 h (c) 
1N BBr3, CH2Cl2, rt, 1-3 h 
Chalcones 1a, 2a, 3a, 4a were afforded through Schmidt condensation by reacting 2ʹ-
hydroxy-4ʹ,6ʹ-dimethoxyacetophenone I and the corresponding 4-benzaldehydes II with  50% 
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sodium hydroxide in ethanol. The intermediate flavonoids 1b, 2b, 3b, 4b were prepared by 
treatment of the chalcones with iodine crystals in minimal amount of DMSO by undergoing 
cyclization. The final compounds 1c, 2c, 3c, 4c were prepared by demethylation of the OH in the 
5
th
 position of the ‘A’ ring, when the intermediates 1b, 2b, 3b, 4b were treated with boron
tribromide (BBr3) in CH2Cl2. 
Scheme 5.2. Synthesis of (oxygenated) flavonoid series with cyclopropane substituent [5] 
Reagents and conditions: (a) acetone, K2CO3, reflux 24 h (b) NaOH 50%, EtOH, rt, 16-20 h (c) 
I2, DMSO, 140 °C, 4-6 h (d) 1N BBr3, CH2Cl2, rt, 1-3 h 
4-(cyclopropylmethoxy)benzaldehyde IV was afforded by reacting 
(bromomethyl)cyclopropane III with 4-hydroxybenzaldehyde II with acetone and potassium 
carbonate. Chalcone 5a was prepared through Schmidt condensation by treatment of the 
cyclopropyl aldehyde IV with 2ʹ-hydroxy-4ʹ,6ʹ-dimethoxyacetophenone I and 50% sodium 
hydroxide in ethanol. The intermediate flavonoid 5b was prepared by the treatment of the 
chalcone with iodine crystals in minimal amount of DMSO by undergoing cyclization. The final 
compound 5c was prepared by demethylation of the OH in the 5
th
 position of the ‘A’ ring, when
the intermediate 5b was treated with boron tribromide in dichloromethane. 
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Scheme 5.3. Synthesis of (nitrogenated) flavonoid series [6-9] 
Reagents and conditions: (a) NaOH 50%, EtOH, rt, 16-20 h (b) I2, DMSO, 140 °C, 4-6 h (c) 
NaO
t
Bu, Pd2(dba)3, corresponding amines [propylamine, isopropylamine, propargylamine, and
(aminomethyl)cyclopropane], BINAP, toluene, 80 °C, 48 h (d) 1N BBr3, CH2Cl2, rt, 1-2 h 
Compounds 6-9 were prepared as shown in scheme 3. The brominated chalcone 6a was 
produced by treating 2ʹ-hydroxy-4ʹ,6ʹ-dimethoxyacetophenone I with 4-bromobenzaldehyde V 
through Schmidt condensation with 50% sodium hydroxide in ethanol. The brominated flavonoid 
6b was prepared from the treatment of the chalcone with iodine crystals in minimal amount of 
DMSO by undergoing cyclization. The intermediates 6c, 7c, 8c, 9c were prepared by treating 
compound 6b with sodium tert-butoxide, tris(dibenzylideneacetone)dipalladium, 1,1ʹ-
binaphthalene-2,2ʹ-diylbis(diphenylphosphine), and the corresponding amines such as 
propylamine, isopropylamine, propargylamine, and (aminomethyl)cyclopropane in toluene. The 
final compounds 6d, 7d, 8d, 9d were prepared by demethylation of the OH in the 5
th
 position of
the ‘A’ ring, when the intermediates 6c, 7c, 8c, 9c were treated with boron tribromide in 
dichloromethane. 
96 
Scheme 5.4. Synthesis of (oxygenated) pyridine series [10-12] 
Reagents and conditions. (a) NaH, DMF, rt, 17 h (b) pyridinium hydrochloride, 190 °C, 17 h 
The diketo intermediates 10a, 11a, 12a were formed from reacting methyl-2-methoxy 
nicotinate VI and the corresponding 4ʹ-acetophenones VII in the presence of sodium hydride and 
dimethyl formamide. The final oxygenated pyridine compounds 10b, 11b, 12b were 
accomplished from the treatment of the corresponding diketo intermediates 10a, 11a, 12a with 
pyridinium hydrochloride through cyclization. 
Scheme 5.5. Synthesis of 2-(4-(cyclopropylmethoxy)phenyl)-4H-pyrano[2,3-b]pyridin-4-one 
[13] 
Reagents and conditions. (a) acetone, K2CO3, reflux 24 h (b) NaH, DMF, rt, 17 h (c) 
pyridinium hydrochloride, 190 °C, 17 h 
The 1-(4-(cyclopropylmethoxy)phenyl)ethan-1-one VIII was formed by treating 
(bromomethyl)cyclopropane III and 4ʹ-hydroxy acetophenone II in the presence of acetone and 
potassium carbonate. The intermediate 13a was prepared by treating VIII with methyl-2-
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methoxy nicotinate VI in the presence of sodium hydride and dimethyl formamide. The final 
compound 13b was furnished from treating the intermediate 13a with pyridinium hydrochloride. 
Scheme 5.6. Synthesis of (nitrogenated) pyridine series [14-16] 
Reagents and conditions. (a) NaH, DMF, rt, 19 h (b) pyridinium hydrochloride, 190 °C, 4 h (c) 
NaO
t
Bu, Pd2(dba)3, corresponding amines [propylamine, isopropylamine, and propargylamine],
BINAP, toluene, 80 °C, 48 h 
The brominated diketo compound 14a was prepared by reacting methyl-2-methoxy 
nicotinate VI and 4ʹ-bromo acetophenone IX with sodium hydride and dimethyl formamide. 
Upon further treatment of the compound 14a with pyridinium hydrochloride resulted in the 
formation of the intermediate 14b. Final compounds 14c, 15c, 16c were accomplished from the 
treatment of the intermediate 14b with sodium tert-butoxide, 
tris(dibenzylideneacetone)dipalladium, 1,1ʹ-binaphthalene-2,2ʹ-diylbis(diphenylphosphine), and 
the corresponding amines such as propylamine, isopropylamine, and propargylamine in toluene. 
5.3. Results and Discussion 
We screened a total of 38 compounds which also included the intermediates along with 
the final compounds for MAO inhibition assay. The potent compounds from Table 5.1 were 
evaluated for the mechanism and kinetics of the inhibition of human MAO-A and B. 
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Table 5.1. Inhibition of recombinant human monoamine oxidase-A and –B by the synthesized 
analogs 
Synthesized Analogs MAO-A [IC50]
a,b 
MAO-B [IC50]
a,b
1a 0.515 ± 0.024 0.40 ± 0.024 
1b > 100 1.70 ± 0.076 
1c 48.78 ± 2.01 0.033 ± 0.0042 
2a 0.117 ± 0.05 0.049 ± 0.0035 
2b > 100 2.64 ± 0.0880 
2c 30.74 ± 0.023 0.016 ± 0.0070 
3a 0.42 ± 0.002 0.22 ± 0.0211 
3b > 100 7.23 ± 2.1438 
3c > 100 0.031 ± 0.0070 
4a 9.42 ± 1.78 8.33 ± 0.7871 
4b > 100 > 100 
4c 62.70 ± 5.21 0.049 ± 0.0014 
5a 1.30 ± 0.09 0.90 ± 0.035 
5b > 100 22.82 ± 2.098 
5c - - 
6a 12.349 ± 0.249 - 
6b 87.830 ± 5.449 28.407 ± 2.639 
6c - 22.097 ± 2.479 
6d 85.484 ± 1.585 1.554 ± 0.137 
99 
7c 37.492 ± 0.476 9.447 ± 0.113 
7d 40.500 ± 2.374 0.417 ± 0.012 
8c - - 
8d - - 
9c 39.095 ± 5.144 12.727 ± 0.290 
9d 39.114 ± 0.555 2.185 ± 0.088 
10a 6.50 ± 1.22 0.23 ± 0.003 
10b 0.104 ± 0.0014 0.020 
11a 10.13 ± 0.085 0.161 ± 0.0022 
11b 0.0875 ± 0.0035 0.010 ± 0.0014 
12a 58.44 ± 0.184 3.98 ± 0.297 
12b - - 
13a 11.10 ± 0.025 0.367 ± 0.0044 
13b 0.207 ± 0.006 < 0.1 
14a - 3.458 ± 0.829 
14b 3.909 ± 0.452 0.284 ± 0.029 
14c 0.569 ± 0.003 0.138 ± 0.012 
15c 0.389 ± 0.008 < 0.1 
16c - - 
Acacetin 0.105 ± 0.0014 0.042 ± 0.0021 
Clorgyline 0.0039 ± 0.0002 2.15 ± 0.212 
Deprenyl 33.00 ± 1.411 0.046 ± 0.0014 
Harmine 0.0031 ± 0.0003 39.000 ± 1.412 
100 
a
The IC50 values computed from the dose-response inhibition curves are mean ± SD of triplicate 
observations; 
b
µM; * Highlighted items represent the potent analogs 
Based on the results, we found that the flavonoid series were more potent and selective 
compared to the pyridine series. The reason behind the flavonoid series being more potent than 
the pyridine series could be explained from the fact that the flavonoid series were large enough 
to completely occupy the MAO-B active site. Among the flavonoid series, we observed that the 
oxygen substituents showed more selectivity towards MAO-B compared to the nitrogen series. 
5.4. Experimental Methods 
The general experimental methods were similar to those mentioned in page 48. CDCl3 
and CD3OD were used as solvents and TMS was used as an internal standard. 
5.4.1. Chemicals 
All the chemicals used were purchased from Sigma-Aldrich. Human recombinant 
monoamine oxidase-A and monoamine oxidase-B enzymes were obtained from BD Biosciences 
(Bedford, MA, USA). Kynuramine, clorgyline, deprenyl, phenelzine, and DMSO were 
purchased from Sigma Chemical (St. Louis, MO, USA). Purified acacetin from previous project 
has been used. 
5.4.2. MAO Inhibition Assay 
Refer to page 77. 
5.4.3. Enzyme Kinetics and Mechanism Studies 
Refer to page 78. 
5.4.4. Time-Dependent Enzyme Inhibition Assay 
Refer to page 78. 
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5.4.5. Analysis of Inhibitor Binding and Reversibility with MAO-A and –B 
Refer to page 79. 
Preparation of the Chalcone (E) 4-Propyloxy-4',6'-Dimethoxy-2'-Hydroxychalcone [1a]: A 
mixture of equimolar amounts of 2ʹ-hydroxy-4ʹ,6ʹ-dimethoxyacetophenone (300 mg, 1.53 mmol) 
and 4-n-propoxybenzaldehyde (251 mg, 1.53 mmol) was taken in a round-bottomed flask (RBF) 
and 10 mL of  50% sodium hydroxide in ethanol was added and left for 16 h at rt. The resulting 
yellow precipitate was then suction filtered and washed with Hex and CH2Cl2 to yield 1a (342 
mg, 65%). 
1
H NMR (400 MHz, CDCl3) δH 14.41 (s, C-2′-OH), 7.79 (s br, 2H, H-α and H-β),
7.55 (d, J = 8.5 Hz, 1H, H-2 and H-6), 6.91 (d, J = 8.5 Hz, 2H, H-3 and H-5), 6.10 (d, J = 1.8 Hz, 
1H, H-3′), 5.96 (d, J = 1.8 Hz, 1H, H-5′), 3.97 (t, J = 6.5, 2H, H2-1′′), 3.93 (s, 3H, OCH3), 3.85 
(s, 3H, OCH3), 1.83 (dt, J = 6.5, 7.4 Hz, 2H, H2-2′′), 1.05 (t, J = 7.4 Hz, 3H, CH3-3′′). 
13
C NMR
(100 MHz, CDCl3) δC 192.6 (C=O), 168.3 (C-2′), 166.0 (C-4′), 162.4 (C-6′), 161.0 (C-4), 142.6 
(C-β), 130.1 (C-2 and C-6), 128.1 (C-1), 124.9 (C-α), 114.8 (C-3 and C-5), 106.3 (C-1′), 93.8 (C-
3′), 91.2 (C-5′), 69.6 (C-1′′), 55.8 (OCH3), 55.5 (OCH3), 22.5 (C-2′′), 10.5 (C-3′′). ESIMS m/z 
343.0897 [M+H]
+
 (calcd C20H22O5 342.1467).
Preparation of Oxygenated Intermediate Flavonoid 5,7-Dimethoxy-4'-Propyloxyflavone 
[1b]: The chalcone 1a (200 mg, 0.584 mmol) was treated with 3-4 mol% of iodine crystals with 
minimal amount of DMSO at 140 °C for 4-6 h. The resulting white precipitate was extracted 
with CH2Cl2 and was removed by filtration. The filtrate was transferred into a separatory funnel, 
where the layers were separated as aqueous and organic layers. The organic layer was washed 
with sodium thiosulfate (Na2S2O3), dried (Na2SO4), and concentrated. The intermediate 
flavonoid 1b was then purified in a silica column using 100% CH2Cl2, 50:1 CH2Cl2-MeOH, 9:1 
CH2Cl2-MeOH, 1:1 CH2Cl2-MeOH, and 100% MeOH (128 mg, 64%). 
1
H NMR (400 MHz,
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CDCl3) δH 7.80 (d, J = 8.9 Hz, 2H, H-2′ and H-6′), 6.98 (d, J = 8.9 Hz, 2H, H-3′ and H-5′), 6.59 
(s, 1H, H-3), 6.57 (d, J = 2.3 Hz, 1H, H-6), 6.37 (d, J = 2.3 Hz, 1H, H-8), 3.99 (t, J = 6.6 Hz, 2H, 
H2-1′′), 3.96 (s, OCH3), 3.91 (s, OCH3), 1.84 (dt, J = 6.5, 7.4 Hz, 2H, H2-2′′), 1.06 (t, J = 7.4 Hz, 
3H CH3-3′′). 
13
C NMR (100 MHz, CDCl3) δC 177.7 (C-4), 163.9 (C-2), 161.6 (C-5), 160.9 (C-
4′), 160.7 (C-9), 159.8 (C-7), 127.5 (C-2′ and C-6′), 123.5 (C-1′), 114.8 (C-3′ and C-5′), 109.2 
(C-10), 107.6 (C-3), 96.0 (C-8), 92.8 (C-6), 69.7 (C-1′′), 56.4 (OCH3), 55.7 (OCH3), 22.5 (C-2′′), 
10.5 (C-3′′). ESIMS m/z 341.0738 [M+H]+ (calcd C20H20O5 340.1311).
Preparation of Final Oxygenated Flavonoid 7-Methoxy-4'-Propyloxy-5-Hydroxyflavone 
[1c]: The intermediate 1b (128 mg, 0.377 mmol) was treated with double the moles of 1N boron 
tribromide (189 mg, 0.754 mmol) in the presence of CH2Cl2 at rt, for 1-3 h. The reactant solution 
was diluted with 10:1 CH2Cl2:MeOH and then washed with brine and water. Na2SO4 was added 
to the solution and left overnight. The solution was then filtered into an RBF, dried, and 
concentrated. The flavonoid 1c was purified in a silica column using 30:1 CH2Cl2-MeOH (35 
mg, 29%). 
1
H NMR (400 MHz, CDCl3) δH 12.83 (s, C-5-OH), 7.82 (d, J = 8.9 Hz, 2H, H-2′ and
H-6′), 7.00 (d, J = 8.9 Hz, 2H, H-3′ and H-5′), 6.56 (s, 1H, H-3), 6.47 (d, J = 2.2 Hz, 1H, H-6), 
6.35 (d, J = 2.2 Hz, 1H, H-8), 4.00 (t, J = 6.6 Hz, 2H, H2-1′′ ), 3.88 (s, OCH3), 1.86 (ddd, J = 6.6, 
7.4 Hz, 2H, H2-2′′), 1.08 (t, J = 7.4 Hz, 3H, CH3-3′′). 
13
C NMR (100 MHz, CDCl3) δC 182.4 (C-
4), 165.4 (C-7), 164.0 (C-2), 162.2 (C-4′), 162.1 (C-5), 157.6 (C-9), 127.7 (C-2′ and C-6′), 123.5 
(C-1′), 115.0 (C-3′ and C-5′), 105.5 (C-10), 104.2 (C-3), 98.0 (C-8), 92.5 (C-6), 69.8 (C-1′′), 55.8 
(OCH3), 22.5 (C-2′′), 10.5 (C-3′′). ESIMS m/z 327.0637 [M+H]
+
 (calcd C19H18O5 326.1154).
Preparation of the Chalcone (E) 4-Isopropyloxy-4',6'-Dimethoxy-2'-Hydroxychalcone [2a]: 
Procedure for the preparation of the chalcone 2a is similar to the preparation of the chalcone 1a 
except for the use of 4-isopropoxybenzaldehyde (251 mg, 1.53 mmol). The chalcone 2a was 
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purified in a silica column using 4:1 Hex-EtOAc, 3:1 Hex-EtOAc, 4:1 EtOAc-Hex, 100% 
EtOAc, and 100% MeOH (411 mg, 79%). 
1
H NMR (400 MHz, CDCl3) δH 14.43 (s, C-2′-OH),
7.80 (s br, 2H, H-α and H-β), 7.55 (d, J = 8.7 Hz, 2H, H-2 and H-6), 6.91 (d, J = 8.7 Hz, 2H, H-3 
and H-5), 6.12 (d, J = 2.3, 1H, H-3′), 5.97 (d, J = 2.3, 1H, H-5′), 4.62 (sept, J = 6.0 Hz, 1H, H-
1′ʹ), 3.93 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 1.37 (d, J = 6.0 Hz, 6H, CH3-2′′ and CH3-3′′). 
13
C
NMR (100 MHz, CDCl3) δC 192.6 (C=O), 168.3 (C-2′), 166.0 (C-4′), 162.4 (C-6′), 159.8 (C-4), 
142.6 (C-β), 130.1 (C-2 and C-6), 127.9 (C-1), 124.9 (C-α), 115.9 (C-3 and C-5), 106.4 (C-1′), 
93.8 (C-3′), 91.2 (C-5′), 70.0 (C-1′′), 55.8 (OCH3), 55.6 (OCH3), 22.0 (C-2′′ and C-3′′). ESIMS 
m/z 343.0876 [M+H]
+
 (calcd C20H22O5 342.1467).
Preparation of Oxygenated Intermediate Flavonoid 5,7-Dimethoxy-4'-Isopropyloxyflavone 
[2b]: Procedure is similar to the preparation of the intermediate flavonoid 1b. The intermediate 
flavonoid 2b was purified in a silica column using 1:1 Hex-EtOAc, 100% EtOAc, 20:1 EtOAc-
MeOH, and 100% MeOH (78 mg, 52%). 
1
H NMR (400 MHz, CDCl3) δH 7.78 (d, J = 8.9 Hz,
2H, H-2′ and H-6′), 6.95 (d, J = 8.9, 2H, H-3′ and H-5′), 6.56 (s, 1H, H-3), 6.53 (d, J = 2.3, 1H, 
H-6), 6.34 (d, J = 2.3, 1H, H-8), 4.62 (sept, J = 6.0 Hz, 1H, H-1′′), 3.93 (s, 3H, OCH3), 3.89 (s, 
3H, OCH3), 1.36 (d, J = 6.0 Hz, 6H, CH3-2
ʹʹ
 and CH3-3′′). 
13
C NMR (100 MHz, CDCl3) δC 177.6
(C-4), 163.8 (C-2), 160.8 (C-5), 160.7 (C-4′), 160.5 (C-9), 159.8 (C-7), 127.6 (C-2′ and C-6′), 
123.3 (C-1′), 115.8 (C-3′ and C-5′), 109.2 (C-3), 109.2 (C-10), 107.5 (C-3), 96.0 (C-8), 92.8 (C-
6), 70.1 (C-1′′), 56.4 (OCH3), 55.7 (OCH3), 21.9 (C-2′′ and C-3ʹʹ). ESIMS m/z 341.0796 [M+H]
+
(calcd C20H20O5 340.1311). 
Preparation of Final Oxygenated Flavonoid 7-Methoxy-4'-Isopropyloxy-5-Hydroxyflavone 
[2c]: Procedure is similar to the preparation of the final flavonoid 1c. The final flavonoid 2c was 
purified in a silica column using 7:3 Hex-EtOAc and 1:1 Hex-EtOAc (6 mg, 10%). 
1
H NMR
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(400 MHz, CDCl3) δH 12.83 (s, C-5-OH), 7.83 (d, J = 8.9 Hz, 2H, H-2′ and H-6′), 6.99 (d, J = 
8.9 Hz, 2H, H-3′ and H-5′), 6.58 (s, 1H, H-3), 6.49 (d, J = 2.2 Hz, 1H, H-6), 6.37 (d, J = 2.2 Hz, 
1H, H-8), 4.66 (sept, J = 6.0 Hz, 1H, H-1′′), 3.89 (s, 3H, OCH3), 1.40 (d, J = 6.0 Hz, 6H, CH3-2ʹʹ 
and CH3-3ʹʹ). 
13
C NMR (100 MHz, CDCl3) δC 182.4 (C-4), 165.4 (C-7), 164.1 (C-2), 162.2 (C-
4′), 161.1 (C-5), 157.3 (C-9), 128.0 (C-2′ and C-6′), 123.1 (C-1′), 115.9 (C-3′ and C-5′), 105.5 
(C-10), 104.2 (C-3), 98.0 (C-8), 92.6 (C-6), 70.2 (C-1′′), 55.8 (OCH3), 21.9 (C-2′′ and C-3′′). 
ESIMS m/z 327.0724 [M+H]
+
 (calcd C19H18O5 326.1154).
Preparation of the Chalcone (E) 4-Isobutyloxy-4',6'-Dimethoxy-2'-Hydroxychalcone [3a]: 
Procedure is similar to the preparation of the chalcone 1a except for the use of 4-isobutoxy 
benzaldehyde (273 mg, 1.53 mmol). The chalcone 3a was purified in a silical column using 
CH2Cl2 (436 mg, 80%). 
1
H NMR (500 MHz, CDCl3) δH 14.45 (s, C-2′-OH), 7.82 (s, br, 2H, H-α
and H-β), 7.57 (d, J = 8.8 Hz, 2H, H-2 and H-6), 6.94 (d, J = 8.8 Hz, 2H, H-3 and H-5), 6.13 (d, 
J = 2.4 Hz, 1H, H-3′), 5.99 (d, J = 2.4 Hz, 1H, H-5′), 3.94 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 
3.79 (d, J = 6.6 Hz, 2H, H2-1′ʹ), 2.13 (sept, J = 6.7 Hz, 1H, H-2′ʹ), 1.06 (d, J = 6.7 Hz, 6H, CH3-
3′′ and CH3-4′′). 
13
C NMR (125 MHz, CDCl3) δC 192.6 (C=O), 168.4 (C-2′), 166.0 (C-4′), 162.4
(C-6′), 161.1 (C-4), 142.6 (C-β), 130.1 (C-2 and C-6), 128.0 (C-1), 124.9 (C-α), 114.9 (C-3 and 
C-5), 106.4 (C-1′), 93.8 (C-3′), 91.2 (C-5′), 74.5 (C-1′′), 55.8 (OCH3), 55.6 (OCH3), 28.2 (C-2′′), 
19.2 (C-3′′ and C-4′′). ESIMS m/z 357.0610 [M+H]+ (calcd C21H24O5 356.1624).
Preparation of Oxygenated Intermediate Flavonoid 5,7-Dimethoxy-4'-Isobutyloxyflavone 
[3b]: Procedure is similar to the preparation of the intermediate flavonoid 1b. The intermediate 
flavonoid 3b was purified in a silica column using 1:1 Hex-EtOAc, 8:2 EtOAc-Hex, 100% 
EtOAc, 20:1 EtOAc, and 9:1 EtOAc-MeOH (113 mg, 57%). 
1
H NMR (400 MHz, CDCl3) δH
7.73 (d, J = 8.6 Hz, 2H, H-2′ and H-6′), 6.92 (d, J = 8.4 Hz, 2H, H-3′ and H-5′), 6.52 (s, 1H, H-
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3), 6.48 (d, J = 1.4 Hz, 1H, H-6), 6.29 (d, J = 1.6 Hz, 1H, H-8), 3.89 (s, 3H, OCH3), 3.85 (s, 3H, 
OCH3), 3.73 (d, J = 6.5 Hz, 2H, H2-1′′), 2.07 (sept, J = 6.7 Hz, 1H, H-2′′), 1.00 (d, J = 6.7 Hz, 
6H, CH3-3′′ and CH3-4′′). 
13
C NMR (100 MHz, CDCl3) δC 177.6 (C-4), 163.8 (C-2), 161.7 (C-5),
160.7 (C-4′ and C-9), 159.7 (C-7), 127.4 (C-2′ and C-6′), 123.4 (C-1′), 114.8 (C-3′ and C-5′), 
109.0 (C-10), 107.4 (C-3), 96.0 (C-8), 92.8 (C-6), 74.5 (C-1′′), 56.3 (OCH3), 55.7 (OCH3), 28.2 
(C-2′′), 19.2 (C-3′′ and C-4′′). ESIMS m/z 355.0958 [M+H]+ (calcd C21H22O5 354.1467).
Preparation of Final Oxygenated Flavonoid 7-Methoxy-4'-Isobutyloxy-5-Hydroxyflavone 
[3c]: Procedure is similar to the preparation of the final flavonoid 1c. The final flavonoid 3c was 
purified in a silica column using 7:3 EtOAc-Hex and 100% EtOAc (40 mg, 44%). 
1
H NMR (400
MHz, CDCl3) δH 12.83 (s, C-5-OH), 7.81 (d, J = 8.9 Hz, 2H, H-2′ and H-6′), 7.00 (d, J = 8.9 Hz, 
2H, H-3′ and H-5′), 6.56 (s, 1H, H-3), 6.47 (d, J = 2.2 Hz, 1H, H-6), 6.36 (d, J = 2.2 Hz, 1H, H-
8), 3.88 (s, 3H, OCH3), 3.80 (d, J = 6.6 Hz, 2H, H2-1′′), 2.14 (sept, J = 6.6 Hz, 1H, CH3-2′′), 1.07 
(d, J = 6.7 Hz, 6H, CH3-3′′ and CH3-4′′). 
13
C NMR (100 MHz, CDCl3) δC 182.4 (C-4), 165.4 (C-
7), 164.1 (C-2), 162.3 (C-4′), 162.1 (C-5), 157.6 (C-9), 127.9 (C-2′ and C-6′), 123.1 (C-1′), 114.9 
(C-3′ and C-5′), 105.5 (C-10), 104.1 (C-3), 98.0 (C-8), 92.5 (C-6), 74.6 (C-1′′), 55.7 (OCH3), 
28.2 (C-2′′), 19.2 (C-3′′ and C-4′′). ESIMS m/z 341.0737 [M+H]+ (calcd C20H20O5 340.1311).
Preparation of the Chalcone (E) 4-Propargyloxy-4',6'-Dimethoxy-2'-Hydroxychalcone [4a]: 
Procedure is similar to the preparation of the chalcone 1a except for the use of 4-(prop-2-
ynyloxy)benzaldehyde (245 mg, 1.53 mmol). The chalcone 4a was purified in a silica column 
using 100% CH2Cl2 (326 mg, 63%). 
1
H NMR (500 MHz, CDCl3) δH 14.38 (s, C-2ʹ-OH), 7.84 (d,
J = 15.6 Hz, 1H, H-β), 7.79 (d, J = 15.6 Hz, 1H, H-α), 7.60 (d, J = 8.8 Hz, 2H, H-2 and H-6), 
7.03 (d, J = 8.8 Hz, 2H, H-3 and H-5), 6.14 (d, J = 2.3 Hz, 1H, H-3′), 5.99 (d, J = 2.3 Hz, 1H, H-
5′), 4.76 (d, J = 2.4 Hz, 2H, H2-1′′), 3.94 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 2.57 (t, J = 2.4 Hz, 
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1H, H-3′′). 13C NMR (125 MHz, CDCl3) δC 192.6 (C=O), 168.4 (C-2′), 166.1 (C-4′), 162.5 (C-
6′), 159.1 (C-4), 142.1 (C-β), 130.0 (C-2 and C-6), 129.2 (C-1), 125.7 (C-α), 115.3 (C-3 and C-
5), 106.4 (C-1′), 93.8 (C-3′), 91.3 (C-5′), 78.1 (C-2′′), 75.9 (C-3′′), 55.9 (2C, OCH3, C-1ʹʹ), 55.6 
(OCH3). ESIMS m/z 339.0599 [M+H]
+
 (calcd C20H18O5 338.1154)
Preparation of Oxygenated Intermediate Flavonoid 5,7-Dimethoxy-4'-Propargyloxyflavone 
[4b]: Procedure is similar to the preparation of the intermediate flavonoid 1b. The intermediate 
flavonoid 4b was purified in a silica column using 1:1 Hex-EtOAc, 100% EtOAc, 20:1 EtOAc-
MeOH, 9:1 EtOAc-MeOH, 1:1 EtOAc-MeOH, and 100% MeOH (87 mg, 54%). 
1
H NMR (400
MHz, CDCl3) δH 7.82 (d, J = 8.9 Hz, 2H, H-2′ and H-6′), 7.07 (d, J = 8.9 Hz, 2H, H-3′ and H-5′), 
6.58 (s, 1H, H-3), 6.54 (d, J = 2.3 Hz, 1H, H-6), 6.36 (d, J = 2.3 Hz, 1H, H-8), 4.76 (d, J = 2.4 
Hz, 2H, H2-1′′), 3.94 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 2.57 (t, J = 2.4 Hz, 1H, H-3′′). 
13
C
NMR (100 MHz, CDCl3) δC 177.6 (C-4), 163.9 (C-2), 160.9 (C-5), 160.4 (C-4ʹ), 159.8 (C-9), 
159.8 (C-7), 127.5 (C-2′ and C-6′), 124.7 (C-1′), 115.2 (C-3′ and C-5′), 109.2 (C-10), 107.9 (C-
3), 96.1 (C-8), 92.8 (C-6), 77.9 (C-2′′), 76.1 (C-3′′), 56.4 (C-1′′), 55.9 (OCH3), 55.7 (OCH3). 
ESIMS m/z 337.0495 [M+H]
+
 (calcd C20H16O5 336.0998)
Preparation of Final Oxygenated Flavonoid 7-Methoxy, 4'-Propargyloxy-5-Hydroxyflavone 
[4c]: Procedure is similar to the preparation of the final flavonoid 1c. The final flavonoid 4c was 
purified in a silica column with 7:3 Hex-EtOAc, 1:1 Hex-EtOAc, 100% EtOAc, 20:1 EtOAc-
MeOH, and 9:1 EtOAc-MeOH (14 mg, 28%). 
1
H NMR (400 MHz, CDCl3) δH 12.79 (s, C-5-
OH), 7.88 (d, J = 8.9 Hz, 2H, H-2′ and H-6′), 7.12 (d, J = 8.9 Hz, 2H, H-3′ and H-5′), 6.60 (s, 
1H, H-3), 6.50 (d, J = 2.2 Hz, 1H, H-6), 6.39 (d, J = 2.2 Hz, 1H, H-8), 4.80 (d, J = 2.3 Hz, 2H, 
H2-1′′), 3.90 (s, 3H, OCH3), 2.59 (t, J = 2.3 Hz, 1H, H-3′′). 
13
C NMR (100 MHz, CDCl3) δC
182.4 (C-4), 165.5 (C-7), 163.8 (C-2), 162.2 (C-4′), 160.4 (C-5), 157.7 (C-9), 128.0 (C-2′ and C-
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6′), 124.4 (C-1′), 115.4 (C-3′ and C-5′), 105.6 (C-10), 104.6 (C-3), 98.1 (C-8), 92.6 (C-6), 77.7 
(C-2′′), 76.2 (C-3′′), 55.9 (C-1′′), 55.8 (OCH3). ESIMS m/z 323.0367 [M+H]
+
 (calcd C19H14O5
322.0841). 
Preparation of 4-(Cyclopropyl Methoxy)Benzaldehyde [Compound IV]: 
(Bromomethyl)cyclopropane (400 mg, 2.96 mmol) was added to 4-hydroxy benzaldehyde (724 
mg, 5.92 mmol) and were dissolved in 15 mL of acetone and potassium carbonate (1.6 g, 11.9 
mmol). The mixture was then refluxed for 36 h until the reaction went through and then diluted 
with EtOAc and washed with water. This compound IV was purified in a silica column using 
95:5 Hex-EtOAc (380 mg, 73%). 
1
H NMR (400 MHz, CDCl3) δH 9.82 (s, 1H, CHO), 7.76 (d, J =
8.8 Hz, 2H, H-2 and H-6), 6.94 (d, J = 8.8 Hz, 2H, H-3 and H-5), 3.84 (dd, J = 8.1, 10.9 Hz, 2H, 
H2-1ʹ), 1.27 – 1.21 (m, 1H, H-2ʹ), 0.64 – 0.61 (m, 2H, H-3ʹa and H-4ʹa), 0.34 – 0.32 (m, 2H, H-
3ʹb and H-4ʹb). 13C NMR (100 MHz, CDCl3) δC 190.7 (CHO), 164.0 (C-4), 131.9 (C-2 and C-6),
129.8 (C-1), 114.8 (C-3 and C-5), 73.0 (C-1ʹ), 10.0 (C-2ʹ), 3.2 (C-3ʹ and C-4ʹ). 
Preparation of the Chalcone (E) 4-(Cyclopropyl Methoxy)-4',6'-Dimethoxy-2'-
Hydroxychalcone [5a]: Procedure is similar to the preparation of the chalcone 1a except for the 
use of 4-(cyclopropyl methoxy)benzaldehyde (compound IV) (270 mg, 1.53 mmol). The 
chalcone 5a was purified in a silica column with 4:1 CH2Cl2-Hex, 100% CH2Cl2, 20:1 CH2Cl2-
MeOH, and 9:1 CH2Cl2-MeOH (287 mg, 53%). 
1
H NMR (400 MHz, CDCl3) δH 14.42 (s, C-2ʹ-
OH), 7.84 (s, br, 2H, H-α and H-β), 7.55 (d, J = 8.7 Hz, 2H, H-2 and H-6), 6.93 (d, J = 8.7 Hz, 
2H, H-3 and H-5), 6.11 (d, J = 2.3 Hz, 1H, H-3′), 5.97 (d, J = 2.3 Hz, 1H, H-5′), 3.86 (s, 2H, H2-
1′′), 3.92 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 1.31 – 1.27 (m, 1H, H-2′′), 0.67 (dd, J = 4.9, 12.9 
Hz, 2H, H-3ʹʹa and H-4ʹʹa), 0.38 (dd, J = 4.9, 10.3 Hz, 2H, H-3ʹʹb and H-4ʹʹb). 13C NMR (100
MHz, CDCl3) δC 192.6 (C=O), 168.3 (C-2′), 166.0 (C-4′), 162.4 (C-6′), 160.8 (C-4), 142.5 (C-β), 
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130.1 (C-2 and C-6), 128.2 (C-1), 125.0 (C-α), 114.9 (C-3 and C-5), 106.3 (C-1′), 93.8 (C-3′), 
91.2 (C-5′), 72.9 (C-1′′), 55.8 (OCH3), 55.5 (OCH3), 10.2 (C-2′′), 3.2 (C-3′′ and C-4′′). ESIMS 
m/z 355.0575 [M+H]
+
 (calcd C21H22O5 354.1467).
Preparation of Oxygenated Intermediate Flavonoid 5,7-Dimethoxy-4'(Cyclopropyl 
Methoxy)Flavone [5b]: Procedure is similar to the preparation of the intermediate flavonoid 1b. 
The intermediate flavonoid 5b was purified in a silica column using 1:1 Hex-EtOAc, 100% 
EtOAc, 20:1 EtOAc-MeOH, 9:1 EtOAc-MeOH, and 1:1 EtOAc-MeOH (120 mg, 78%). 
1
H 
NMR (400 MHz, CDCl3) δH 7.78 (d, J = 9.0 Hz, 2H, H-2′ and H-6′), 6.97 (d, J = 9.0 Hz, 2H, H-
3′ and H-5′), 6.56 (s, 1H, H-3), 6.53 (d, J = 2.3 Hz, 1H, H-6), 6.34 (d, J = 2.3 Hz, 1H, H-8), 3.93 
(s, 3H, OCH3), 3.89 (s, 3H, OCH3), 3.85 (d, J = 6.9 Hz, 2H, H2-1′′), 1.25 (t, J = 7.2, 1H, H-2′′), 
0.66 (dd, J = 4.8, 12.9 Hz, 2H, H-3ʹʹa and H-4ʹʹa), 0.37 (dd, J = 4.8, 10.6 Hz, 2H, H-3ʹʹb and H-
4ʹʹb). 13C NMR (100 MHz, CDCl3) δC 177.6 (C-4), 163.9 (C-2), 161.5 (C-5), 160.8 (C-4′), 160.7
(C-9), 159.8 (C-7), 127.5 (C-2′ and C-6′), 123.6 (C-1′), 114.9 (C-3′ and C-5′), 109.1 (C-10), 
107.5 (C-3), 96.0 (C-8), 92.8 (C-6), 72.9 (C-1′′), 56.4 (OCH3), 55.7 (OCH3), 10.1 (C-2′′), 3.2 (C-
3′′ and C-4′′). ESIMS m/z 353.0805 [M+H]+ (calcd C21H20O5 352.1311).
Preparation of Brominated Chalcone (E) 4-Bromo-4',6'-Dimethoxy-2'-Hydroxychalcone 
[6a]: A mixture of equimolar amounts of 2ʹ-hydroxy-4ʹ,6ʹ-dimethoxyacetophenone (300 mg, 
1.53 mmol) and the 4-bromobenzaldehyde (285 mg, 1.53 mmol) was taken in a RBF and 10 mL 
of  50% sodium hydroxide in ethanol was added and left for 16 h at rt. The resulting yellow 
precipitate was then suction filtered and washed with Hex and CH2Cl2. The brominated chalcone 
6a was then purified in a silica column using 10% EtOAc and Hex (361 mg, 65%). 
1
H NMR
(400 MHz, CDCl3) δH 14.23 (s, C-2ʹ-OH), 7.89 (d, J = 15.6 Hz, 1H, H-β), 7.71 (d, J = 15.6 Hz, 
1H, H-α), 7.55 (d, J = 8.4 Hz, 2H, H-2 and H-6), 7.47 (d, J = 8.4 Hz, 2H, H-3 and H-5), 6.13 (d, 
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J = 2.2 Hz, 1H, H-3′), 5.98 (d, J = 2.2 Hz, 1H, H-5′), 3.93 (s, 3H, OCH3), 3.86 (s, 3H, OCH3). 
13
C NMR (100 MHz, CDCl3) δC 192.3 (C=O), 168.4 (C-4′), 166.4 (C-6′), 162.5 (C-2′), 140.8 (C-
β), 134.5 (C-1), 132.1 (C-3 and C-5), 129.7 (C-2 and C-6), 128.1 (C-α), 124.2 (C-4), 106.3 (C-
1′), 93.8 (C-3′), 91.3 (C-5′), 55.9 (OCH3), 55.6 (OCH3). ESIMS m/z 363.1418 [M+H]
+
 (calcd
C17H15BrO4 362.0154). 
Preparation of Brominated Intermediate Flavonoid 5,7-Dimethoxy-4'-Bromoflavone [6b]: 
The brominated chalcone [6a] (200 mg, 0.551 mmol) was treated with 3-4 mol% of iodine 
crystals with minimal amount of DMSO at 140 °C for 4-6 h. The resulting white precipitate was 
extracted with CH2Cl2 and was removed by filtration. The filtrate was transferred into a 
separatory funnel, where the layers were separated as aqueous and organic layers. The organic 
layer was washed with Na2S2O3, dried Na2SO4, and concentrated. The intermediate flavonoid 6b 
was purified in a silica column with 1:1 Hex-EtOAc, 3:2 EtOAc-Hex, 4:1 EtOAc-Hex, and 9:1 
EtOAc-Hex (134 mg, 67%). 
1
H NMR (400 MHz, CDCl3) δH 7.72 (d, J = 8.7 Hz, 2H, H-3′ and H-
5′), 7.62 (d, J = 8.7 Hz, 2H, H-2′ and H-6′), 6.64 (s, 1H, H-3), 6.55 (d, J = 2.3 Hz, 1H, H-6), 6.37 
(d, J = 2.3 Hz, 1H, H-8), 3.95 (s, 3H, OCH3), 3.91 (s, 3H, OCH3). 
13
C NMR (100 MHz, CDCl3)
δC 177.3 (C-4), 164.2 (C-2), 160.9 (C-5), 159.8 (C-9), 159.5 (C-7), 132.2 (C-3′ and C-5′), 130.4 
(C-1ʹ), 127.3 (C-2′ and C-6′), 125.8 (C-4ʹ), 109.2 (C-10 and C-3), 96.3 (C-8), 92.8 (C-6), 56.4 
(OCH3), 55.8 (OCH3). ESIMS m/z 361.1324 [M+H]
+
 (calcd C17H13BrO4 359.9997).
Preparation of Nitrogenated Intermediate Flavonoid 5,7-Dimethoxy-4'-
Aminopropylflavone [6c]: Sodium tert-butoxide (17 mg, 0.18 mmol), 
tris(dibenzylideneacetone)dipalladium (11 mg, 0.012 mmol),  and 1,1ʹ-binaphthalene-2,2ʹ-
diylbis(diphenylphosphine) (8 mg, 0.012 mmol) were dissolved in 5 mL of toluene. To this, the 
brominated intermediate flavonoid 6b (50 mg, 0.138 mmol) and propylamine (11 mg, 0.18 
110 
mmol) were added dropwise with stirring at rt, and the mixture was refluxed at 80 °C for 48 h. 
The nitrogenated intermediate flavonoid was purified in a silica column using 7:3 EtOAc-Hex, 
9:1 EtOAc-Hex, 100% EtOAc, and 9:1 EtOAc-MeOH (24 mg, 52%). 
1
H NMR (500 MHz, 
CDCl3) δH 7.67 (d, J = 10.9 Hz, 2H, H-2′ and H-6′), 6.61 (d, J = 10.9 Hz, 2H, H-3′ and H-5′), 
6.52 (d, J = 2.6 Hz, 1H, H-6), 6.50 (s, 1H, H-3), 6.33 (d, J = 2.5 Hz, 1H, H-8), 3.92 (s, 3H, 
OCH3), 3.88 (s, 3H, OCH3), 3.13 (t, J = 9.0 Hz, 2H, H2-1′′), 1.66 (ddd, J = 9.2, 18.2, 9.0 Hz, 2H, 
H2-2′′), 1.00 (t, J = 9.2 Hz, 3H, CH3-3′′). 
13
C NMR (125 MHz, CDCl3) δC 177.8 (C-4), 163.6 (C-
2), 161.6 (C-5), 160.7 (C-4′), 159.7 (C-9), 150.9 (C-7), 127.5 (C-2′ and C-6′), 119.0 (C-1′), 112.1 
(C-3′ and C-5′), 109.2 (C-10), 105.8 (C-3), 95.8 (C-8), 92.8 (C-6), 56.3 (OCH3), 55.7 (OCH3), 
45.2 (C-1′′), 22.5 (C-2′′), 11.5 (C-3′′). ESIMS m/z 340.2991 [M+H]+ (calcd C20H21NO4 
339.1471). 
Preparation of Nitrogenated Final Compound 7-Methoxy-4'-Aminopropyl-5-
Hydroxyflavone [6d]: The nitrogenated intermediate flavonoid 6c (15 mg, 0.044 mmol) was 
treated with double the moles of 1N boron tribromide (22 mg, 0.088 mmol) in the presence of 
CH2Cl2 at rt, for 1-3 h. The reactant solution was diluted with 10:1 CH2Cl2:MeOH and then 
washed with brine and water. Na2SO4 was added to the solution and left overnight. The solution 
was then filtered into an RBF, dried, and concentrated. The final compound 6d was purified in a 
silica column using 1:1 Hex-EtOAc (11 mg, 77%). 
1
H NMR (500 MHz, CDCl3) δH 12.90 (s, C-
5-OH), 7.65 (d, J = 8.8 Hz, 2H, H-2′ and H-6′), 6.58 (d, J = 8.7 Hz, 2H, H-3′ and H-5′), 6.43 (s, 
1H, H-3), 6.39 (d, J = 2.2 Hz, 1H, H-6), 6.27 (d, J = 2.2 Hz, 1H, H-8), 3.80 (s, 3H, OCH3), 3.10 
(t, J = 7.2 Hz, 2H, H2-1′′), 1.62 (ddd, J = 7.4, 7.2, 7.3 Hz, 2H, H2-2′′), 0.96 (t, J = 7.4 Hz, 3H, 
CH3-3′′). 
13
C NMR (125 MHz, CDCl3) δC 182.3 (C-4), 165.2 (C-7), 164.4 (C-2), 162.1 (C-5 and
C-4′), 157.6 (C-9), 128.0 (C-2′ and C-6′), 127.5 (C-1ʹ), 114.0 (C-3′ and C-5′), 105.4 (C-10), 
111 
103.0 (C-3), 97.9 (C-8), 92.5 (C-6), 55.8 (OCH3), 29.7 (C-1′′), 22.1 (C-2′′), 11.5 (C-3′′). ESIMS 
m/z 326.2691 [M+H]
+
 (calcd C19H19NO4 325.1314).
Preparation of Nitrogenated Intermediate Flavonoid 5,7-Dimethoxy-4'-
Aminoisopropylflavone [7c]: Procedure is similar to the preparation of the intermediate 
flavonoid 6c except for the use of isopropylamine (11 mg, 0.18 mmol). The intermediate 
flavonoid 7c was purified in a silica column using 9:1 EtOAc-Hex (37 mg, 79%). 
1
H NMR (400
MHz, CDCl3) 7.65 (d, J = 8.7 Hz, 2H, H-2′ and H-6′), 6.58 (d, J = 8.7 Hz, 2H, H-3′ and H-5′), 
6.50 (d, J = 2.2 Hz, 1H, H-6), 6.48 (s, 1H, H-3), 6.31 (d, J = 2.2 Hz, 1H, H-8), 3.90 (s, 3H, 
OCH3), 3.86 (s, 3H, OCH3), 3.67 (sept, J = 6.4 Hz, 1H, H-1′′), 1.22 (d, J = 6.4 Hz, 6H, H-2′′ and 
H-3′′). 13C NMR (100 MHz, CDCl3) δC 177.7 (C-4), 163.6 (C-2), 161.5 (C-5), 160.7 (C-4′),
159.7 (C-9), 150.0 (C-7), 127.5 (C-2′ and C-6′), 118.8 (C-1′), 112.5 (C-3′ and C-5′), 109.1 (C-
10), 105.7 (C-3), 95.8 (C-8), 92.8 (C-6), 56.3 (OCH3), 55.6 (OCH3), 43.9 (C-1′′), 22.7 (C-2ʹʹ and 
C-3ʹʹ). ESIMS m/z 340.3005 [M+H]+ (calcd C20H21NO4 339.1471).
Preparation of Nitrogenated Final Compound 7-Methoxy-4'-Aminoisopropyl-5-
Hydroxyflavone [7d]: Procedure is similar to the preparation of the final compound 6d. The 
final compound 7d was purified in a silica column with 9:1 Hex-EtOAc (16 mg, 83%). 
1
H NMR
(500 MHz, CDCl3) 13.00 (s, C-5-OH), 7.74 (d, J = 8.9 Hz, 2H, H-2′ and H-6′), 6.64 (d, J = 8.9 
Hz, 2H, H-3′ and H-5′), 6.52 (s, 1H, H-3), 6.48 (d, J = 2.3 Hz, 1H, H-6), 6.37 (d, J = 2.3 Hz, 1H, 
H-8), 3.90 (s, 3H, OCH3), 3.75 (sept, J = 6.3 Hz, 1H, H-1′′), 1.29 (d, J = 6.3 Hz, 6H, CH3-2′′ and 
CH3-3′′). 
13
C NMR (125 MHz, CDCl3) δC 182.4 (C-4), 165.1 (C-7), 164.9 (C-2), 162.1 (C-4′),
157.6 (C-5), 150.5 (C-9), 128.1 (C-2′ and C-6′), 118.6 (C-1′), 112.6 (C-3′ and C-5′), 105.5 (C-
10), 102.4 (C-3), 97.8 (C-8), 92.5 (C-6), 55.7 (OCH3), 44.1 (C-1′′), 22.8 (C-2′′ and C-3′′). ESIMS 
m/z 326.2691 [M+H]
+
 (calcd C19H19NO4 325.1314).
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Preparation of Nitrogenated Intermediate Flavonoid 5,7-Dimethoxy-4'-(Cyclopropyl 
Methylamino)Flavone [9c]: Procedure is similar to the preparation of the intermediate 
flavonoid 6c except for the use of (aminomethyl)cyclopropane (13 mg, 0.18 mmol). The 
intermediate flavonoid 9c was purified in a silica column using 7:3 EtOAc-Hex, 100% EtOAc, 
10:1 EtOAc-MeOH, and 100% MeOH (40 mg, 83%). 
1
H NMR (500 MHz, CDCl3) 7.66 (d, J =
8.5 Hz, 2H, H-2′ and H-6′), 6.66 (d, J = 8.7 Hz, 2H, H-3′ and H-5′), 6.56 (s, 1H, H-3), 6.41 (d, J 
= 2.2 Hz, 1H, H-6), 6.38 (d, J = 2.2 Hz, 1H, H-8), 3.97 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 3.05 
(d, J = 6.9 Hz, 2H, H2-1′′), 1.12 (m, 1H, H-2′′), 0.61 (dd, J = 6.0, 13.6 Hz, 2H, H-3′′a and H-4′′a), 
0.30 (dd, J = 5.5, 10.5 Hz, 2H, H-3′′b and H-4′′b). 13C NMR (125 MHz, CDCl3) δC 177.8 (C-4),
163.7 (C-2), 161.5 (C-5), 160.8 (C-4′), 160.9 (C-9), 159.8 (C-7), 127.5 (C-2′ and C-6′), 119.3 (C-
1′), 112.3 (C-3′ and C-5′), 109.3 (C-10), 106.0 (C-3), 96.3 (C-8), 92.8 (C-6), 56.5 (OCH3), 55.7 
(OCH3), 48.5 (C-1′′), 10.7 (C-2′′), 3.6 (C-3′′ and C-4′′). ESIMS m/z 352.2586 [M+H]
+
 (calcd
C21H21NO4 351.1471). 
Preparation of Nitrogenated Final Compound 7-Methoxy-4'-(Cyclopropyl Methylamino)-5-
Hydroxyflavone [9d]: Procedure is similar to the preparation of the final compound 6d. The 
final compound 9d was purified in a sephadex column with 1:1 Hex-EtOAC (2 mg, 7%). 
1
H
NMR (500 MHz, CDCl3) 13.00 (s, C-5-OH), 7.75 (d, J = 8.8 Hz, 2H, H-2′ and H-6′), 6.67 (d, J = 
8.8 Hz, 2H, H-3′ and H-5′), 6.53 (s, 1H, H-3), 6.48 (d, J = 2.1 Hz, 1H, H-6), 6.37 (d, J = 2.1 Hz, 
1H, H-8), 3.90 (s, 3H, OCH3), 3.07 (d, J = 6.9 Hz, 2H, H2-1′′), 1.14 (m, 1H, H-2′′), 0.63 (dd, J = 
5.9, 13.0 Hz, 2H, H-3′′a and H-4′′a), 0.31 (dd, J = 4.9, 9.9 Hz, 2H, H-3′′b and H-4′′b). 13C NMR
(125 MHz, CDCl3) δC 182.4 (C-4), 165.1 (C-7), 164.9 (C-2), 162.1 (C-4′), 157.6 (C-5), 151.3 (C-
9), 128.1 (C-2′ and C-6′), 118.9 (C-1′), 112.3 (C-3′ and C-5′), 105.5 (C-10), 102.5 (C-3), 97.8 (C-
113 
8), 92.5 (C-6), 55.7 (OCH3), 48.4 (C-1′′), 10.7 (C-2′′), 3.6 (C-3′′ and C-4′′). ESIMS m/z 338.2880 
[M+H]
+
 (calcd C20H19NO4 337.1314).
Preparation of Oxygenated Diketo Intermediate 1-3ʹ(2ʹ-Methoxypyridin-3ʹ-yl)-(4ʹʹ-
(Propyloxy)Phenyl)Propane-1,3-Dione [10a]: A mixture of equimolar amounts of methyl-2-
methoxy nicotinate (500 mg, 2.99 mmol) and 1-(4-propoxyphenyl)ethanone (533 mg, 2.99 
mmol) was used to prepare the oxygenated diketo intermediate 10a. Methyl-2-methoxy 
nicotinate (500 mg, 2.99 mmol) and double the molar amounts of sodium hydride (144 mg, 5.98 
mmol) were taken in a RBF and dissolved in 2.5 mL of  dry dimethyl formamide. A solution of 
1-(4-propoxyphenyl)ethanone (533 mg, 2.99 mmol) dissolved in 2 mL of dry dimethyl 
formamide was added dropwise and left at rt, for 2 h. Monosodium phosphate (NaH2PO4) was 
added to adjust the pH to 7.4 and the solution was then washed with CH2Cl2 in a separating 
funnel and dried in Na2SO4 and left overnight. The solution was then filtered into an RBF, dried, 
and concentrated. The diketo intermediate 10a was purified in a silica column using 9:1 Hex-
EtOAc, 4:1 Hex-EtOAc, and 1:1 Hex-EtOAc (71 mg, 8%). 
1
H NMR (400 MHz, CDCl3) δH 8.31
(dd, J = 1.8, 7.5 Hz, 1H, H-6ʹ), 8.27 (dd, J = 1.8, 4.8 Hz, 1H, H-4ʹ), 7.95 (d, J = 8.8 Hz, 2H, H-2ʹʹ 
and H-6ʹʹ), 7.02 (dd, J = 4.8, 7.5 Hz, 1H, H-5ʹ), 6.96 (d, J = 8.8 Hz, 2H, H-3ʹʹ and H-5ʹʹ), 4.11 (s, 
3H, OCH3), 3.99 (t, J = 6.6 Hz, 2H, H2-1ʹʹʹ), 1.83 (m, 2H, H2-2ʹʹʹ), 1.06 (t, J = 7.4 Hz, 3H, CH3-
3ʹʹʹ). 13C NMR (100 MHz, CDCl3) δC 187.7 (C-3), 178.8 (C-1), 162.9 (C-2ʹ), 161.5 (C-4ʹʹ), 149.5
(C-4ʹ), 139.0 (C-6ʹ), 129.5 (C-2ʹʹ and C-6ʹʹ), 128.3 (C-1ʹʹ), 118.7 (C-1ʹ), 117.1 (C-5ʹ), 114.4 (C-3ʹʹ 
and C-5ʹʹ), 97.2 (C-2), 69.7 (C-1′′ʹ), 53.9 (OCH3), 22.5 (C-2′′ʹ), 10.4 (C-3′′ʹ). ESIMS m/z 
314.0791 [M+H]
+
 (calcd C18H19NO4 313.1314).
Preparation of Final Oxygenated Pyridine Compound 2-(4ʹ-Propyloxyphenyl)-4H-
Pyrano[2,3-b]Pyridin-4-one [10b]: The oxygenated diketo intermediate 10a (48 mg, 0.17 
114 
mmol) was treated with 10 times the amount of pyridinium hydrochloride (480 mg, 4.154 mmol) 
and heated at 190 °C for 4 h. The resultant solution was diluted with water, neutralized with 
sodium bicarbonate (NaHCO3) and extracted with EtOAc. Na2SO4 was added and left overnight. 
The solution was then filtered into an RBF, dried, and concentrated. The final pyridine 
compound 10b was purified in a silica column using 1:1 CH2Cl2-Hex (37 mg, 86%). 
1
H NMR
(400 MHz, CDCl3) δH 8.66 (dd, J = 1.6, 4.3 Hz, 1H, H-7), 8.55 (dd, J = 1.8, 7.6 Hz, 1H, H-5), 
7.90 (d, J = 8.8 Hz, 2H, H-2ʹ and H-6ʹ), 7.42 (dd, J = 4.6, 7.6 Hz, 1H, H-6), 6.96 (d, J = 8.8 Hz, 
2H, H-3ʹ and H-5ʹ), 6.73 (s, 1H, H-3), 3.96 (t, J = 6.5 Hz, 2H, H2-1ʹʹ), 1.81 (ddd, J = 7.2, 6.8, 7.1 
Hz, 2H, H2-2ʹʹ), 1.02 (t, J = 7.4 Hz, 3H, CH3-3ʹʹ). 
13
C NMR (100 MHz, CDCl3) δC 178.5 (C-4),
164.1 (C-9), 162.4 (C-2), 160.7 (C-4ʹ), 152.9 (C-7), 136.2 (C-5), 128.3 (C-2ʹ and C-6ʹ), 122.8 (C-
1ʹ), 122.0 (C-6), 118.7 (C-10), 115.0 (C-3ʹ and C-5ʹ), 106.0 (C-3), 69.7 (C-1ʹʹ), 22.4 (C-2ʹʹ), 10.4 
(CH3-3ʹʹ). ESIMS m/z 282.1133 [M+H]
+
 (calcd C17H15NO3 281.1052).
Preparation of Oxygenated Diketo Intermediate 1-3ʹ(2ʹ-Methoxypyridin-3ʹ-yl)-(4ʹʹ-
(Isopropyloxy)Phenyl)Propane-1,3-Dione [11a]: Procedure is similar to the preparation of the 
diketo intermediate 10a except for the use of 1-(4-isopropoxy phenyl)ethan-1-one (533 mg, 2.99 
mmol). The compound 11a was purified in a silica column using 9:1 Hex-EtOAc (221 mg, 24%). 
1
H NMR (500 MHz, CDCl3) δH 8.29 (dd, J = 1.9, 7.6 Hz, 1H, H-6ʹ), 8.24 (dd, J = 1.9, 4.8 Hz, 
1H, H-4ʹ), 7.94 (d, J = 8.8 Hz, 2H, H-2ʹʹ and H-6ʹʹ), 6.98 (dd, J = 4.8, 7.5 Hz, 1H, H-5ʹ), 6.92 (d, 
J = 8.8 Hz, 2H, H-3ʹʹ and H-5ʹʹ), 4.62 (sept, J = 6.0 Hz, 1H, H-1ʹʹʹ), 4.09 (s, 3H, OCH3), 1.35 (d, 
J = 6.0 Hz, 6H, CH3-2ʹʹʹ and CH3-3ʹʹʹ). 
13
C NMR (125 MHz, CDCl3) δC 187.7 (C-3), 178.7 (C-1),
161.8 (C-2ʹ), 161.4 (C-4ʹʹ), 149.5 (C-4ʹ), 139.0 (C-6ʹ), 129.6 (C-2ʹʹ and C-6ʹʹ), 128.0 (C-1ʹʹ), 
118.7 (C-1ʹ), 117.1 (C-5ʹ), 115.3 (C-3ʹʹ and C-5ʹʹ), 97.2 (C-2), 70.1 (C-1ʹʹʹ), 53.9 (OCH3), 21.9 
(CH3-2ʹʹʹ and CH3-3ʹʹʹ). ESIMS m/z 314.2995 [M+H]
+
 (calcd C18H19NO4 313.1314).
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Preparation of Final Oxygenated Pyridine Compound 2-(4ʹ-Isopropyloxyphenyl)-4H-
Pyrano[2,3-b]Pyridin-4-one [11b]: Procedure is similar to the preparation of the final pyridine 
compound 10b. The final pyridine compound 11b was purified in a silica column with 1:1 Hex-
EtOAc (18 mg, 20%). 
1
H NMR (400 MHz, CDCl3) δH 8.70 (dd, J =  2.5, 5.7 Hz, 1H, H-7), 8.60
(dd, J = 2.5, 9.6 Hz, 1H, H-5), 7.95 (d, J = 8.92 Hz, 2H, H-2ʹ and H-6ʹ), 7.46 (dd, J = 5.7, 9.5 Hz, 
1H, H-6), 7.00 (d, J = 8.96 Hz, 2H, H-3ʹ and H-5ʹ), 6.78 (s, 1H, H-3), 4.66 (sept, J = 7.5 Hz, 1H, 
H-1ʹʹ), 1.38 (d, J = 7.5 Hz, 6H, CH3-2ʹʹ and CH3-3ʹʹ). 
13
C NMR (100 MHz, CDCl3) δC 178.5 (C-
4), 164.2 (C-9), 161.3 (C-2), 160.7 (C-4ʹ), 152.9 (C-7), 136.3 (C-5), 128.4 (C-2ʹ and C-6ʹ), 122.7 
(C-1ʹ), 122.0 (C-6), 118.8 (C-10), 115.9 (C-3ʹ and C-5ʹ), 106.0 (C-3), 70.2 (C-1ʹʹ), 21.9 (CH3-2ʹʹ 
and CH3-3ʹʹ). ESIMS m/z 282.1133 [M+H]
+
 (calcd C17H15NO3 281.1052).
Preparation of Oxygenated Diketo Intermediate 1-3ʹ(2ʹ-Methoxypyridin-3ʹ-yl)-(4ʹʹ-
(Propargyloxy)Phenyl)Propane-1,3-Dione [12a]: Procedure is similar to the preparation of the 
diketo intermediate 10a except for the use of 1-(4-(prop-2-yn-1-yloxy)phenyl)ethan-1-one (521 
mg, 2.99 mmol). The diketo intermediate 12a was purified in a silica column using 9:1 Hex-
EtOAc, 7:3 Hex-EtOAc, and 100% EtOAc (30 mg, 3%). 
1
H NMR (400 MHz, CDCl3) δH 8.33
(dd, J = 1.9, 7.5 Hz, 1H, H-6ʹ), 8.29 (dd, J = 1.9, 4.8 Hz, 1H, H-4ʹ), 7.99 (d, J = 8.9 Hz, 2H, H-2ʹʹ 
and H-6ʹʹ), 7.08 (d, J = 8.9 Hz, 2H, H-3ʹʹ and H-5ʹʹ), 7.04 (dd, J = 4.9, 7.6 Hz, 1H, H-5ʹ), 4.78 (d, 
J = 2.4 Hz, 2H, H-1ʹʹʹ), 4.13 (s, OCH3), 2.58 (t, J = 2.4 Hz, 1H, H-3ʹʹʹ). 
13
C NMR (100 MHz,
CDCl3) δC 187.4 (C-3), 179.3 (C-1), 161.5 (C-2ʹ), 161.0 (C-4ʹʹ), 149.6 (C-4ʹ), 139.1 (C-6ʹ), 129.5 
(C-2ʹʹ and C-6ʹʹ), 129.4 (C-1ʹʹ), 118.7 (C-1ʹ), 117.2 (C-5ʹ), 114.8 (C-3ʹʹ and C-5ʹʹ), 97.4 (C-2), 
76.1 (C-1ʹʹʹ), 55.9 (C-2ʹʹʹ), 54.0 (OCH3), 53.4 (C-3ʹʹʹ). ESIMS m/z 310.0542 [M+H]
+
 (calcd
C18H15NO4 309.1001). 
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Preparation of 4-(Cyclopropyl)Acetophenone [Compound VIII]: 
(Bromomethyl)cyclopropane (400 mg, 2.96 mmol) was added to 4ʹ-hydroxy acetophenone (806 
mg, 5.92 mmol) and were dissolved in 15 mL of acetone and potassium carbonate (1.6 g, 11.9 
mmol). The mixture was then refluxed for 24 h until the reaction went through and then diluted 
with EtOAc and washed with water. This compound VIII was purified in a silica column using 
9:1 Hex-EtOAc, 7:3 Hex-EtOAc, and 100% EtOAc (551 mg, 98%). 
1
H NMR (400 MHz, CDCl3)
δH 7.72 (d, J = 8.9 Hz, 2H, H-2 and H-6), 6.72 (d, J = 8.9 Hz, 2H, H-3 and H-5), 3.66 (d, J = 6.9 
Hz, 2H, H2-1ʹ), 2.34 (s, CH3), 1.06 (m, 1H, H-2ʹ), 0.48 (m, 2H, H-3ʹa and H-4ʹa), 0.20 (m, 2H, H-
3ʹb and H-4ʹb). 13C NMR (100 MHz, CDCl3) δC 196.2 (C=O), 162. 8 (C-4), 130.4 (C-2 and C-6),
129.9 (C-1), 114.0 (C-3 and C-5), 72.6 (C-1ʹ), 26.0 (CH3), 10.0 (C-2ʹ), 3.1 (C-3ʹ and C-4ʹ). 
ESIMS m/z 191.1628 [M+H]
+
 (calcd C12H14O2 190.0994).
Preparation of Oxygenated Diketo Intermediate 1-3ʹ(2ʹ-Methoxypyridin-3ʹ-yl)-(4ʹʹ- 
(Cyclopropyl Methyloxy)Phenyl)Propane-1,3-Dione [13a]: Procedure is similar to the 
preparation of the diketo intermediate 10a except for the use of 1-(4-cyclopropyl 
methoxy)phenyl)ethan-1-one (300 mg, 1.58 mmol). The diketo intermediate 13a was purified in 
a silica column using 9:1 Hex-EtOAc (73 mg, 14%). 
1
H NMR (400 MHz, CDCl3) δH 8.32 (dd, J
= 2.0, 7.5 Hz, 1H, H-6ʹ), 8.28 (dd, J = 2.0, 4.9 Hz, 1H, H-4ʹ), 7.96 (d, J = 8.9 Hz, 2H, H-2ʹʹ and 
H-6ʹʹ), 7.04 (dd, J = 4.9, 7.5 Hz, 1H, H-5ʹ), 6.98 (d, J = 8.9 Hz, 2H, H-3ʹʹ and H-5ʹʹ), 4.12 (s, 
OCH3), 3.89 (d, J = 6.9 Hz, 2H, H-1ʹʹʹ), 1.26 (m, 1H, H-2ʹʹʹ), 0.68 (dd, J = 6.1, 13.0 Hz, 2H, H-
3ʹʹʹa and  H-4ʹʹʹa), 0.39 (dd, J = 4.8, 10.6 Hz, 2H, H-3ʹʹʹb and  H-4ʹʹʹb). 13C NMR (100 MHz,
CDCl3) δC 187.6 (C-3), 178.9 (C-1), 162.8 (C-2ʹ), 161.5 (C-4ʹʹ), 149.5 (C-4ʹ), 139.1 (C-6ʹ), 129.5 
(C-2ʹʹ and C-6ʹʹ), 128.4 (C-1ʹʹ), 118.8 (C-1ʹ), 117.1 (C-5ʹ), 114.5 (C-3ʹʹ and C-5ʹʹ), 97.3 (C-2), 
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73.0 (C-1ʹʹʹ), 53.9 (OCH3), 10.1 (C-2ʹʹʹ), 3.3 (C-3ʹʹʹ and C-4ʹʹʹ). ESIMS m/z 326.2691 [M+H]
+
(calcd C19H19NO4 325.1314). 
Preparation of Final Oxygenated Pyridine Compound 2-(4ʹ-Cyclopropyl Methoxyphenyl)-
4H-Pyrano[2,3-b]Pyridin-4-one [13b]: 2-(4ʹ-cyclopropyl methoxyphenyl)-4H-pyrano[2,3-
b]pyridin-4-one was not yielded when procedure similar to 10b was followed. 13b was prepared
when (Bromomethyl)cyclopropane (11 mg, 0.084 mmol) was added to 2-(4ʹ-hydroxyphenyl)-
4H-pyrano[2,3-b]pyridin-4-one (20 mg, 0.084 mmol) and were dissolved in 5 mL of acetone and 
potassium carbonate (46 mg, 0.336 mmol). The mixture was then refluxed for 24 h until the 
reaction went through and then diluted with EtOAc and washed with water. The final pyridine 
compound 13b was purified in a silica column with 1:1 Hex-EtOAc (13 mg, 52%). 
1
H NMR
(500 MHz, CDCl3) δH 8.72 (dd, J = 2.0, 4.6 Hz, 1H, H-7), 8.62 (dd, J = 2.0, 7.7 Hz, 1H, H-5), 
7.98 (d, J = 8.9 Hz, 2H, H-2ʹ and H-6ʹ), 7.48 (dd, J = 4.6, 7.7 Hz, 1H, H-6), 7.04 (d, J = 8.9 Hz, 
2H, H-3ʹ and H-5ʹ), 6.81 (s, 1H, H-3), 3.92 (d, J = 7.0 Hz, 2H, H-1ʹʹ), 1.33 (m, 1H, H-2ʹʹ), 0.70 
(dd, J = 6.1, 13.0 Hz, 2H, H-3ʹʹa and  H-4ʹʹa), 0.41 (dd, J = 4.9, 10.7 Hz, 2H, H-3ʹʹb and  H-4ʹʹb). 
13
C NMR (125 MHz, CDCl3) δC 178.6 (C-4), 164.2 (C-9), 162.3 (C-2), 160.7 (C-4ʹ), 153.0 (C-7), 
136.3 (C-5), 128.4 (C-2ʹ and C-6ʹ), 123.1 (C-1ʹ), 122.1 (C-6), 118.8 (C-10), 115.1 (C-3ʹ and C-
5ʹ), 106.1 (C-3), 73.1 (C-1ʹʹ), 10.1 (C-2ʹʹ), 3.3 (C-3ʹʹ and C-4ʹʹ). ESIMS m/z 294.0721 [M+H]+
(calcd C18H15NO3 293.1052).    
Preparation of Brominated Diketo Intermediate 1-3ʹ(2ʹ-Methoxypyridin-3ʹ-yl)-(4ʹʹ- 
Bromophenyl)Propane-1,3-Dione [14a]: A mixture of equimolar amounts of methyl-2-
methoxy nicotinate (500 mg, 2.99 mmol) and 4ʹ-bromo acetophenone (595 mg, 2.99 mmol) was 
used to prepare the brominated diketo intermediate 14a. Methyl-2-methoxy nicotinate (500 mg, 
2.99 mmol) and double the molar amounts of sodium hydride (144 mg, 5.98 mmol) were taken 
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in a RBF and dissolved in 2.5 mL of  dry dimethyl formamide. A solution of 4ʹ-bromo 
acetophenone (595 mg, 2.99 mmol) dissolved in 2 mL of dry dimethyl formamide was added 
dropwise and left at rt, for 2 h. NaH2PO4 was added to adjust the pH to 7.4 and the solution was 
then washed with CH2Cl2 in a separating funnel and dried in Na2SO4 and left overnight. The 
solution was then filtered into an RBF, dried, and concentrated. The diketo intermediate 14a was 
purified in a silica column using 9:1 Hex-EtOAc (313 mg, 31%). 
1
H NMR (500 MHz, CDCl3) δH 
8.35 (dd, J = 2.0, 7.5 Hz, 1H, H-6ʹ), 8.33 (dd, J = 2.0, 4.9 Hz, 1H, H-4ʹ), 7.87 (d, J = 8.5 Hz, 2H, 
H-2ʹʹ and H-6ʹʹ), 7.66 (d, J = 8.5 Hz, 2H, H-3ʹʹ and H-5ʹʹ), 7.08 (dd, J = 4.9, 7.5 Hz, 1H, H-5ʹ), 
4.14 (s, OCH3). 
13
C NMR (125 MHz, CDCl3) δC 186.1 (C-3), 181.2 (C-1), 161.6 (C-2ʹ), 150.2
(C-4ʹʹ), 139.4 (C-4ʹ), 134.8 (C-6ʹ), 132.1 (C-2ʹʹ and C-6ʹʹ), 128.9 (C-3ʹʹ and C-5ʹʹ), 127.2 (C-1ʹʹ), 
118.2 (C-1ʹ), 117.1 (C-5ʹ), 97.4 (C-2), 54.1 (OCH3). ESIMS m/z 334.1347 [M+H]
+
 (calcd
C15H12BrNO3 333.0001). 
Preparation of Brominated Intermediate 2-(4ʹ-Bromophenyl)-4H-Pyrano[2,3-b]Pyridin-4-
one [14b]: The brominated diketo intermediate [14a] (250 mg, 0.748 mmol) was treated with 10 
times the amount of pyridinium hydrochloride (2.5 g, 21.6 mmol) and heated at 190 °C for 4 h. 
The resultant solution was diluted with water, neutralized with NaHCO3 and extracted with 
EtOAc. Na2SO4 was added and left overnight. The solution was then filtered into an RBF, dried, 
and concentrated to yield 14b (196 mg, 87%). 
1
H NMR (400 MHz, CDCl3) δH 8.73 (dd, J = 2.0,
4.6 Hz, 1H, H-7), 8.61 (dd, J = 2.0, 7.7 Hz, 1H, H-5), 7.88 (d, J = 8.6 Hz, 2H, H-2ʹ and H-6ʹ), 
7.68 (d, J = 8.6 Hz, 2H, H-3ʹ and H-5ʹ), 7.49 (dd, J = 4.6, 7.7 Hz, 1H, H-6), 6.85 (s, 1H, H-3). 
13
C NMR (100 MHz, CDCl3) δC 178.5 (C-4), 163.0 (C-2), 160.6 (C-9), 153.4 (C-7), 136.4 (C-5), 
132.5 (C-2ʹ and C-6ʹ), 130.0 (C-1ʹ), 128.0 (C-3ʹ and C-5ʹ), 126.9 (C-4ʹ), 122.4 (C-6), 118.7 (C-
10), 107.8 (C-3). ESIMS m/z 302.1248 [M+H]
+
 (calcd C14H8BrNO2 300.9738).
119 
Preparation of Final Nitrogenated Pyridine Compound 2-(4ʹ-Propyloxyphenyl)-4H-
Pyrano[2,3-b]Pyridin-4-one [14c]: Sodium tert-butoxide (25 mg, 0.255 mmol), 
tris(dibenzylideneacetone)dipalladium (16 mg, 0.017 mmol),  and 1,1ʹ-binaphthalene-2,2ʹ-
diylbis(diphenylphosphine) (11 mg, 0.017 mmol) were dissolved in 5 mL of toluene. To this, the 
brominated pyridine intermediate 14b (50 mg, 0.17 mmol) and propylamine (15 mg, 0.255 
mmol) were added dropwise with stirring at rt, and the mixture was refluxed at 80 °C for 48 h. 
The final pyridine compound 14c was purified in a silica column using 20:1 Hex-EtOAc, 9:1 
Hex-EtOAc, and 1:1 Hex-EtOAc (21 mg, 45%). 
1
H NMR (500 MHz, CDCl3) δH 8.69 (dd, J =
1.9, 4.5 Hz, 1H, H-7), 8.60 (dd, J = 1.8, 7.6 Hz, 1H, H-5), 7.86 (d, J = 8.6 Hz, 2H, H-2ʹ and H-
6ʹ), 7.44 (dd, J = 4.6, 7.6 Hz, 1H, H-6), 6.73 (s, 1H, H-3), 6.67 (d, J = 8.6 Hz, 2H, H-3ʹ and H-
5ʹ), 3.19 (t, J = 7.2 Hz, 2H, H2-1ʹʹ), 1.70 (dd, J = 7.4, 14.7 Hz, 2H, H2-2ʹʹ), 1.04 (t, J = 7.4 Hz, 
CH3-3ʹʹ). 
13
C NMR (125 MHz, CDCl3) δC 178.4 (C-4), 165.0 (C-9), 163.02 (C-2), 152.6 (C-4ʹ),
151.7 (C-7), 136.1 (C-5), 128.5 (C-2ʹ and C-6ʹ), 121.8 (C-1ʹ), 118.9 (C-6), 118.3 (C-10), 112.3 
(C-3ʹ and C-5ʹ), 104.2 (C-3), 45.1 (C-1ʹʹ), 22.5 (C-2ʹʹ), 11.6 (CH3-3ʹʹ). ESIMS m/z 281.2853 
[M+H]
+
 (calcd C17H16N2O2 280.1212).
Preparation of Final Nitrogenated Pyridine Compound 2-(4ʹ-Isopropyloxyphenyl)-4H-
Pyrano[2,3-b]Pyridin-4-one [15c]: Procedure is similar to the preparation of the final pyridine 
compound 14c except for the use of isopropylamine (15 mg, 0.255 mmol). The final compound 
15c  was purified in a silica column using 20:1 Hex-EtOAc, 9:1 Hex-EtOAc, and 1:1 Hex-
EtOAc (25 mg, 54%). 
1
H NMR (500 MHz, CDCl3) δH 8.67 (dd, J = 1.6, 4.3 Hz, 1H, H-7), 8.58
(dd, J = 1.8, 7.6 Hz, 1H, H-5), 7.84 (d, J = 8.8 Hz, 2H, H-2ʹ and H-6ʹ), 7.43 (dd, J = 4.6, 7.6 Hz, 
1H, H-6), 6.71 (s, 1H, H-3), 6.64 (d, J = 8.8 Hz, 2H, H-3ʹ and H-5ʹ), 3.73 (sept, J = 6.3 Hz, 1H, 
H-1ʹʹ), 1.26 (d, J = 6.3 Hz, 6H, CH3-2ʹʹ and CH3-3ʹʹ). 
13
C NMR (125 MHz, CDCl3) δC 178.4 (C-
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4), 165.0 (C-9), 160.7 (C-2), 152.6 (C-4ʹ), 150.8 (C-7), 136.1 (C-5), 128.5 (C-2ʹ and C-6ʹ), 121.8 
(C-1ʹ), 118.9 (C-6), 118.0 (C-10), 112.6 (C-3ʹ and C-5ʹ), 104.1 (C-3), 44.0 (C-1ʹʹ), 22.8 (CH3-2ʹʹ 
and CH3-3ʹʹ). ESIMS m/z 281.2853 [M+H]
+
 (calcd C17H16N2O2 280.1212).
5.5. Drawbacks/Pitfalls 
The synthesis of the flavonoid and pyridine series of various subsituents involved various 
conditions and times. But the synthesis of certain compounds did not go through with the 
schemes used for other substituents. For example, the flavonoid with the O-methyl cyclopropyl 
was not yielded when the intermediate flavonoid [5b] was treated with boron tribromide for 1-3 
h. The methyl cyclopropyl substituent was lost even when the reaction was tried for shorter time
to prevent the loss of the methyl cyclopropyl substituent (10 min). Moreover, no methylation was 
seen on position-7 of the ‘A’ ring. Boron trichloride (BCl3) was also tried instead of boron 
tribromide. 5c was not accomplished during the synthesis of oxygenated flavonoid series. 
There was problem in the synthesis of the flavonoid with the propargylamine substituent. 
The treatment of the brominated flavonoid [6b] with the treatment of sodium tert-butoxide, 
tris(dibenzylideneacetone)dipalladium,  and 1,1ʹ-binaphthalene-2,2ʹ-diylbis(diphenylphosphine) 
with propargylamine in the presence of toluene did not yield either the intermediate flavonoid 
[8c] or the final flavonoid [8d]. The propargylamine substituent was lost even with reduced 
solvents and time. 
The synthesis of the pyridine compound with the O-methyl propyl substituent [12b] was 
not furnished when the diketo intermediate with the O-methyl propyl substituent [12a] was 
treated with pyridinium hydrochloride. Similarly, the synthesis of the pyridine compound with 
the propargylamine substituent [16c] was not accomplished when the brominated intermediate 
[14b] was treated with sodium tert-butoxide, tris(dibenzylideneacetone)dipalladium,  and 1,1ʹ-
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binaphthalene-2,2ʹ-diylbis(diphenylphosphine) with propargylamine in the presence of toluene. 
Different reactant concentrations and varying times were used but to no avail. 
Getting good yields was another challenge that is generally involved with any synthesis. 
Since, the main focus of my project is to initially furnish the designed analogs, methodologies to 
improve the yields were not developed. 
5.6. Summary 
The synthesis of the designed analogs was successfully performed. The synthesized 
analogs were subjected to MAO inhibition assays. The potent analogs were further assayed for 
enzyme kinetics and mechanism studies along with time-dependent enzyme inhibition assay and 
the analysis of inhibitor binding and reversibility with MAO-A and –B studies. The flavonoid 
compounds with O-propyl [1c], O-isopropyl [2c], O-isobutyl [3c], and O-propargyl [4c] 
substituents showed about 1500, 2000, 3500, and 1300-fold difference respectively, in their 
selectivity towards MAO-B vs MAO-A. 
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CHAPTER 6. FUTURE PLANS 
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We designed flavonoid and pyridine series with different substituents to study the 
interaction of these analogs on MAO-A and –B. We also studied the effect of the flavonoid and 
pyridine skeleton on these isoenzymes. The MAO-inhibition studies of these analogs showed 
that the flavonoid series exhibited more selectivity towards MAO-B vs MAO-A. Hence, we plan 
to conduct in vivo studies on these analogs to understand their potential as therapeutic 
compounds. 
We plan to dock the hit compounds which were identified as potent MAO-B compounds 
in the active site of the MAO-B to understand their binding interactions. The interactions of these 
analogs on these active sites would help understand the binding modes, to design novel scaffolds 
as PD hits, and to achieve higher MAO-B selectivity because selective MAO-B compounds are 
known to possess less adverse-effects. 
Since we studied the interactions of the flavonoid and pyridine series on MAO 
isoenzymes, one of the future plans is to study the effect of other substituents on the ‘C’ ring. 
Then, we will compare these results with the potent flavonoid compounds on the MAO enzymes. 
This strategy would be helpful to identify the substituents that play a significant role in MAO-B 
selectivity. We would also consider the cytotoxicity studies and the promiscuity of the 
synthesized analogs on the MAO-B enzyme. PK studies will be done on the potent and selective 
compounds along with the drug-metabolism studies, to understand how the compounds are 
excreted and what the active and inactive metabolites are. Understanding the routes of 
metabolism would significantly affect the drug’s efficacy and safety, and also the directions for 
use. If the elimination occurs primarily through metabolism, then the principal routes of 
metabolism should be understood. If the elimination occurs through a single metabolic pathway, 
then the individual differences in the metabolic-rates would lead to large differences in the 
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concentration of the drug and the metabolites in the blood and tissue. The major goals of the 
drug-metabolism studies are to characterize and identify the major metabolites of the synthesized 
compounds and the specific enzymes involved in its metabolism; to evaluate the impacts of these 
metabolites on the drug’s safety and efficacy; and to utilize this information to maximize its 
intellectual property. 
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All the synthesized analogs were purified using the following parameters: 
Injection Volume: 10.00 µL 
Run Time: 15.00 min 
Acquisition Method Set: Isocratic 20% H2O_80% MeOH 
Wavelength: PDA 254.0 nm 
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